Associations of affective temperaments with arterial stiffness and Brain-derived Neurotrophic Factor in hypertension by László, Andrea























Programvezető: Dr. Szökő Éva, egyetemi tanár 
Témavezető: Dr. Nemcsik János, családorvos 
 
 
                   
DOI:10.14753/SE.2020.2300
Associations of affective temperaments with arterial 
stiffness and Brain-derived Neurotrophic Factor in 
hypertension 
Ph.D. Thesis 
Andrea László M.D. 
Semmelweis University School of Ph.D. 
Studies Pharmaceutical Science  
 
Tutor: János Nemcsik, M.D., Ph.D. 
Opponents:  
László József Wágner, M.D., Ph.D. 
Tibor Kovács, M.D., Ph.D. 
Head of the Complex Examination Committee:  
Szabolcs Várbíró, M.D., Ph.D. 
Members of the Complex Examination Committee:  
Krisztián Szabolcs Vörös, M.D., Ph.D. 







ABBREVIATIONS .......................................................................................................... 5 
1. BACKGROUND ....................................................................................................... 8 
1.1. Cardiovascular diseases, hypertension and mood disorders: incidence and 
connections ................................................................................................................... 8 
1.1.1. Cardiovascular diseases in the XXIst century ............................................ 8 
1.1.2. The importance of hypertension ................................................................. 8 
1.1.3. Mood disorders: a common public health problem in the Western world . 9 
1.1.4. Well-known connections between CVDs and depression .......................... 9 
1.2. Affective temperaments: risk factors for psychiatric disorders and CVDs ..... 10 
1.2.1. Background, definition and assessing of affective temperaments ............ 10 
1.2.2. Five types of affective temperaments ....................................................... 12 
1.2.3. Dominant affective temperaments and their relation to affective disorders 
– a spectrum concept ............................................................................................... 13 
1.2.4. Affective temperaments: molecular genetic backgrounds........................ 14 
1.2.5. Affective temperaments are, in healthy populations, part of the bipolar and 
unipolar mood disorder spectrum ............................................................................ 15 
1.2.6. The role of affective temperaments in the psychopathology: bipolar and 
unipolar mood disorders .......................................................................................... 15 
1.2.7. Affective temperaments and cardiovascular risk...................................... 16 
1.3. Arterial stiffening as a risk factor for CVDs .................................................... 17 
1.3.1. Definition and pathophysiology of arterial stiffness ................................ 17 
1.3.2. Methods for measuring arterial stiffness, focused on arterial tonometry . 18 
1.3.3. Parameters of arterial stiffness ................................................................. 19 
1.3.4. Pulse wave velocity .................................................................................. 19 
1.3.5. Arterial stiffness parameters and CV risk estimation, according to actual 




1.4. New psychosomatic connections: the possible role of the brain-derived 
neurotrophic factor (BDNF) in psychopathology and cardiovascular diseases .......... 26 
1.4.1. Brain-derived neurotrophic factor (BDNF) .............................................. 26 
1.4.2. BDNF in mood disorders .......................................................................... 26 
1.4.3. BDNF and CV pathology ......................................................................... 27 
1.4.4. BDNF polymorphism ............................................................................... 27 
2. OBJECTIVES ......................................................................................................... 29 
3. PATIENTS AND METHODS ................................................................................ 30 
3.1. Study 1: patients and methods in the study measuring arterial stiffness and 
serum BDNF level in patients with and without dominant affective temperaments .. 30 
3.1.1. Questionnaires .......................................................................................... 31 
3.1.2. Clinical measurements .............................................................................. 32 
3.1.3. Statistical analysis .................................................................................... 33 
3.2. Study 2: patients and methods in the study exploring the association of 
affective temperaments with blood pressure and arterial stiffness in hypertensive 
patients ........................................................................................................................ 33 
3.2.1. Statistical analysis .................................................................................... 34 
3.3. Study 3: patients and methods in the study measuring serum BDNF levels in a 
hypertensive and a control population to discover the associations of BDNF with 
affective temperaments, depression, anxiety and arterial stiffness ............................. 34 
3.3.1. Statistical analysis .................................................................................... 35 
4. RESULTS................................................................................................................ 36 
4.1. Study 1: results of hemodynamic, arterial stiffness and serum BDNF levels in 
hypertensive patients with or without dominant affective temperaments .................. 36 
4.2. Study 2: results of affective temperaments’ association with blood pressure 




4.3. Study 3: results of serum BDNF levels in hypertensive patients and healthy 
controls; associations of serum BDNF with affective temperaments, depression, 
anxiety and arterial stiffness ....................................................................................... 47 
5. DISCUSSION ......................................................................................................... 53 
5.1. Study 1: arterial stiffness and serum BDNF levels in hypertensive patients with 
or without dominant affective temperaments ............................................................. 53 
5.2. Study 2: association of affective temperaments with blood pressure and arterial 
stiffness in hypertensive patients ................................................................................ 56 
5.3. Study 3: serum BDNF levels in a hypertensive and a control population; 
associations of serum BDNF with affective temperaments, depression, anxiety and 
arterial stiffness. .......................................................................................................... 60 
5.4. Limitation of the studies .................................................................................. 67 
5.4.1. Limitations of Study 1 .............................................................................. 67 
5.4.2. Limitations of Study 2 .............................................................................. 68 
5.4.3. Limitations of Study 3 .............................................................................. 68 
5.5. Future perspectives .......................................................................................... 68 
6. CONCLUSIONS ..................................................................................................... 69 
7. SUMMARY ............................................................................................................ 70 
ÖSSZEFOGLALÁS ....................................................................................................... 71 
8. REFERENCES ........................................................................................................ 72 
9. PUBLICATION SUMMARY............................................................................... 106 
9.1. Publications related to the thesis .................................................................... 106 
9.2. Publications not directly related to the thesis ................................................ 106 







CCTA Coronary computed tomography angiography 
5-HTTLPR Serotonin-transporter-linked polymorphic region  
AC Abdominal circumference  
ACE Angiotensin-converting enzyme 
AIx Augmentation index 
Alp Patients regularly using alprazolam;  
AP Augmentation pressure 
ARB Angiotensin II receptor blocker 
AT Angiotensin  
BDNF Brain-derived neurotrophic factor 
BMI Body mass index 
cDBP Central diastolic blood pressure 
CHD Coronary heart disease 
cMBP Central mean blood pressure 
CONT Controls 
cPP Central pulse pressure 
CREB cAMP response element binding protein 
CRH Corticotropin-releasing hormone  
CRP C-reactive protein 
cSBP Central systolic blood pressure  
CV Cardiovascular 
CVD Cardiovascular disease 
DBP Diastolic blood pressure 
DBPB Diastolic brachial blood pressure 
DOM Patients with dominant affective temperaments 
DT Diastolic time 
ECG Electrocardiography 
ESBP End-systolic blood pressure 
ESC European Society of Cardiology 




ESRD End-stage renal disease 
GABA Gamma-Aminobutyric acid 
GFR-EPI Glomerular filtration rate assessed by the chronic kidney disease 
epidemiology collaboration glomerular filtration rate equation 
HDL High-density lipoprotein 
HP Heart periode 
HPA Hypothalamic-pituitary-adrenal 
HR Heart rate 
HT Hypertensive patients 
ICAM-1 Intercellular Adhesion Molecule 1  
IL Interleukin 
IMT Intima media thickness  
LDL Low-density lipoprotein 
LPR LDL receptor-related protein 
LV Left ventricular 
LVET Left ventricular ejection time 
MAP Mean arterial pressure 
MDBP Mean diastolic blood pressure 
MDD Major depressive disorder 
MRI Magnetic resonance imaging 
MSBP Mean systolic blood pressure 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B 
NGF Nerve growth factor  
NO Nitric oxide  
NT Neurotrophin 
NT-3 Neurotrophin 3  
NT-4 Neurotrophin 4  
p75Ntr Neurotrophin receptor p75 
Partial Ra Partial correlation coefficient 
PP Pulse pressure 
PPAmp Pulse pressure amplification 




PWV Pulse Wave Velocity 
QOL Quality of life  
RAAS Renin-angiotensin-aldosterone system 
RAS Renin-angiotensin system 
Rpm Revolutions per minute 
SBP Systolic blood pressure  
SBPAmp Systolic blood pressure amplification 
SBPB Systolic brachial blood pressure 
SD Standard deviation  
SE Standard error 
seBDNF Serum Brain-derived neurotrophic factor 
SEM Standard error of the mean 
TEMPS-A Temperament Evaluation of Memphis, Pisa, Paris and San Diego 
Autoquestionnaire 
TIA Transient ischemic attack 
TNF Tumour necrosis factor  
Trk Tropomyosin receptor kinase 
VEGF Vascular endothelial growth factor  







1.1. Cardiovascular diseases, hypertension and mood disorders: incidence and 
connections 
1.1.1. Cardiovascular diseases in the XXIst century 
Cardiovascular diseases (CVDs) are leading causes of death, major causes of health loss 
worldwide and therefore major barriers to sustainable human development (1). In 2011, 
the United Nations formally recognized noncommunicable diseases, including CVDs – 
among cancer, chronic respiratory disease, and diabetes – as major concerns for global 
health. According to the World Health Statistics, an estimated 17.9 million deaths 
occurred due to CVDs, accounting for 31.4% of the overall total of 57 million deaths in 
the year 2016 (2). Ischemic heart disease was the leading cause of CVD health lost 
globally and also in each world region, followed by stroke. Even though over the past 
25 years sociodemographic changes have been associated with dramatic declines in 
CVDs, at present there is only a gradual decrease or no change in most regions. So, the 
trends in CVD mortality have plateaued and are no longer declining in high-income 
regions (3).  
1.1.2. The importance of hypertension 
Among the risk factors of CVDs hypertension has a major role affecting 1 billion adults 
globally (4): it is the leading cause of death and disability-adjusted life years (5) having 
an excessive impact on mortality worldwide. In the United States hypertension 
accounted for more cardiovascular (CV) deaths than any other modifiable CVD risk 
factor and was second only to cigarette smoking as a preventable cause of death for any 
reason (6, 7). In Europe the prevalence of high blood pressure among adults is between 
30 and 45%, rising with aging (8). In Hungary, the number of subjects with 
hypertension is approximately 3.5 million and this high prevalence contributes 
markedly to the poor Hungarian CV morbidity and mortality figures (9): in 2014, 51.7% 
of all-cause mortality was due to CVDs (10). 
There are modifiable (e.g. smoking, obesity, unhealthy diet) and non-modifiable (e.g. 
positive family history, age, male sex) risk factors of CVD which have a complex and 




pathophysiological pathways which are also involved in the development of 
hypertension, such as the renin-angiotensin-aldosterone system (RAAS), sympathetic 
nervous system, cardiac natriuretic peptide system or the endothelial function (11-13). 
Consequently, hypertension can also be considered as an outcome of different harmful 
processes, not only a simple disease. On the other hand, the development of high blood 
pressure can lead in longer term to adverse CV outcomes (14). 
Hypertension is the most prevalent modifiable risk factor for global disease burden in 
both sexes, regardless of ancestry, geographic region or income (5), thus early diagnosis 
and treatment of this condition is essential. Among the healthy population it would be 
required to find subpopulations, in which the risk of the onset of this disease is higher. 
Furthermore, among the hypertensive subjects the recognition of patients with elevated 
CV risk would help reach more effective primary and secondary prevention. 
Hypertension prevention receives a great attention, but the role of personality in the 
development of high blood pressure has not been fully clarified yet. 
1.1.3.  Mood disorders: a common public health problem in the Western world 
According to the World Health Organisation (WHO) depression is a common disease 
worldwide, involving up to 15% of the general population, with more than 350 million 
people affected in 2018 (15). According to WHO’s estimation, by 2020 depression will 
be already the second leading cause of world disability (16) and by 2030 it is expected 
to be the largest contributor to disease burden (17). Major depressive disorder (MDD) 
accounts for 12.3% of the global burden of disease (18). Based on the fact that 
depressive disorders often start at a young age – reducing the person’s functioning and 
oftentimes recurring – it is not surprising, that depression is the leading cause of 
disability for both men and women worldwide in terms of total years lost due to 
disability (19). While in 1990 depressive disorders were listed as the fourth leading 
cause of burden in the Global Burden of Disease (20), in 2000 they reached the third 
place (21). 
1.1.4.  Well-known connections between CVDs and depression 
There is growing evidence, that physical and psychological diseases are not independent 
from each other. Between 9.3% and 23% of individuals with one or more chronic 




complex reciprocal interrelationship between depression and coronary heart disease 
(CHD) (23, 24). Depression is associated with a 3- to 4-fold increase in the risk of 
recurrent cardiac events and death (25). In addition, among people with CHD, 
depression increases the risk of future cardiac mortality and morbidity (26, 27). On the 
other hand, patients with CHD have a depression prevalence of about 300% than 
healthy subjects (28). In patients after an acute myocardial infarction, major depression 
is three times more common than in the general population (29). 
There are multiple mechanisms by which depression could increase the probability of 
vascular diseases. These include increased platelet activation (30), endothelial 
dysfunction (31), elevation of inflammatory markers (32), as well as reduced heart rate 
variability (33). Dysregulation of metabolic, immune-inflammatory and autonomic 
systems, as well as the hypothalamic-pituitary axis, also seem to build a link between 
MDD and CVDs (34). Furthermore neurohormonal factors, and genetic linkages – such 
as with the serotonin transporter mechanism (35, 36) –, and also behaviour mechanisms 
are part of the pathophysiological background connecting both diseases (37). 
1.2. Affective temperaments: risk factors for psychiatric disorders and 
CVDs 
Parallel to depression, well-established biomarkers of inflammation were also found to 
be elevated in subjects in states of anger or hostility (38, 39), while a reduced function 
of the autonomic nervous system was observed in subjects in states of anxiety (40), and 
interpersonal antagonism was connected with carotid arterial intima-media thickening 
(41). These findings suggest that there are also psychological conditions in the range of 
normality which could influence CV risk. These data suggest that besides the evaluation 
of depression, analysing people’s characteristics based on their individual nature would 
lead us to a better understanding and prevention of CV risk. 
1.2.1. Background, definition and assessing of affective temperaments 
The concept of human personality dates back to Hippocrates (ca. 460 BC - ca. 370 BC) 
and Aristotle (384-322 BC). Four temperamental types were differentiated based on 
body fluids (called “humors”): melancholic, choleric, sanguine and phlegmatic (42). 
Not only the ancient Greeks, but much later Luois XIV was delighted by the theory of 




ordered to decorate the gardens of the Palace of Versailles in 1674. Among the 24 
statues, the “The Four Humors of Man” were also included (Figure 1). 
 
Figure 1. Charles Le Brun: The Four Humors of Man. 
From left to right: choleric, melancholic, sanguine and phlegmatic. 
Building on such classical theory and on Kraepelin's four distinct basic temperament 
types from 1913, professor Hagop S. Akiskal formulated the modern concept of 
affective temperaments and completed them with another one. Since then, we speak 
about five affective temperaments: depressive, irritable, hyperthymic, cyclothymic and 
anxious (43). Furthermore, Akiskal gave a new point of view on the definition of 
temperament and widened the term “temperament” to include healthy personality. Thus 
temperament – like personality – does not by itself necessarily constitute a pathology 
(44). All of us have our own characteristic temperamental profile determining our 
emotional response to environmental stimuli. In their natural mixture affective 
temperaments are responsible for cultural characteristics on a national level and can be 
associated with desirable outcomes such as adaptation and achievement (44-46). 
The presence of these affective temperaments can be evaluated with the 




Diego (TEMPS-A). The questionnaire was developed by Akiskal and his co-workers 
(47, 48), and since 2005 it has been translated and/or validated in more than 30 
languages, including such diverse cultures as the USA, Egypt, Japan, Lebanon, 
Portugal, Italy, Turkey, Germany, France, China, Korea, Russia, Tunis, Argentina, 
Brazil, Armenia, Hungary and many others (49). The questionnaire consists of 5 
subscales – according to the 5 affective temperaments, requiring only simple “yes” 
(score 1) or “no” (score 0) answers. 
1.2.2. Five types of affective temperaments 
As mentioned above, according to Akiskal's concept, 5 affective temperament types can 
be distinguished: depressive, cyclothymic, irritable, anxious and hyperthymic. A person 
with a depressive temperament can be described as pessimistic, highly self-critical, 
gloomy, excessively worrying, preoccupied with personal failure, lacking assertiveness, 
self-denying, and striving to please others (48). In cyclothymic temperament, a person 
shows abrupt biphasic alterations in mood between highs and lows in energy, self-
confidence and agility of mind with a frequency of several days each (50). A person 
with an irritable temperament reacts to negative events with negative emotions, 
presents fluctuations in mood and complaints, and shows close linkages to the 
cyclothymic temperament (51). People with anxious temperaments show uncontrolled 
worry even about their routine, an unfounded sense of danger, a real fear of unhappiness 
and an overalertness. They are unable to relax, stressed, restless and anxious (52). The 
difference between the hyperthymic temperament and the other four is that it proves to 
be more adaptive and beneficial for the patient, since it involves potentially positive 
characteristics: inter alia higher scores in sociability, energy and mood. On the other 
hand, such characteristics come in excess, and the flip side of this temperament is that it 
can involve maladaptive behavior, e.g. overconfidence, over-socialization, 
irresponsibility and ruthlessness, which can all result in undesirable outcomes of a 
person’s actions (50). 
It is important to note that sex differences are present in relation with affective 
temperaments. Vázquez et al. – and also other studies – found in the general population 
significantly higher irritable and hyperthymic temperament scores in men, and 




(43, 53-55). On the other hand, each person scores differently in the different 
temperament directions and these are not fully independent form each other: positive 
associations were described between depressive and anxious, and cyclothymic and 
irritable temperaments (43). 
1.2.3. Dominant affective temperaments and their relation to affective 
disorders – a spectrum concept 
Dominant affective temperaments are defined with a cut-off point of z-scores above +2 
standard deviation (SD) in the TEMPS-A questionnaire. Investigating the different 
countries, 13 to 20% of the population has some kind of dominant affective 
temperaments; in Hungary this value is 16.8 % (54). Temperaments can also be so 
extreme that they could be considered abnormal in a statistical sense – even with the 
absence of mental disorder (44). 
It is unclear whether Aristotle discovered the concept of the bipolar spectrum, but he 
seems to have placed the query on exceptional greatness within the dimensional space 
between temperament and affective disease. At the beginning of the twentieth century, 
Kraepelin believed that the temperaments are subclinical forms and many times the 
precursors of major affective psychoses (56). According to Akiskal's theory of dominant 
affective temperaments – temperaments in their extreme forms, these are regarded as 
the subclinical/trait-related manifestations or phenotypes of bipolar or unipolar mood 
disorders (49). They often present an increased inclination towards these diseases and 
are located at the end of the continuum, close to affective illness (45, 49, 57, 58). Based 
on these facts, Akiskal visualized the spectrum concept of temperament and bipolar 
disease on the basis of Kretschmer’s work (1936) (42). In a Gaussian curve Figure 2 
shows the normal population, the 13-20% of people having dominant affective 
temperaments and the remaining small part of the population with bipolar diseases – 





Figure 2. Temperament and bipolar disease in a spectrum concept. 
Adopted from: (42). 
1.2.4. Affective temperaments: molecular genetic backgrounds 
Since different affective temperaments are predominant in the population in different 
geographic regions and cultures, a connection to genetic causes appears logical. 
Temperament in general (59) and affective temperaments in particular are biological in 
nature and are strongly determined by genetic factors (60-62). Molecular genetic studies 
show a strong connection to the central serotonergic regulation in depressive, 
cyclothymic, irritable and anxious temperaments, while the involvement of 
dopaminergic regulation seems to be significant in hyperthymic temperament (49). 
Gonda et al. found a significant association between the “s” allele of serotonin-
transporter-linked polymorphic region (5-HTTLPR) gene and the TEMPS-A scores of 
depressive, anxious, irritable, and particularly of cyclothymic temperaments – like in 
depression (63). While people with one or two short alleles of the 5-HTT serotonin 
transporter gene become more often depressed after stressful events, subjects with two 
long alleles of this gene are less prone to such mood changes. No such association 
emerged with respect to the hyperthymic temperament (64). However, the same 
findings could not be demonstrated in South Korea. This may be due to the very 
different genotype distribution of 5-HTTLPR in the populations of the two mentioned 




between the dopamine receptor 4 polymorphism and cyclothymic and irritable 
temperaments in men (65). 
1.2.5. Affective temperaments are, in healthy populations, part of the bipolar 
and unipolar mood disorder spectrum 
Not only in cases of affective temperaments, but also in unipolar and bipolar major 
mood disorders, the role of genetic modulation related to the disturbance of central 
serotonin and dopamine/noradrenaline neurotransmission is proven. The “s” allele of 
the HTTLPR gene shows a strong association with major depression (67), as well as 
with subthreshold forms of depression (66). So, these findings show that the genetic 
potential of major mood disorder episodes is based on affective temperaments (49). 
It is already known that there is a continuum between dysthymia, subsyndromal 
depression, minor depression and unipolar major depression (68-72). Such a continuum 
could be demonstrated between cyclothymic disorder, bipolar I, and bipolar II disorders 
(73-75). Other studies on affective temperaments in healthy controls without affective 
family history showed the lowest, and in recovered bipolar I patients the highest mean 
hyperthymic and cyclothymic scores (60-62). In line with these findings, a pronounced 
onset of hyperthymic and cyclothymic temperaments was demonstrated in nonaffected 
first-degree relatives of bipolar I disorder patients. However, this does not mean that 
cyclothymic temperament itself is necessarily a good genetic marker for bipolar 
disorders in general (61). It is possible however, that it is relevant for bipolar II disorder 
(76). 
1.2.6. The role of affective temperaments in the psychopathology: bipolar and 
unipolar mood disorders 
According to data in literature, the relationship between affective temperaments and 
major mood episodes is quite complex. It is already known that hyperthymic and – to a 
lesser degree of magnitude – cyclothymic temperament are characteristic for bipolar I 





Among bipolar I patients with higher frequency of maniac episodes, hyperthymic 
temperament is more pronounced, whereas among those with predominant depressive 
polarity, the characteristic temperament type is the depressive one (77). 
However, cyclothymic temperament is the most common affective temperament type 
among patients with bipolar II disorder (47, 76, 78, 79). It is the precursor of bipolar 
disorder often with earlier onset, atypical features, more relapses and worse prognosis 
(49, 80). This temperament is 88% sensitive in identifying bipolar II disorder (81) and it 
has high predictive power for bipolar, especially for bipolar II transformation (82). 
Interestingly, in a smaller number of “unipolar” depressive patients – especially with a 
positive family history of bipolar disorder – the core feature of cyclothymic 
temperament can also be detected because it is typically accompanied by mood and 
energy alterations (83). On the other hand, cyclothymic temperament was also shown to 
be associated with atypical depression (49, 84). 
1.2.7. Affective temperaments and cardiovascular risk 
According to the European Guidelines on CVD prevention in clinical practice, 
personality can also affect vulnerability to and prognosis of CV disorders (85). 
Hostility, anxiety, and type D personality promote the development, clinical course and 
prognosis of CVD. The reasons are behavioral risk factors, such as unhealthy lifestyle, 
low adherence to behavior-change recommendations or to cardiac medications, which 
are preponderant in CV disorders (85). Thus, personality patterns and possibly 
temperaments can also be considered moderators, and not causes of specific diseases 
(86, 87). 
We had limited knowledge about the association between affective temperaments and 
hypertension. Eőry et al. demonstrated that dominant cyclothymic temperament is 
associated with the presence of chronic hypertension – independently of age, diabetes 
mellitus and obesity; suggesting an additional risk factor in CV morbidity (88). 
Unfortunately, in this study, the patients‘ blood pressure was not measured, only the 
diagnosis of high blood pressure was present in their medical history. In another study 
of Eőry et al., cyclothymic temperament was also associated with the history of 




depressive symptoms, age, gender and smoking, but in this cross sectional study only a 
very low number of patients (n=16) had CV events in their history (89). 
Based on these results, it was reasonable to study in more depth the associations 
between affective temperaments and hypertension, including hemodynamic parameters, 
as well as to evaluate the differences between men and women. 
1.3. Arterial stiffening as a risk factor for CVDs 
1.3.1. Definition and pathophysiology of arterial stiffness 
Arterial stiffness is a generic term describing the rigidity of the arterial wall. Vascular 
stiffening develops from a complex interaction between stable and dynamic changes 
including structural and cellular elements of the vessel wall (90). Interestingly, stiffness 
is not uniformly disseminated throughout the vascular tree (91-93) occurring in elastic 
arteries, while mostly sparing peripheral arteries (94, 95). 
The pathophysiological background of arterial stiffening is complex. The chronic 
cyclical stress on the walls of large arteries leads to irreversible elastin fracturing and 
thinning (96). The activation of RAAS also enhances arterial stiffening through 
stimulating multiple inflammatory pathways such as tissue growth factor-β and nuclear 
factor kappa-light-chain-enhancer of activated B (NF-κB), promoting reactive oxygen 
species production with reduction in nitric oxide bioavailability (97-99). Inflammatory 
processes disturb the balance between the production of proteases and their inhibitors 
and promote the synthesis of advanced glycation end-products (97). Sodium also plays 
an important role in the process of arterial stiffening: a high sodium level causes 
vascular smooth muscle cell hypertrophy (100), while in sodium sensitive patients it 
seems to lead to alterations in the viscoelastic properties of arterial wall characteristics 
(101). 
Arterial stiffness and blood pressure are closely related. Although arterial stiffness was 
for a long time considered to be one of the complications of hypertension, there is now 
growing evidence that arterial stiffening itself can lead to an increase in systolic blood 
pressure (SBP); and in this vicious circle, this blood pressure elevation causes further 
arterial stiffening (102-104), suggesting that arterial stiffening is both a cause and a 




The result of the pathophysiological changes described above is the increased arterial 
stiffness in the aorta and in the carotid arteries, but not in the large peripheral muscular 
arteries. Thus, the peripheral impedance to the forward component of the arterial pulse-
wave is reduced and the pulsatile energy transmission to the microcirculation is 
increased (106). The increase of blood flow and pressure pulsatility can lead to damage 
of high flow, low impedance organs, especially the kidneys and the brain (106). 
Additionally, aortic stiffening promotes left ventricular (LV) remodelling, hypertrophy 
and dysfunction (107, 108). 
1.3.2. Methods for measuring arterial stiffness, focused on arterial tonometry 
In clinical practice, non-invasive measurements of arterial stiffness using numerous 
devices are becoming more and more relevant. Regional methods are based on direct 
measurements of parameters strongly linked to wall stiffness. The most commonly 
applied non-invasive, “gold standard” method of evaluating arterial stiffness involves 
the use of a tonometer or a mechanotransducer to measure carotid and femoral pulse 
waves (109). Arterial tonometry is based on the applanation tonometry principle. The 
sensor must be placed on the skin above the artery, applying a moderate pressure. In this 
way the artery becomes slightly compressed with a balance of the circumferential forces 
inside the vessel, enabling the sensor to record the pressure in the middle of the 
compressed artery. However, these devices require a skilled operator to produce 
measurements of acceptable quality. With this method, the carotid-femoral pulse wave 
velocity (PWV) can be determined, which means the velocity of pulse wave as it travels 
from the heart to the carotid and then to the femoral artery. The pulse waves are usually 
registered on the right common carotid and the right femoral arteries (105). There are 
also other possibilities for regional arterial stiffness measurements: new and less 
operator-dependent methods are available. Some of these oscillometric methods are 
accompanied by ambulatory blood pressure monitoring and are able to determine the 
24-hour profile of arterial stiffness and central blood pressure. Although clinical data 
are accumulating, questions remain as to the real relevance of these new devices, which 




1.3.3. Parameters of arterial stiffness 
Various parameters can be measured and calculated in order to evaluate arterial stiffness 
and wave reflections in a non-invasive manner. Central SBP (cSBP), central pulse 
pressure (cPP), augmentation index (AIx) and PWV all show an increase with age and 
in association with CV risk factors, like hypertension, diabetes mellitus, and 
hypercholesterolemia. Although all of them are associated with target organ damage – 
like LV hypertrophy, increased carotid intima media thickness (IMT), 
microalbuminuria, endothelial dysfunction – and clinical outcomes, these are not 
replaceable indexes of arterial stiffness. 
1.3.4. Pulse wave velocity 
PWV is defined as the speed of the pulse pressure wave travelling along the arterial 
system. Arterial pressure waves are recorded on both proximal and distal arteries. The 
length of the arterial segment (ΔL) between the two measured points with surface tape 
must be determined, as well. The wave transit time (Δt) is obtained either by using the 
QRS complex of a simultaneously recorded electrocardiography (ECG) in order to have 
a reference frame, or by using two probes above the femoral and the carotid arteries at 
the same time (Figure 3) (109). 
 
Figure 3. Measurement of carotid-femoral PWV with the foot-to-foot method. 
Adopted from: (109). 
Arterial wall properties are also important in determining PWV. These factors are 








Here, PWV is the pulse wave velocity, Einc is the Young’s elastic modulus of arterial 
wall describing the intrinsic elastic properties of the vessel walls, h is the arterial wall 
thickness, ρ is the blood density and D is the vessel diameter. An increase of Einc, and 
of arterial wall thickness results in elevated PWV, while the arterial calibre is inversely 
proportional to PWV. Taken together, arterial stiffness can be modulated directly by 
arterial wall mechanical properties, thickness and changes in vascular tone, but also 
indirectly, by changes in blood pressure (97). 
The “gold standard” PWV measurement is usually evaluated using the “foot-to-foot” 
velocity method, as mentioned above, from a number of waveforms using the following 





D is the distance between the two recording sites and Dt is the time delay between the 
“foot” of the carotid and the femoral waveforms. The “foot” of the wave is defined at 
the end of the diastole, when the steep rise of the waveform begins (111). In order to 
reach a proper result, the correct measurement of the covered distance is essential: 
according to a consensus document from 2012, 80 % of the direct carotid to femoral 
distance shall be used (112). The more elasticity the great arteries show, the lower is the 
PWV value; while a higher PWV value indicates increased arterial stiffness. 
1.3.4.1. Central systolic blood pressure 
Brachial blood pressure is only a surrogate marker of central, i.e., aortic blood pressure. 
Recalculation of the artery tonometer pressure wave that was measured on the carotid 
artery is based on the observation that diastolic and mean arterial pressures are 
relatively constant throughout the large artery tree. However, systolic blood pressure 
may be up to 40 mmHg higher in the brachial artery compared to the aorta due to an 
increase in arterial stiffness moving away from the heart (113-115). This phenomenon is 
called the systolic blood pressure amplification (SBPAmp). As the pressure wave 
travels from the elastic central arteries to the stiffer peripheral (brachial) artery, the 




prominent, and systolic pressure increases (116). In practice, blood pressure is measured 
at the reference (brachial) artery with a validated blood pressure device. From the direct 
measured peripheral diastolic blood pressure (DBP) and SBP mean arterial pressure 
(MAP) can be calculated. Using brachial DBP and MAP carotid SBP can be determined 
(Figure 4). 
Figure 4. Calibration method for central pulse pressure. 
Adapted from Kelly and Fitchett and Verbekeet al. (117, 118). SBPBA: systolic brachial blood 
pressure; DBPBA: diastolic brachial blood pressure; MAPBA: mean brachial blood pressure; 
SBPCA: systolic carotid blood pressure; DBPCA: diastolic carotid blood pressure; MAPCA: 
mean carotid blood pressure. 
1.3.4.2. Central pulse pressure 
Arterial blood pressure and flow waves are generated by LV contraction and its 
interaction with the elastic arterial walls. In order to provide a steady flow distribution 
to the tissues and organs, arteries distend while accommodating the sudden increase in 
blood volume caused by cardiac contraction, and contract in the diastole, when the 
elastic energy generated during distension is released. As a result of this phenomenon, 
arteries present a regular beating, the pulse, which follows the heartbeat and propagates 
in the form of pulse waves (119). The arterial pressure waveform itself is a mixture of 




reflected wave from the periphery, mainly at branch points or sites of impedance 
mismatch (pressure wave running towards the heart) (109). Therefore, pulse pressure 
and pulse wave shape are determined by the physical properties of the CV system, like 
the arterial geometry and distensibility, the LV ejection, and the impedance due to the 
smallest blood vessels (119). A schematic representation of central pulse pressure is 
shown in Figure 5.  
1.3.4.3. Augmentation index 
From the central diastolic to the systolic pressure the inflection point (Pi) can be 
determined, where the pressure indicates the beginning upstroke of the reflected wave. 
The time (Ti) – belonging to the inflection point – defines the timing of the reflection. 
Augmentation pressure (AP) is the pressure above the inflection point – the point in 
time which coincides with the peak of the flow wave in the artery. AIx is defined as the 
ratio between the second and first systolic peaks, the AP and pulse pressure (PP), 
usually expressed in percentage (Figure 5) (120, 121). 
 
Figure 5. Pulse wave of the carotid artery. 
AP: augmentation pressure; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic 
blood pressure, MAP: mean arterial blood pressure; MSBP: mean systolic blood pressure; 
MDBP: diastolic blood pressure; ESBP: end-systolic blood pressure; PP: pulse pressure; Ti: 
rise time of the reflected wave; Pi: arterial pressure at the Ti; dPi: pulse pressure at the Ti; 




In elastic vessels the reflected wave tends to arrive back at the central arteries during 
diastole. If the arteries are stiff, the reflected wave arrives back at the aortic root earlier, 
adding to the forward wave and augmenting the systolic pressure (Figure 6) (109). 
Thus, for young patients the AIx value tends to be negative, while it will almost 
certainly be positive in elderly patients (Figure 6, left graph AIx=-5%; right graph 
AIx=+10%). 
 
Figure 6. Changes of the carotid pulse curve with ageing: on the left side of a young patient 
(29 years), on the right side of an aged patient (84 years). 
The red points indicate the systolic peak, the green points the end-systolic blood pressure. (The 
curves are selected from our own patients.) 
1.3.5. Arterial stiffness parameters and CV risk estimation, according to actual 
guidelines 
The association of the above mentioned arterial stiffness parameters with different CV 
risk factors as well as their role in the recent European Society of Cardiology (ESC) and 





Table 1. The association of pulse wave velocity, Augmentation index, central systolic and 
pulse pressure with different CV risk factors and their role in the actual guidelines. 
PWV: pulse wave velocity; AIx: augmentation index; ESDR: end-stage renal disease; IMT: 
intima-media thickness; CV: cardiovascular; cSBP: central systolic blood pressure; cPP: 
central pulse pressure; CAD: coronary artery disease; LVH: left ventricular hypertrophy; 









PWV Hypertension (123-126), ESRD 
(127), ischemic stroke (128), 
metabolic syndrome (129), 
echogenic plaques and increased 
IMT of the carotid artery (130, 131), 
endothelial dysfunction (132) 
CV events and 
mortality (133-
136). 
class IIb, level 
of evidence B 
method (122) 




class IIb, level 
of evidence C 
methods (122) 
cPP carotid IMT (142), severity of CAD 
and endothelial dysfunction (143) 
vascular hypertrophy, the extent of 
atherosclerosis, incident CVD (138) 
CV events and 
mortality (140, 
144-148) 
class IIb, level 
of evidence C 
methods (122) 
AIx hypercholesterolemia (149), heavy 
alcohol intake and smoking (150), 
type 1 diabetes mellitus (151, 152), 
endothelial function (132), high 
sensitivity CRP (153), premature 
CAD (154) 
CV mortality in 
ESRD (140, 
148) and CAD 









Patients at intermediate risk could be reclassified into a lower or higher CV risk 
category based on PWV measurements (136, 156, 157). In the Framingham follow-up 
study of 7.8 years for individuals at intermediate CV risk, higher aortic PWV was 
associated with a 48% increase in CVD risk. After adding PWV to a standard risk factor 
model, a result of an integrated discrimination improvement of 0.7% was achieved. 
Consequently, PWV resulted in upward reclassification of 14.3 % of subjects who 
suffered a CV event and downward reclassification of 1.4 % of participants who did not 
experience any CV events, meaning a reclassification altogether of 15.7 % (156). A 
recent meta-analysis demonstrated clearly the independent predictive value of PWV in 
CV risk. Ben-Shlomo et al. found that after the adjustment of additional risk factors an 
increase of 1 SD in log PWV is related to a 30% increase in CV events, a 28% increase 
in CV mortality and a 17% increase in all-cause mortality (133). In other words it 
means that for a 60-year-old non-smoker, non-diabetic, normotensive and normolipemic 
man, an increase of 1 m/s of PWV leads to a 7% growth of the hazard for CV events 
(133, 158). Reference values for PWV are available in healthy populations and also in 
patients with increased CV risk (159). The recent cut-off value of PWV>10 m/s is 
considered a conservative estimate of significant alterations of aortic function in 
middle-aged hypertensive patients (112). Whereas such cut-off value is set for PWV, 
indicating target organ damage and an increased CV risk, the other arterial stiffness 
parameters are showing less evidence. 
In summary, the measurement of arterial stiffness can be considered to assess CV risk. 
As depression is connected to CV risk, it is not surprising, that depression was found to 
be associated with elevated arterial stiffness as well. Tiermeier et al found in their 
population-based, cross-sectional study including 3704 elderly subjects that patients 
with increased arterial stiffness were more likely to have depressive symptoms. The 
association was stronger in cases with diagnosed depressive disorders. The authors 
concluded that arterial stiffness may partly cause the proposed relationship between 
vascular factors and depression (160). Since dominant affective temperaments can be 
the precursors of depression, a question arises: is it possible that increased blood 
pressure values and elevated arterial stiffness can be detected in hypertensive patients 
with dominant affective temperaments, indicating an increased CV risk compared with 




can be described as continuous variables, it would be important to ascertain the 
continuous association between affective temperament scores and blood pressure or 
arterial stiffness parameters. 
1.4. New psychosomatic connections: the possible role of the brain-derived 
neurotrophic factor (BDNF) in psychopathology and cardiovascular 
diseases 
Neurortophic factors or neurotrophins (NTs) consist a family of trophic factors of 
secreted proteins that promote growth, survival and differentiation of neurons both in 
the central and peripheral nervous system (161). We summarized the role of NTs in 
psychopathology and CV diseases in a recent review paper (162).  
1.4.1. Brain-derived neurotrophic factor (BDNF) 
BDNF is the most frequently studied NT. It is initially synthesized in the endoplasmic 
reticulum as its precursor protein, preproBDNF. After the cleavage of the signal peptide 
this form becomes proBDNF, and proBDNF is converted by extracellular proteases to 
mature BDNF (163, 164). 
Mature BDNF binds with higher-affinity Trk family receptors (165) – especially TrkB – 
increasing cell survival and differentiation, dendritic spine complexity, long-term 
potentiation (166, 167), synaptic plasticity (168), and the resculpting of neuronal 
networks (169). ProBDNF is also biologically active, it mediates its actions through 
binding to low-affinity p75Ntr, having antagonistic effect compared to matured BDNF: 
reducing spine complexity and density (170) and promoting neuronal cell death (171). 
1.4.2. BDNF in mood disorders 
Although NTs themselves do not control mood directly, they are fundamental in the 
activity-dependent modulation of networks and changes in plasticity can affect mood as 
well (172). Numerous clinical studies confirm the involvement of BDNF in the 
pathophysiology of depression (173). Reductions in serum and plasma mature BDNF 
have been demonstrated in patients suffering from depression (164, 174) and in those 
who committed suicide (175, 176). Significantly lower levels of serum BDNF were 
found in antidepressant-free patients with major depressive disorder compared with 
healthy controls (177), which findings were confirmed by a large cohort study (178) and 




1.4.3. BDNF and CV pathology 
BDNF plays an important role during development of the CV system: the activated 
TrkB receptor leads to the survival of endothelial cells and the formation of the cardiac 
vasculature (182). Embryonic BDNF deficiency impairs the development of 
intramyocardial vessels and can also lead to cardiac hypercontractility (183). This NT 
functions as an angiogenic regulator, promoting angiogenesis (184). It is expressed in a 
greater amount in the peripheral vessels, where it could influence vasoreactivity (185, 
186). BDNF is able to enhance vascular flow and can regulate the revascularization of 
ischemic tissues (184). It was shown to be vasorelaxant on pulmonary arteries (187) and 
on rat aortic rings (185). Furthermore, it improves left-ventricular function in ischemic 
myocardium (188). 
Numerous data are available about the association between BDNF and CV health. In the 
general population a significant positive correlation was observed between plasma 
BDNF and diastolic blood pressure and sex differences were demonstrated in relation 
with different serum lipids (189). As it was a cross-sectional study, it is unclear whether 
the associations observed are casual or elevated plasma BDNF represents a 
compensatory response for the disrupted lipid metabolism and hypertension. 
Increased BDNF expression was found in atherosclerotic coronary arteries in humans 
(190), and decreased plasma BDNF level was observed in metabolic syndrome (191), in 
acute coronary syndrome (192, 193) and in type 2 diabetes mellitus (194). In patients 
with angina pectoris Jiang at al. found that plasma BDNF was inversely associated with 
triglyceride and low-density lipoprotein (LDL)-cholesterol, male sex and age, while it 
was correlated positively with (HDL)-cholesterol. In this cohort, during the 4-year 
follow-up period, low plasma BDNF was an independent predictor of future coronary 
events and mortality (195). The predictive role of BDNF for future CV events and 
mortality was confirmed by other studies as well: higher serum BDNF (seBDNF) was 
found to be associated with decreased risk of CV morbidity and mortality (196). On the 
contrary, decreased serum BDNF was found to be associated with increased risk of 
incident stroke/transient ischemic attack (TIA) (197).  
1.4.4. BDNF polymorphism 
A functional polymorphism Val66Met in the BDNF gene – an amino acid substitution 




found to influence BDNF’s secretion and function. Moreover, it is also associated with 
mood and cognitive-related phenotypes. There is ample biological evidence that the 
BDNF gene is an attractive candidate gene for MDDs (199). Nevertheless, a recent 
meta-analysis of Li et al. showed that the Val66Met polymorphism was significantly 
associated with bipolar disorder in Europeans, but not with MDD (200). Regarding to 
affective temperaments, the variant of BDNF polymorphism has already been studied. 
However, no significant difference in the frequency of alleles between subjects with and 
without affective temperaments was shown (201). 
Taken together, the role of BDNF is already proven in psychiatric disorders, and it 
seems to have an influence on CV risk. In different animal models BDNF was shown to 
be vasorelaxant, also on aortic rings. Based on these data, a possible association 
between the seBDNF level and different arterial stiffness parameters in hypertension 
can also be supposed in humans. On the other hand, BDNF polymorphism has already 
been investigated in MDDs and in affective temperaments, but in hypertension the 







1. In the first study, our aim was to measure arterial stiffness and serum BDNF 
levels in hypertensive patients with and without dominant affective temperaments. 
We hypothesised that hypertensive patients with dominant affective temperaments 
score higher depression and anxiety values and have impaired arterial stiffness, 
central blood pressure or serum BDNF compared with hypertensive patients without 
dominant affective temperaments, forming a high-risk subgroup patient population.  
2. In the second study, our aim was to explore the associations of affective 
temperaments with blood pressure and arterial stiffness in hypertensive patients. We 
hypothesized that individual affective temperament scores may be related to brachial 
blood pressure as well as arterial stiffness in chronic hypertensive patients. We 
speculated a positive association in instances of depressive, cyclothymic, irritable or 
anxious temperaments and an inverse association in instances of hyperthymic 
temperament. We also hypothesized the presence of sex differences in relation to 
these studied associations.  
3. In our third study, our aim was to measure BDNF serum levels in hypertensive 
patients and in healthy controls to discover the associations of BDNF with affective 
temperaments, depression, anxiety and arterial stiffness. We hypothesized that as 
hypertension is a risk factor for cardiovascular diseases and BDNF is protective in 
cardiovascular pathology, seBDNF can be altered in hypertension. We also 
presumed that seBDNF is associated with different affective temperaments, 
depression, anxiety, and arterial stiffness parameters providing a new bridge of 





3. PATIENTS AND METHODS 
3.1. Study 1: patients and methods in the study measuring arterial stiffness and 
serum BDNF level in patients with and without dominant affective 
temperaments 
Caucasian patients were selected from two primary care practices in Budapest, 
Hungary. Out of the 183 patients 175 completed the TEMPS-A, Beck Depression 
Inventory (BDI) and Hamilton Anxiety Scale (HAM-A) questionnaires in order to 
evaluate the presence of affective temperaments, or the depression and anxiety, 
respectively. Exclusion criteria were the history or ongoing treatment of depression or 
anxiety (as with arterial stiffening the associations are clarified (160)), bipolar disorders, 
schizophrenia, dementia posing an obstacle to completing questionnaires or denial of 
consent, the presence of atrial fibrillation or uncontrolled hypertension (>145/95 mmHg 
in repeated office measurements). In patients with an average blood pressure between 
140/90 and 145/95 mmHg in repeated office blood pressure measurements, ambulatory 
24-hour blood pressure monitoring or home blood pressure monitoring was performed 
and only well-controlled patients were admitted into the study. Prior to the participation, 
all patients gave their written informed consent. All the studies were approved by the 
Scientific and Research Ethics Committee of the Medical Research Council, Hungarian 
Ministry of Health and carried out in accordance with the tenets of the Declaration of 
Helsinki. 
Following the initial screening, 29 hypertensive patients with dominant affective 
temperaments (reaching the mean+2 SD point scores or higher in each affective 
temperament subscale, DOM) were identified, and 24 were investigated in our study. 24 
hypertensive controls without DOM, matched in age, gender and presence of diabetes, 
were selected from the initial hypertensive patient cohort and included in the arterial 
stiffness and seBDNF measurements. As blood pressure medication can highly 
influence arterial stiffness, it was further analyzed, but patients were not matched in this 
aspect.  
During the initial visit patients completed the questionnaires. Physical examination 




data on medical history (with special attention to CV risk factors, complications and 
depression) as well as on current medication was collected. 
3.1.1. Questionnaires 
3.1.1.1. Temperament Evaluation of Memphis, Pisa, Paris and San Diego 
Autoquestionnaire 
The TEMPS-A was used to assess affective temperaments on depressive, cyclothymic, 
hyperthymic, irritable and anxious subscales, requiring “yes” (score 1) or “no” (score 0) 
answers [17]. TEMPS-A contains 110 items (109 in the version for males) and the 
questions of the various temperament types are grouped together as follows: 
 depressive temperament: questions 1 to 21 (21 points) 
 cyclothymic temperament: questions 22 to 42 (21 points) 
 hyperthymic temperament: questions 23 to 63 (21 points) 
 irritable temperament: questions 64 to 84 (21 points in women, 20 in the men’s 
version) 
 anxious temperament: questions 85 to 110 (26 points). 
TEMPS-A is used to assess the point scores of each subscale and also to measure the 
presence of the dominant form of affective temperaments by taking the mean of the 
subscale and adding up two standard deviations to it. Those reaching the mean+2 SD 
level or higher in each subscale are considered to have dominant affective 
temperaments. 
3.1.1.2. The Beck Depression Inventory 
The BDI, created by Aaron T. Beck, is a 21-question multiple-choice self-report 
questionnaire, one of the widely used instruments for measuring the severity of 
depression. This questionnaire is designed as a measure of severity of depressive 
symptoms, not as a diagnostic instrument. In the 21 items the most common depressive 
symptoms (e.g. sad mood, pessimism, failure, dissatisfaction, guilt, crying, irritability, 
social withdrawal, inability to resolve, insomnia, appetite loss, etc.) are evaluated. 
Participants are asked to make ratings on a four-point scale, where a higher score 
correlates with more severe depression. The total value of the BDI can range from 0 to 




accepted thresholds. Values below 11 points are considered normal. Values between 11 
and 17 points are regarded as a mild to moderate expression of depressive symptoms. 
Values of 18 and more are considered as a clinically relevant depression (202). 
3.1.1.3. Hamilton Anxiety Scale 
HAM-A was evaluated by the examiner. This questionnaire was one of the first rating 
scales developed to measure the severity of anxiety symptoms, and is still widely used 
today in both clinical and research settings. The scale consists of 14 items, each defined 
by a series of symptoms, and measures both psychic anxiety (mental agitation and 
psychological distress) and somatic anxiety (physical complaints related to anxiety). 
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 
0–56, where <17 indicates mild severity, 18–24 mild to moderate severity and 25–30 
moderate to severe (203). 
3.1.2. Clinical measurements 
3.1.2.1.Arterial stiffness recordings 
Measurements were performed in a temperature-controlled room in supine position, on 
the day of blood sampling, prior to it, between 7:00 and 8:00 a.m. Patients were asked 
to refrain from eating, smoking, and caffeine containing drinks in the morning of the 
procedure, but to take their regular antihypertensive medication. Upon arrival after 5 
minutes rest, two brachial blood pressure measurements were taken on each arm in the 
sitting position with a validated oscillometric blood pressure device (Omron M3). The 
mean value of the higher side was further taken into calculation as brachial systolic and 
diastolic blood pressures (SBPB and DBPB) and heart rate. Brachial pulse pressure 
(PPB) was also calculated from these data. Next, subjects were equipped with arterial 
stiffness measurement device and then rested in the supine position for approximately 
15 minutes before being measured. Arterial stiffness parameters were evaluated with the 
gold-standard tonometric method (PulsePen, DiaTecne, Milan, Italy) (204). This 
method provides estimates of PWV and in which cSBP, cPP and pulse pressure 
amplification (PPAmp) can be calculated. Aix, a widely used wave reflection parameter, 
can also be measured by automatic identification of the “first shoulder” (inflection 
point) of the averaged carotid pulse signal by the PulsePen software. This index is 




and calculated as a percentage. In these calculations, brachial blood pressure values 
measured in the supine position were used, which were required for calibration after 
each (carotid or femoral) pulse wave detection. In each subject, two sequences of 
arterial stiffness measurements were performed and their mean used for statistical 
analysis. In the PWV calculations, 80 % of the carotid-femoral distance was used, 
according the most recent recommendation guideline (112). The intra- and interobserver 
variability of PWV measurements obtained by the PulsePen device in hypertensive 
patients was 4.6 and 6.3 %, respectively. Since PulsePen calculates pressures based on 
brachial diastolic blood pressure calibration, the calculated central diastolic blood 
pressure is identical to the brachial diastolic blood pressure assessed in the supine 
position (204). 
3.1.2.2. Measurement of serum BDNF concentrations 
Peripheral blood samples of patients were collected in anticoagulant-free tubes, right 
after the measurement of arterial stiffness. After centrifugation at 3600 revolutions per 
minute (rpm) for 6 minutes, the serum was stored at -20 °C. SeBDNF was measured 
using commercially available sandwich enzyme-linked immunosorbent assay (R&D 
Systems, Minneapolis MN, USA) according to the manufacturer’s protocol, and 
seBDNF level was determined in pg/ml. 
3.1.3. Statistical analysis 
Differences in variables between controls and DOM patients were analyzed using 
unpaired Student’s t-tests or Mann-Whitney rank-sum tests for data failing tests of 
normality. Blood pressure medications were calculated and compared using equivalent 
doses, differences were analysed with unpaired Student’s t-tests or Mann-Whitney rank-
sum tests. Data were expressed as mean±SEM and medians, significance was accepted 
at p<0.05. Statistical analysis was performed using the SigmaStat for Windows Version 
3.5 (SPSS) program package. 
3.2. Study 2: patients and methods in the study exploring the association of 
affective temperaments with blood pressure and arterial stiffness in 
hypertensive patients 
The difference in patient selection compared to the first study was that in the second 




more than 3 months) hypertension were investigated from three primary care practices 
in Budapest. In this study a total of 173 subjects were included. Moderate use of the 
anxiolytic alprazolam (less than 0.5 mg/day) was not a restrictive criterion. All of the 
patients of Study 1 were also involved. 
The methods regarding to the questionnaires and arterial stiffness measurement were the 
same like in the first study, but seBDNF was not investigated. 
3.2.1. Statistical analysis 
Normality of continuous parameters was tested with the Kolmogorov-Smirnov test. 
Pearson correlation coefficients were calculated to study the relationship between 
affective temperament scores and demographic, hemodynamic or arterial stiffness 
parameters. Multiple linear regression analysis was used to study the determinants of 
these hemodynamic or arterial stiffness parameters which were associated in univariate 
analysis with affective temperaments. Based on literature data, sex differences in the 
association between affective temperaments and the studied hemodynamic or arterial 
stiffness parameters (43) were expected, and therefore sex and its interaction with the 
given affective parameter was included into all regression models and where an 
interaction was found, such interaction was further studied. Descriptive data were 
expressed as mean±SD or median with interquartile ranges or percentages. A two-sided 
p<0.05 was considered to be significant. SPSS 13.0 for Windows was used for all 
calculations. 
3.3. Study 3: patients and methods in the study measuring serum BDNF levels 
in a hypertensive and a control population to discover the associations of 
BDNF with affective temperaments, depression, anxiety and arterial 
stiffness 
The difference in patient selection compared to the first study was that in the third 
cross-sectional study chronic (>12 months medication) well-controlled or grade 1 
consecutive hypertensive patients (HT) and age-matched healthy controls (CONT) were 
involved from three primary care practices in Budapest. In this study a total number of 
183 patients were investigated: 151 HT and 32 CONT. Moderate use of the anxiolytic 
alprazolam (less than 0.5 mg/day) was not a restrictive criterion. All of the chronic 




of consent was the only exclusion criterion. Data of the subjects were analysed for the 
relationship between the seBDNF level, routine laboratory parameters, affective 
temperaments, anxiety, depression, and arterial stiffness parameters.  
The methods were the same like in Study 1.  
3.3.1. Statistical analysis 
Normality of the parameters was tested with the Kolmogorov–Smirnov test. Descriptive 
characteristics, laboratory, arterial stiffness parameters and TEMPS-A, BDI, HAM-A 
scores were compared between CONT and HT groups using unpaired Student’s t-tests 
or Mann-Whitney rank sum test for data failing tests of normality. The equality of 
variances was studied with Levene’s test. Pearson correlation coefficients were 
calculated to study the relationship between seBDNF and all other factors measured. 
Hierarchic linear regression analysis was used to study the determinants of seBDNF in 
the whole population with a stepwise entry of variables with either previously described 
association with seBDNF or with a significant univariate correlation with seBDNF in 
the present data set. As a bidirectional association can be hypothesized between 
affective temperaments and hypertension (88), predetermined interaction analysis was 
performed to investigate moderation between hypertension and affective temperament 
scores on seBDNF level. Data were expressed as mean±SD or mean with interquartile 







4.1. Study 1: results of hemodynamic, arterial stiffness and serum BDNF levels 
in hypertensive patients with or without dominant affective temperaments 
In this cross-sectional case-control study well-treated chronic (>12 months medication) 
hypertensive patients were investigated. Out of the 29 DOM four patients declined to 
further participate in our study and one died 3 days prior to the planned arterial stiffness 
measurement. The arterial stiffness and BDNF of altogether 48 hypertensive patients 
was evaluated: 24 DOM and 24 control subjects matched in age, gender and presence of 
diabetes. Among the DOM patients, six subjects were found to have a depressive, five 
an irritable and four an anxious dominant temperament. In the other patients, 
combinations of dominant temperaments were present: three patients had cyclothymic 
and depressive, two had cyclothymic and irritable, two had cyclothymic, depressive and 
anxious, one had cyclothymic, irritable and anxious temperaments and one patient was 
dominant for cyclothymic, irritable, anxious and depressive affective temperaments. No 
patient with a dominant hyperthymic temperament was found in our cohort. 
Comparing the control and DOM patients for statistical differences baseline 
demographic, anthropometric and laboratory parameters and the used CV medications 





Table 2. Baseline demographic, anthropometric and laboratory parameters and the used 
cardiovascular medication of the patients. 
The values are means±SEM or medians (quartiles). DOM: patients with dominant affective 
temperament; AC: abdominal circumference; BMI: body mass index; CKD-EPI GFR: 
glomerular filtration rate assessed by the chronic kidney disease epidemiology collaboration 
glomerular filtration rate equation; BDNF: brain-derived neurotrophic factor; ARBs: 
angiotensin II receptor blockers. The groups were compared for differences by using Student’s 
t-test or the Mann–Whitney rank-sum for data failing tests of normality. *p<0.05 compared with 
controls. 
 
 Control DOM 
N (male:female) 24 (9:15) 24 (9:15) 
Age (year) 63.7±2.54 64.3±2.52 
Body height [cm] 164.5±1.51 166±2,06 
Body weight [kg] 76.3±2.66 81±3.34 
AC [cm] 101.5±4.1 102±5.5 
BMI [kg/m2] 28.2 (26-31.2) 29.8 (24.4-34.6) 
Glucose [mmol/l] 5.36 (5.03-6.07) 5.7 (4.94-6.63) 
CKD-EPI GFR [mmol/l] 77.5 (62.5-86) 78.5 (60.8-90) 
Uric acid [µmol/l] 309.3±15.26 321.6±16.82 
Cholesterol [mmol/l] 5.48±0.22 5±0.35 
Triglyceride [mmol/l] 1.36 (1.08-2.18) 1.82 (0.99-2,15) 
BDNF [pg/ml] 27290 (24200-30350) 20100 (14740-27110)* 
ACE-inhibitors [n (%)] 13 (54.2) 13 (54.2) 
ARBs  9 (37.5) 5 (20.8) 
Calcium-channel blockers  11 (45.8) 11 (45.8) 
Beta-blockers 12 (50) 18 (75)* 
Diuretics 11 (45.8) 11 (45.8) 
Antiplatelet medication 8 (33.3) 11 (45.8) 
 
SeBDNF levels were lower in DOM patients. Compared with controls, beta-blockers 




(0.63-6.88) mg, calculated for bisoprolol, respectively, p<0.05]. No differences were 
found in the mean duration of hypertension among controls and DOM patients [10.5 (4-
15.8) vs. 12 (6.5-17.8), p=0.238, respectively]. No differences were found among the 
groups studied in smoking habits and in the frequency of physical training (data are not 
shown). 
Table 3 represents the differences in the five affective temperaments and in the BDI and 
HAM-A scores. Compared with controls, in DOM patients depressive, cyclothymic, 
irritable and anxious scores were higher, while hyperthymic scores were equal. Both 
BDI and HAM-A scores were markedly higher in DOM patients than in the controls. 
Table 3. TEMPS-A scores of affective temperaments, BDI and HAM-A scores. 
DOM: patients with dominant affective temperament; TEMPS-A: The Temperament Evaluation 
of Memphis Pisa, Paris and San Diego questionnaire; BDI: Beck Depression Inventory; HAM-
A: Hamilton Anxiety Scale. The values are means±SEM and medians (quartiles). The groups 
were compared for differences by using Student’s t-test or the Mann-Whitney rank-sum for data 
failing tests of normality. *p<0.05 compared with controls. 
 
 Control N=24 DOM N=24 
Depressive 6 (4.25-8.75) 12.5 (7-13.75)* 
Cyclothymic 3 (1-5) 9.5 (7-13.75)* 
Hyperthymic 12.13±0.73 10.46±0.99 
Irritable 2 (1-4.75) 9.5 (5-11)* 
Anxious 5.08±0.81 14.67±0.88* 
BDI 5 (2-7.75) 14.5 (8.5-19.75)* 
HAM-A 7±1.27 16.67±1.68* 
 
Brachial and central hemodynamic and arterial stiffness parameters are shown in Table 
4. Brachial systolic and both brachial and central diastolic and mean blood pressures 






Table 4. Brachial and central hemodynamic and arterial stiffness parameters.  
The values are means±SEM and medians (quartiles). DOM: patients with dominant affective 
temperament; HR: heart rate; SBPB: systolic brachial blood pressure; DBPB: diastolic 
brachial blood pressure; MBPB: mean brachial blood pressure; PPB: brachial pulse pressure; 
cSBP: central systolic blood pressure; cDBP: central diastolic blood pressure; cMBP: central 
mean blood pressure; cPP: central pulse pressure; PWV: pulse wave velocity; AIx: 
augmentation index. The groups were compared for differences by using Student’s t-test or the 
Mann-Whitney rank-sum for data failing tests of normality. *p<0.05 compared with controls. 
 
 Control N=24 DOM N=24 
HR [1/min] 66±1.25 63.1±1.17 
SBPB [mmHg] 130.8 (122-137.1) 122.6 (116.4-129.7)* 
DBPB [mmHg] 71.2±1.5 66.6±1.71* 
MBPB [mmHg] 91.9±1.53 86.6±1.94* 
PPB [mmHg] 59.3 (49.4-67.5) 54.3 (50.1-61.9) 
cSBP [mmHg] 124.3 (113.5-136.4) 117 (112.6-131.7) 
cDBP [mmHg] 71.2±1.5 66.5±1.71* 
cMBP [mmHg] 94.1±1.55 88.9±1.96* 
cPP [mmHg] 50.6 (44.5-66.6) 52.3 (48.8-1.72) 
PWV [m/sec] 9.32 (8.02-11.25) 8.74 (8.32-9.87) 
AIx (%) 16.04±2.24 14.54±2.66 
 
4.2. Study 2: results of affective temperaments’ association with blood pressure 
and arterial stiffness in hypertensive patients 
Baseline demographic and laboratory parameters, current medication, TEMPS-A, BDI 
and HAM-A scores, central blood pressure and arterial stiffness parameters are 






Table 5. Baseline demographic, laboratory, hemodynamic and arterial stiffness parameters 
and the scores of the different questionnaires.  
Data are presented as mean±SD or mean (interquartile range). Categorical parameters are 
presented as n (%).CV diseases: cardiovascular diseases; BMI: body mass index; GFR-EPI: 
glomerular filtration rate assessed by the chronic kidney disease epidemiology collaboration 
glomerular filtration rate equation; ACE: angiotensin converting enzyme; ARB: angiotensin II 
receptor blocker; TEMPS-A: Temperament Evaluation of Memphis Pisa, Paris and San Diego 
questionnaire; BDI: Beck Depression Inventory; HAM-A: Hamilton Anxiety Scale; SBPB: 
systolic brachial blood pressure; DBPB: diastolic brachial blood pressure; PPB: brachial pulse 
pressure; cSBP: central systolic pressure; cPP: central pulse pressure; PPAmp: pulse pressure 
amplification; PWV: carotid-femoral pulse wave velocity; AIx: augmentation index. 
 
N (male/female) 173 (68/105) 
Age (years) 63 (53-70) 
Duration of hypertension (year) 9 (3-16) 
Diabetes [n (%)] 38 (22) 
CV disease [n (%)] 26 (15) 
Current smokers [n (%)] 33 (19.1) 
Body height [cm] 168 (160-174) 
Body weight [kg] 80 (70-90) 
BMI [kg/m2] 27.8 (25.3-31.2) 
Blood glucose [mmol/l] 5.6 (5.1-6.6) 
GFR-EPI [ml/min/1.73m2] 81.9 (67.9-90) 
Uric acid [µmol/l] 324.2±79.6 
Cholesterol [mmol/l] 5.2±1.1 
Triglyceride [mmol/l] 1.4 (1.1-2.1) 
Medications 
ACE-inhibitors 116 (67.1) 
ARBs 35 (20.2) 
Calcium channel blockers 88 (50.9) 
Beta-blockers 98 (56.6) 
Diuretics 72 (41.6) 




Statins 57 (33.4) 
Alprazolam 23 (13.3) 
TEMPS-A, BDI, HAM-A scores 
Depressive 6 (4-9) 
Cyclothymic 3 (1-5) 
Hyperthymic 12 (9-14) 
Irritable  3 (2-6) 
Anxious  4 (2-9) 
BDI 5 (2-9) 
HAM-A 5 (2-10) 
Hemodynamic and arterial stiffness parameters 
Heart rate [1/min] 70.8 (64.8-78) 
SBPB [mmHg] 133.5±12 
DBPB [mmHg] 75.6±9.2 
PPB [mmHg] 54.2 (47.1-62.4) 
cSBP [mmHg] 123 (113.2-130.8) 
cDBP [mmHg] 70.5±8 
cPP [mmHg] 51 (43.5-60.4) 
PPAmp 1.07 (1.00-1.13) 
PWV 8.7 (7.7-9.9) 
AIx 15.5 (8.5-25.2) 
 
Table 6 lists the hemodynamic or arterial stiffness parameters and their significant 
correlations for which affective temperaments were also significantly associated. Table 
6 also shows those variables which were not significantly correlated with outcome 
variables, but were entered into the final multiple regression models. Partial correlations 
corrected for age and sex are also demonstrated. Although, in univariate models, 
affective temperament scores were associated with hemodynamic or arterial stiffness 
parameters in many cases, however, upon further correction for age and sex, certain 
temperaments failed to be independent covariables of these parameters, notably irritable 
temperament score of brachial systolic blood pressure (p=0.056) and depressive 




Table 6. Variables with significant Pearson correlations and variables entered in the final 
multiple linear regression model showing the independent predictors of brachial systolic 
blood pressure, pulse wave velocity and augmentation index.  
Partial Ra: partial correlation coefficient, corrected for age and sex; SBPAmp: systolic blood 
pressure amplification. See Table 5 for the rest of abbreviations. 
 
Variable R P Partial Ra P 
Brachial systolic blood pressure     
Sex -0.155 0.048 - - 
Cholesterol [mmol/l] -0.179 0.022 -0.072 0.365 
DBPB [mmHg] 0.428 <0.001 0.474 <0.001 
PPB [mmHg] 0.484 <0.001 0.489 <0.001 
cSBP [mmHg] 0.591 <0.001 0.598 <0.001 
cDBP [mmHg] 0.284 <0.001 0.329 <0.001 
cPP [mmHg] 0.461 <0.001 0.471 <0.001 
SBPAmp [mmHg] 0.281 <0.001 0.300 <0.001 
PWV [m/s] 0.261 <0.001 0.265 0.001 
TEMPS-A Irritable 0.171 0.030 0.151 0.056 
TEMPS-A Cyclothymic  0.167 0.032 0.171 0.030 
Age 0.037 0.630 - - 
BDI 0.006 0.932 0.026 0.738 
HAM-A 0.062 0.430 0.082 0.299 
Alprazolam 0.007 0.932 0.018 0.820 
Pulse wave velocity     
Age [year] 0.544 <0.001 - - 
Duration of hypertension [year] 0.250 <0.001 -0.019 0.808 
CV disease 0.241 0.001 0.095 0.218 
Blood glucose [mmol/l] 0.213 0.005 0.128 0.097 
GFR-EPI [ml/min/1.73m2] - 0.308 <0.001 -0.112 0.154 
SBPB [mmHg] 0.260 <0.001 0.265 0.001 
PPB [mmHg] 0.507 <0.001 0.408 <0.001 




cPP [mmHg] 0.478 <0.001 0.338 <0.001 
TEMPS-A Irritable 0.156 0.040 0.173 0.025 
TEMPS-A Anxious  0.157 0.039 0.156 0.043 
BDI 0.164 0.031 0.104 0.176 
HAM-A 0.173 0.024 0.179 0.021 
Sex -0.143 0.059 - - 
Alprazolam 0.121 0.111 0.078 0.308 
Augmentation index     
Age [year] 0.203 <0.001 - - 
Sex 0.347 <0.001 - - 
Current smoking [p/y] 0.159 0.038 0.175 0.023 
Body height [cm] 0.247 0.001 -0.021 0.791 
Heart rate [1/min] -0.195 0.013 -0.151 0.058 
Uric acid [µmol/l] -0.255 <0.001 -0.163 0.035 
TEMPS-A Depressive 0.168 0.027 0.041 0.595 
TEMPS-A Hyperthymic -0.215 0.004 -0.158 0.034 
BDI 0.054 0.478 -0.097 0.210 
HAM-A 0.040 0.605 -0.057 0.467 
Alprazolam 0.048 0.525 -0.023 0.768 
 
Table 7 demonstrates that cyclothymic temperament score was an independent covariate 
of brachial systolic blood pressure and hyperthymic temperament of AIx after 
adjustment for further relevant confounders. In the final model adjusted for all potential 
confounders, a one-unit increase in cyclothymic score was associated with 0.529 (95% 
CI: 0.019-1.040) mmHg higher brachial systolic blood pressure while a one-unit 






Table 7. Predictive value of cyclothymic affective temperament scores on brachial systolic 
blood pressure and of hyperthymic affective temperament scores on augmentation index in 
the various models.  
The progressive involvement of variables into models and other significant predictors in the 
final models are also demonstrated. B: Beta; SE: standard error; Std. Beta: Standardized Beta; 
Adj. R2: adjusted R2; Cyclothymic temp. score: cyclothymic affective temperament score; 
DBPB: brachial diastolic blood pressure; BDI: Beck Depression Inventory; HAM-A: Hamilton 
Anxiety Scale; Alp: patients regularly using alprazolam; Hyperthymic temp. score: hyperthymic 
affective temperament score 
 
Model B SE Std. Beta P R2 
Brachial systolic blood pressure 
Model 1 
    
0.029 
Cyclothymic temp. score  0.539 0.247 0.171 0.030 
 
Model 2: Model 1+Age+Sex 
    
0.059 
Cyclothymic temp. score  0.568 0.245 0.180 0.0216 
 
Model 3: Model 2+DBPB  
    
0.264 
Cyclothymic temp. score  0.464 0.218 0.147 0.034 
 
Model 4: Model 
3+Triglyceride+Cholesterol      
0.302 
Cyclothymic temp. score  0.431 0.214 0.137 0.045 
 
Model 5: Model 4+ BDI+HAMA-A+Alp 
    
0.310 
Cyclothymic temp. score  0.529 0.258 0.167 0.042 
 
Age 0.177 0.076 0.181 0.021 
 
DBPB 0.629 0.094 0.482 <0.001 
 




    
0.052 
Hyperthymic temp. score  -0.733 0.255 -0.227 0.004 
 
Model 2: Model 1+Age+Sex 
    
0.203 
Hyperthymic temp. score -0.509 0.239 -0.158 0.034 
 
Model 3: Model 2+Smoking  
    
0.230 





Model 4: Model 3+Heart rate 
    
0.256 
Hyperthymic temp. score  -0.555 0.234 -0.172 0.019 
 
Model 5: Model 4+Uric acid 
    
0.272 
Hyperthymic temp. Score -0.523 0.232 -0.162 0.026 
 
Model 6: Model 5+BDI+HAM-A+Alp 
    
0.288 
Hyperthymic temp. score -0.612 0.243 -0.189 0.013 
 
Age 0.297 0.087 0.258 0.001 
 
Sex 7.445 2.189 0.264 0.001 
 
Smoking 6.159 2.610 0.176 0.020 
 
Heart rate -0.209 0.098 -0.152 0.035 
 
 
With regard to the association between PWV and irritable temperament score, the 
correlation still remained significant (p=0.012) after adjustment for age, sex, brachial 
systolic blood pressure, GFR-EPI, blood glucose and duration of hypertension, although 
became nonsignificant after further adjustment for BDI and HAM-A scores and the use 
of alprazolam (p=0.078). The same results were also found for anxious temperament 
score and PWV: the significant association (p=0.043) that was present after adjustment 
for age, sex, brachial systolic blood pressure, GFR-EPI, blood glucose and duration of 
hypertension disappeared after further adjustment for BDI and HAM-A scores and the 
use of alprazolam (p=0.475).  
When studying the interaction between cyclothymic temperament score and sex in 
predicting brachial systolic blood pressure, a significant association was found 
(p=0.025, Fig. 7a). There was a positive association between cyclothymic temperament 
score and brachial systolic blood pressure in men (B=1.012, SE=0.392, p=0.011) which 
was absent in women (B=0.294, SE=0.311, p=0.346). After adjustment for age, brachial 
diastolic blood pressure, cholesterol and triglycerides, this interaction became 
nonsignificant (p=0.090; in men B=0.680, SE=0.347, p=0.052 and in women B=0.279, 
SE=0.272, p=0.307). 
There was also a significant interaction between irritable temperament score and sex in 
predicting PWV (p=0.021). There was a positive association between irritable 




in women (B=0.076, SE=0.064, p=0.235) (Fig. 7b). After adjustment for age, blood 
glucose, brachial systolic blood pressure and GFR-EPI, the interaction p-value was 
attenuated (p=0.037), however the strength of the association remained similar (in men 
B=0.104, SE=0.050, p=0.039 and in women B=0.082, SE=0.052, p=0.116). The 
interaction became nonsignificant (p=0.168) after further adjustment for BDI and 
HAMA-A scores and the regular use of alprazolam (in men B=0.091, SE=0.051, 
p=0.078 and in women B=0.054, SE=0.061, p=0.375). 
Similarly to irritable temperament, there was also a significant interaction between the 
anxious temperament score and sex in predicting PWV (p=0.023). There was a positive 
association between anxious temperament score and PWV in men (B=0.106, SE=0.043, 
p=0.015) which was absent in women (B=0.047, SE=0.036, p=0.189) (Fig. 7c). After 
adjustment for age, blood glucose, brachial systolic blood pressure and GFR-EPI, the 
interaction p-value was attenuated (p=0.046), however the strength of the association 
remained similar in men (in men B=0.088, SE=0.036, p=0.017 and in women B=0.021, 
SE=0.030, p=0.484). The interaction became nonsignificant (p=0.135) after further 
adjustment for BDI and HAMA-A scores and the regular use of alprazolam (in men 
B=0.070, SE=0.039, p=0.075 and in women B=-0.017, SE=0.037, p=0.656). An 
interaction with borderline significance (p=0.052) was found between sex and 
hyperthymic affective temperament in predicting Aix. An inverse association was found 
in women (B=-0.754, SE=0.326, p=0.022) which was absent in men (B=-0.305, 
SE=0.370, p=0.411) (Fig. 7d). This interaction became weaker (p=0.064) after further 
adjustment for age, smoking, heart rate and uric acid (in women B=-0.678, SE=0.312, 






Fig. 7. The interaction between sex and different affective temperaments in the prediction of 
the studied variables.  
a: cyclothymic temperament score and brachial systolic blood pressure; b: irritable 
temperament score and pulse wave velocity; c: anxious temperament score and pulse wave 
velocity; d: hyperthymic temperament score and augmentation index. Continuous lines with 
squares represents females, while broken lines with rhombs represent males. Error bars 
represent±1 standard errors. *p<0.05 
4.3.Study 3: results of serum BDNF levels in hypertensive patients and healthy 
controls; associations of serum BDNF with affective temperaments, 
depression, anxiety and arterial stiffness 
Baseline demographic and laboratory parameters, current medication, TEMPS-A, BDI, 
and HAM-A scores, central blood pressure, and arterial stiffness parameters as well as 








compounds was 2 (IQR: 2–3). Differences between CONT and HT were found in body 
weight and BMI, serum glucose, cholesterol, LDL and HDL, BDI and HAM-A scores, 
in the brachial and central systolic blood pressure and the brachial pulse pressure. 
SeBDNF was elevated in HT (Table 8). 
Table 8. Demographic, laboratory, hemodynamic and arterial stiffness parameters; subjects’ 
autoquestionnaires scores.  
Continuous data are presented as mean (SD) or mean (interquartile range). *p<0.05. 
Categorical parameters are presented as % (n). BMI: body mass index; ARBs: angiotensin II 
receptor blockers; CCBs: calcium channel blockers; SBPB: systolic brachial blood pressure; 
DBPB: diastolic brachial blood pressure; PPB: brachial pulse pressure; cSBP: central systolic 
blood pressure, cDBP: central diastolic blood pressure, cPP: central pulse pressure, PWV: 
pulse wave velocity; AIx: augmentation index; TEMPS-A: Temperament Evaluation of 
Memphis, Pisa, Paris and San Diego Autoquestionnaire; BDI: Beck Depression Inventory; 
HAM-A: Hamilton Anxiety Scale. 
 
  CONT HT 
N (male:female) 32 (12:20) 151 (58:93)  
Age [year] 61.1 (55.9-70.5) 63.7 (57-71) 
Duration of hypertension [year]  - 11 (5-18) 
Diabetes [n (%)] - 38 (25.2) 
Cardiovascular disease [n (%)] - 21 (13.9) 
Current smoker [n (%)] 3 (9.4) 22 (14.6) 
Body height [cm] 168.8±8.6 166.8±8.6 
Body weight [kg] 72.4±12.1 79.7±14* 
BMI [kg/m2] 24.5±5.4 28.6±4.5* 
Platelet count [G/l] 239.6 (215-277) 257 (209.7-303.2) 
Glucose [mmol/l] 5.36 (4.88-5.81) 6.15 (5.11-6.7)* 
GFR-EPI [ml/min/1.73m2] 79.7 (69.5-82.2)  77.9 (67-90)  
Uric acid [µmol/l] 313.7±11.6 318.4±6.3  
Cholesterol [mmol/l] 5.57 (4.97-6.05) 5.18 (4.37-5.98)* 
LDL [mmol/l] 3.46±0.91 3.07±1.04* 




Triglyceride [mmol/l] 1.16 (0.75-1.43) 1.67 (1.08-2.06)* 
Regular medication [n (%)]:     
ACE inhibitors - 93 (61.5) 
ARBs - 34 (22.5) 
CCBs - 67 (44.4) 
Beta blockers - 87 (57.6) 
Diuretics - 68 (45) 
Antiplatelet drugs - 44 (29.1) 
Statins 5 (15.7) 54 (35.7) 
Alprazolam - 23 (15.2) 
TEMPS-A:     
Depressive 5.9 (4-7) 7.1 (5-9) 
Cyclothymic 2.9 (0-4) 3.9 (1-6) 
Hyperthymic 11.2±4 11 (4.2)  
Irritable 3.2 (2-4) 4.3 (2-6)  
Anxious 4.1 (1-6) 6.3 (2-9)  
BDI 2.8 (1-4) 6.3 (3-9)* 
HAM-A 3.9 (1-6) 7.4 (2-10)* 
Heart rate [1/min] 72.1 (66.6-78.2) 72.7 (64.1-77.2) 
SBPB [mmHg] 125.5±9.3 133.0±12.3* 
DBPB [mmHg] 72±6.4 75±9  
PPB [mmHg] 51.5 (46.4-56.7) 56.7 (46.4-63)* 
cSBP [mmHg] 117 (111.2-122.3) 124.1 (113.4-131.6)* 
cDBP [mmHg] 67.1±7 69.8±8.2 
cPP [mmHg] 49.9 (43.2-54.5) 54.3 (45.2-61) 
Pulse pressure amplification 1.08 (1.03-1.14) 1.07 (0.98-1.12)  
PWV [m/sec] 8.6 (7.4-9.2) 9.3 (7.8-10)  
AIx (%) 13.2 (5.75-23) 17.8 (8.5-25.1)  
Serum BDNF (pg/ml) 21202.6±6045.5 24880±8279* 
 
In the analysis of simple correlations, the following parameters were found to be 




cholesterol (r=0.194, p=0.009), LDL (r=0.208, p=0.015) and HDL level (r=0.204, 
p=0.006), platelet count (r=0.188, p=0.011), pulse pressure amplification (r=0.157, 
p=0.037), and hyperthymic temperament score (r=0.189, p=0.010). Tendencies of 
inverse correlations were found with the presence of diabetes or the use of alprazolam, 
but these were not significant (r=-0.114, p=0.12 and r=-0.103, p=0.16, respectively).  
Table 9 demonstrates the results of hierarchical linear regression models. In the final 
model adjusted for all potential confounders, one unit increase in the hyperthymic score 
was associated with a 405.8 pg/ml higher seBDNF and the presence of hypertension 
with a 6121.2 pg/ml higher seBDNF. We found an interaction (p=0.002) between 
hypertension and hyperthymic temperament score on seBDNF in the whole study 
population: there was no significant association between hyperthymic score and 
seBDNF in CONT (p=0.545) and a unit increase in hyperthymic score was associated 
with a 533.3 (95 %CI 241.3–825.3) pg/ml higher seBDNF level in HT (p<0.001). The 
different impact of hyperthymic score in seBDNF in HT and CONT is shown in Fig. 8. 
Table 9. The predictive values of hypertension and hyperthymic affective temperament score 
on serum BDNF level in different models evaluated with linear regression analysis in the 
whole study population (n=183).  
B: Beta; Hyperthymic temp. score: hyperthymic affective temperament score; BDI: Beck 
Depression Inventory; HAM-A: Hamilton Anxiety Scale; Alp: patients regularly using 
alprazolam; PPamp: pulse pressure amplification. 
 
Models B Std. Error Std. Beta p R2 
Model 1 0.036 
Hypertension 4149.6 1681.8 0.190 0.015 
Model 2 0.050 
Hyperthymic temp. score 410.7 140 0.225 0.004 
Model 3 
Hypertension+ Hyperthymic temp. score 0.089 
Hypertension 4310.3 1640.6 0.198 0.009 
Hyperthymic temp. score 422.2 137.6 0.231 0.003 




Hypertension 4365.1 1636.7 0.200 0.008 
Hyperthymic temp. score 449.8 138.1 0.246 0.001 
Model 5: Model 4+diabetes 0.132 
Hypertension 5161.4 1661.2 0.237 0.002 
Hyperthymic temp. score 459.4 136.6 0.251 0.001 
Model 6: Model 5+cholesterol+HDL 0.158 
Hypertension 5954.7 1685.5 0.273 0.001 
Hyp. temp. score 430.6 136.8 0.235 0.002 
Model 7: Model 6+platelet number 0.176 
Hypertension 5540 1688.4 0.254 0.001 
Hyperthymic temp. score 431.9 135.8 0.236 0.002 
Model 8: Model 7+BDI+HAMA-A+Alp 0.191 
Hypertension 6167 1748.4 0.283 0.001 
Hyperthymic temp. score 408 140.9 0.223 0.004 
Model 9: Model 8+PPamp. 0.202 
Hypertension 6121.2 1742.3 0.281 0.001 







Figure 8. Association between serum BDNF level and hyperthymic affective temperament 
score in hypertensive patients (HT) and in controls (CONT). 








5.1. Study 1: arterial stiffness and serum BDNF levels in hypertensive patients 
with or without dominant affective temperaments 
Our study was performed on hypertensive patients with dominant cyclothymic, irritable, 
depressive or anxious affective temperaments without the history or any present 
psychiatric medications. We found that DOM patients had higher anxiety and 
depression scores and lower seBDNF level. DOM patients had similar levels of arterial 
stiffening with a lower peripheral and central blood pressure compared with 
hypertensive controls. 
As affective temperaments are tightly related to affective disorders, it is not surprising, 
that in our cohort DOM patients also had higher depression and anxiety scores. These 
results suggest the importance of a joint evaluation of affective temperaments together 
with depression and anxiety even in those hypertensive patients who have no records of 
previous psychiatric diseases or any present antidepressant or anxiolytic medication. 
Although the presence of dominant affective temperaments frequently precedes the 
onset of minor and major affective illness which are related with CVD (49), and 
therefore screening for their presence would be an important target in the prevention 
and early intervention of CV disorders as well, only few studies are available which aim 
to investigate the role of affective temperaments in the development and risk of 
different CV risk factors or CVDs. Patients with depressive temperament were found to 
have worse metabolic control in type-2 diabetes (205), cyclothymic, irritable and 
anxious temperaments showed affinity to obesity (206), while anxious temperament was 
associated with an increased likelihood for the presence of prediabetic condition (207). 
As already mentioned above, recently Eőry et al., evaluating the role of affective 
temperaments in primary hypertension, found a significant association with the 
dominant cyclothymic temperament (88), and showed a connection between 
cyclothymic temperament and the history of acute coronary events (89).  
In our first study, patients with dominant affective temperaments had lower brachial and 
central diastolic and mean blood pressure values compared with controls. It is well 




(208). In the study of Staessen et al. 15693 patients with isolated systolic hypertension 
in eight trials were followed up for 3.8 years. Independently of systolic blood pressure, 
diastolic blood pressure was found to be inversely correlated with total mortality, 
focusing on the role of pulse pressure as a risk factor (208). Parallel to the findings of 
Eőry et al. (88, 89), this phenomenon of decreased blood pressure values might be more 
expressed in cyclothymic patients and would in this case suggest their increased 
susceptibility to CV complications. However, the clarification of this hypothesis 
requires further studies. 
As our DOM patients had higher depression score compared with control patients, one 
explanation of the decreased blood pressure might reflect the fact that lower blood 
pressure levels are often accompanied with a pronounced presence of depressive 
symptoms, and in follow-up studies symptoms of anxiety and depression predicted the 
development of lower blood pressure (209, 210). In case of a co-occurring onset of 
depression and hypotension, the pathophysiological mechanisms are considered to be 
the alterations in neurohormonal, immune and autonomic regulations (211). Whether 
only the increased depression per se caused the decreased blood pressure in our DOM 
patients, or another independent factor is also involved, is a question still to be 
answered. 
Most of the studies support the idea that antagonistic traits, depression and anxiety 
increase the probability of the development of CVDs (41, 212, 213), and data are also 
available with respect to arterial stiffness. In contrast to the findings of Tiemeier at al – 
that depression is associated with elevated arterial stiffness (160) – we found no 
difference in PWV or augmentation index between our DOM and control hypertensive 
patients. An explanation to this phenomenon can be that in the study of Tiermeier et al. 
the patients’ arterial stiffness was much higher, as the border of the lowest PWV 
quartile was 11.4 m/s. This suggests a very poor vascular status of those patients, while 
in our patients PWV values were much lower. 
In a study of Seldenrijk et al., depression and anxiety sensitivity and their association 
with arterial stiffening were evaluated. The authors found that out of these, only anxiety 
sensitivity was associated with arterial stiffness; however, they studied only the AIx, 




vessels, that can be dysfunctional in patients with anxiety (214, 215). It is also worth 
mentioning that the population of Seldenrijk et al. was much younger (46 years) 
compared with ours and only 18% of the patients regularly took antihypertensive 
medication which suggests their better general resistance vessel function. Considering 
all these results we suppose that in older patients besides optimal vascular therapy, the 
deleterious effects of depression and anxiety for arterial stiffening can be attenuated, but 
in younger population without vascular medication the deleterious effects of anxiety can 
lead to detectable dysfunction of resistance vessels in comparison to healthy controls. 
In Study 1 seBDNF was also measured and we observed its decreased level in our DOM 
patients. As already mentioned, seBDNF was found to be lower in patients suffering 
from major depressive disorder (177), and also in increased CV risk, such as acute 
coronary syndrome and type 2 diabetes (193, 194). Taking these into consideration and 
the fact, that seBDNF is also decreased in some types of anxiety disorders (216), and in 
animal models the regulation of BDNF was suggested to contribute both to anxiety-like 
behavior and hypertension (217), a common background of BDNF level changes in 
psychopathology and CVDs might be assumed. Whether the decreased seBDNF in our 
hypertensive DOM patients is correlated with their higher depression and anxiety and 
bears any clinical relevance with respect to the CV outcome or not, further studies need 
to clarify. 
One explanation of our results can be described with the theory of “allostatic load”. The 
term allostatic load refers to a cumulative, multisystem view of the physiologic toll that 
is required for adaptation to stress. In mood disorders, especially in bipolar disorder 
allostatic load increases progressively as mood episodes occur over time (218). Among 
many mediators, neurotrophic factors such as decreased level of BDNF indicates 
allostatic load (219). Seeman et al. found in their longitudinal, community-based study 
that allostatic load may play a role in CV disorders (220) and there is evidence that 
reduction in allostatic load is associated with lower all-cause mortality, even in geriatric 
patients (221). As affective temperaments are the subclinical manifestations of minor 
and major mood disorders and we found decreased BDNF level in patients with 




well. According to this theory the increased CV risk could also be explained with the 
phenomenon of allostatic load. 
In our first study the depressive, cyclothymic, irritable and anxious temperaments or 
their combinations were investigated together. The neurobiological background of these 
temperaments seems to be at least partly common, as all were found to be associated 
with the 5-HTTLPR polymorphism of the serotonin transporter gene, namely the 
presence of the s allele, which is connected with decreased serotonin uptake of cells – 
mentioned already in chapter 1.2.4. (64). Moreover, the scales of depressive, anxious, 
cyclothymic and irritable temperaments were found to be closely associated in different 
populations suggesting real phenotypical connections beyond the similarities in the 
neurobiological background (54, 222). Whether the clustering of dominant 
temperaments has any pronounced clinical relevance above single dominant 
temperaments is another question to be answered. 
5.2. Study 2: association of affective temperaments with blood pressure and 
arterial stiffness in hypertensive patients 
In our second study we demonstrated for the first time that in chronic hypertensive 
patients cyclothymic temperament score is associated with brachial systolic blood 
pressure, while hyperthymic temperament score is independently related to the 
augmentation index after adjustment for potential confounders including severity of 
depression and anxiety and the use of alprazolam. Sex differences were also found in 
relation with brachial systolic blood pressure and cyclothymic temperament score, pulse 
wave velocity and irritable and anxious temperament scores and augmentation index 
and hyperthymic temperament score. 
Previous findings support our observations in our Study 2, that affective temperaments 
are associated with CV pathology (205-207). Our result regarding to cyclothymic 
temperament is in line with the previous findings in which dominant cyclothymic 
temperament demonstrated a significant association with the presence of hypertension 
(88) and with acute coronary events in a hypertensive patient population (89). 
An increasing cyclothymic temperament score was found herein to be associated with a 




can span from lethargy to eutonia, from pessimistic brooding to optimism, from 
hypersomnia to decreased need for sleep or from introverted self-absorption to 
uninhibited people-seeking (223). In contrast, subjects with hyperthymic temperament 
are cheerful, overoptimistic, overconfident as well as over-talkative and vigorous (223). 
While the hyperthymic temperament is associated with better quality of life (QOL), the 
cyclothymic temperament is conversely associated with worse QOL (223). Moreover, 
people with hyperthymic temperament can better cope with somatic problems (224), 
while cyclothymic disposition is related to a high somatic risk (225). Based on these 
results, we hypothesize that there is a likely differential impact of these two 
temperaments on vascular pathology, although prospective studies are required to 
confirm this hypothesis. 
There are existing data in the literature regarding the association between personality 
traits and arterial stiffening. In a study by Midei and Matthews, higher trait anxiety and 
hostility were associated with a higher PWV (226). In the Baltimore Longitudinal study 
of Aging, middle-aged adults with suppressed anger had elevated carotid arterial 
stiffness (227). In keeping with these studies, irritable and anxious affective 
temperament scores were found herein to be covariates of PWV after adjustment for 
age, sex, brachial systolic blood pressure, blood glucose, GFR-EPI and duration of 
hypertension. However, these associations became nonsignificant after further 
adjustment with severity of depression and anxiety and the use of alprazolam. Given 
that arterial stiffness is associated with depression and anxiety (160, 214), we can 
hypothesize that, similarly to the relationship between life stress and arterial stiffness 
(228), the association between anxious and irritable affective temperaments and PWV is 
partly mediated by severity of depressive and anxiety symptoms. 
Augmentation index is an accepted parameter of pulse wave analysis and a predictor of 
mortality in various pathological conditions (148, 155). AIx is associated with age, sex, 
body height, smoking and heart rate (229, 230), associations which were also 
reproduced in the present study. Furthermore, its predictive value was also confirmed 
by a meta-analysis: a 10% increase of AIx was associated with a relative risk of almost 
1.4 for all-cause mortality (231). On the other hand, Seldenrijk et al. also found that 




results of our second study indicate that hyperthymic affective temperament score is an 
independent covariable of AIx with higher scores being associated with better wave 
reflection and thus a preserved elasticity of the arteries. This suggests a protective role 
of hyperthymic temperament on CV pathology and emphasizes the potential of further 
evaluation of affective temperaments with wave reflection parameters. 
Significant interactions were also found in our second study between sex and 
cyclothymic temperament score in predicting brachial systolic blood pressure, between 
sex and irritable temperament as well as between sex and anxious temperament scores 
in predicting PWV, while the interaction between sex and hyperthymic temperament 
score in predicting AIx had borderline significance. These findings are consistent with 
the study of Williams et al., where trait anger was associated with elevated arterial 
stiffness in men, while in women the association was marginally significant (232). 
These results suggest that, similarly to the presence of sex differences in scoring in 
different affective temperament directions (43), sex differences are also present in the 
associations between affective temperament scores and brachial systolic blood pressure 
and arterial stiffness parameters. Additional studies are likely needed to specify these 
observed sex differences, including taking into consideration menopausal status or the 
use of hormone replacement therapy. 
Based on these findings we tried to deepen our knowledge about affective temperaments 
and CV risk. While Eőry et al. found that cyclothymic affective temperament showed a 
correlation with the diagnosis of chronic hypertension (88) and with the history of acute 
coronary events in hypertensive patients (89), we managed to find a more demonstrative 
association: brachial systolic blood pressure values and cyclothymic temperament score, 
as well as arterial stiffness and hyperthymic score are correlated in chronic hypertensive 
patients. In order to prove the role of affective temperaments in CV risk more 
objectively, we decided to evaluate the associations between different affective 
temperaments and the presence of coronary atherosclerosis among 200 patients, who 
were examined due to suspected coronary artery disease by coronary computed 
tomography angiography (CCTA). In this study, 39 subjects were found free of any 
coronary atherosclerosis (CCTA-), while the other 161 had coronary atherosclerosis 




subjects as compared to CCTA+ (13.1±3.0 vs. 11.5±4.6, p=0.010, respectively). 
Hyperthymic affective temperament score showed a significant independent, inverse 
relationship with coronary atherosclerosis (OR: 0.91 CI: 0.82–0.99, p=0.04). These 
results suggest that hyperthymic affective temperament is independently associated with 
the absence of coronary artery disease (CAD). It requires further research to delineate 
the mechanism mediating the effect of hyperthymia on better coronary artery health and 
establishing potential biochemical or behavioral factors, both of which could be 
exploited for prevention and treatment purposes (233). 
Based on our studies, another question arises: if affective temperaments have a role in 
the development of hypertension, is there a possible association between these 
temperaments and the age of hypertension onset? In our next cross-sectional study on 
353 hypertensive patients, the independent predictors of the age of hypertension onset 
were male sex (B=-4.57 [95%CI=-1.40–-7.74], p=0.005), smoking (B=-4.31 [-7.41–
-1.22], p=0.006) and positive family history (B=-6.84 [-10.22–-3.45], p<0.001). In 
women cyclothymic temperament score was an independent predictor of the initiation 
of hypertension (B=-0.83 [-1.54–-0.12], p=0.023), while this association was absent in 
men (B=0.26 [-0.71-1.23], p=0.595). So, besides traditional factors, cyclothymic 
affective temperament might also contribute to the earlier initiation of hypertension in 
women (234).  
As affective temperaments can be associated with the time of onset of hypertension, 
blood pressure values, arterial stiffness and CV risk, it can be hypothesized, that they 
influence the severity of hypertension. In order to prove it, we evaluated affective 
temperament scores hemodynamic and arterial stiffness parameters in healthy subjects 
(Cont), as well as in chronic well-treated (Chr), chronic resistant (Res) and white-coat 
(Wh) hypertensive patient populations. Among the 261 patients (148 Chr, 29 Res, 17 
Wh and 67 Cont subjects) as far as cyclothymic affective temperament scores was 
concerned, we found significant differences between the Cont, Chr and Res groups (2 
(0–4), 3 (1–5), 4 (3–8), respectively) with the highest score in Res (p<0.05 compared 
with Cont and Chr). Therefore, the evaluation of affective temperaments might be 
helpful in identifying high-risk subgroups of hypertensive patients, but of course, 




5.3. Study 3: serum BDNF levels in a hypertensive and a control population; 
associations of serum BDNF with affective temperaments, depression, 
anxiety and arterial stiffness.  
In our third study we demonstrated for the first time in the literature that in chronic 
hypertensive patients seBDNF is elevated, and hyperthymic affective temperament 
score, and the presence of hypertension are independent determinants of seBDNF level. 
In hypertensive patients the elevation of hyperthymic temperament score is associated 
with the elevation of seBDNF; however, this association is not present in healthy 
subjects. 
As the association between seBDNF level and CV morbidity and mortality have been 
proven (195, 196), we suppose that the observed BDNF elevation in hypertension can 
be part of a protective compensatory mechanism targeting peripheral neurons and 
vascular cells. BDNF has beneficial effects on the regulation of blood pressure, as it is 
involved not only in the development, but also in the survival of arterial baroreceptor 
system (236), and this NT is produced by vascular endothelial cells (186). In our study, 
the positive correlation with HDL and also with pulse pressure amplification, where 
higher values refer to better vascular conditions (237), also supports the plausible 
beneficial effect of BDNF in hypertension. 
Some of the findings of our study were already described in the literature, such as the 
seBDNF correlation with cholesterol and LDL (189), as well as with platelets (238). As 
stored BDNF is released from platelets during clotting (238) and in essential 
hypertension increased platelet activation is a trigger of hypercoagulable state (239), our 
finding, that platelet count is positively correlated with seBDNF may refer to a chief 
source of seBDNF in this pathological condition. 
If elevated BDNF is associated with hypertension, what could be the common 
background in the psychopathology? How can BDNF influence blood pressure, 
potentially playing an important role in the development of hypertension? We aimed to 
address these questions in our recent review paper analysing the psychosomatic 




Axonal guidance is among the top pathways explaining the association between mood 
disorders and cardio-metabolic-disease risk (240). Mutant axonal guidance genes – 
including BDNF – followed by abnormal axonal guidance and connectivity can cause 
disorders primarily in the brain and subsequently in peripheral organs (241). During 
embryonic development, BDNF is found to be not only a target-derived survival factor 
for a large subset of nodose ganglion neurons, such as arterial baroreceptors (236) but is 
also involved in the development of chemoafferent sensory neurons innervating the 
carotid body (242, 243). Furthermore, postnatally BDNF is expressed by the nodose 
ganglion neurons themselves (244, 245) and can be also released from these neurons by 
activity (246). BDNF is expressed in arterial baroreceptors and their central terminals in 
medial nucleus tractus solitarius in vivo. BDNF release from cultured nodose ganglion 
neurons is increased by electrical stimulation with patterns that mimic the in vivo 
activity of baroreceptor afferents (247). So it seems, that BDNF is involved not only in 
the development and survival of baroreceptors, but also in their normal functioning in 
adulthood. 
During normal conditions when blood pressure increases, the activated baroreflex 
reduces heart rate and blood pressure by a negative feedback loop. In addition, elevated 
blood pressure activates inhibitory GABAergic (Gamma-Aminobutyric acid) neurons in 
the hypothalamus, reducing the secretion of the blood pressure-elevating hormone 
vasopressin (248). But different pathophysiological changes can influence the 
mechanism of the baroreflex loop. It is already shown that high dietary salt intake can 
affect blood pressure through NT-mediated changes of the central homeostatic circuit. 
Choe et al. proved in an animal study, that chronic high salt intake is able to decrease 
the baroreceptor-mediated inhibition of vasopressin neurons through a BDNF-
dependent activation of TrkB receptors and through the downregulation of 
potassium/chloride co-transporter 2 expression, which prevents inhibitory of 
GABAergic signalling (249). Furthermore, reduced BDNF level in mice results in 
elevated heart rate, and infusion of this NT into the cerebral ventricles can restore this 
effect (250). In the same study Wan et al. showed that GABAergic responses are 
increased in brainstem cardiovagal neurons of BDNF+/- mice, suggesting that BDNF 
increases the activity of the parasympathetic neurons to reduce heart rate (250). In 




and heart rate regulation and these effects can be blunted in pathological conditions, like 
high salt intake, which can lead to the development of hypertension. 
Another pathway explaining the association between BDNF, CV function and 
susceptibility to mental diseases as well is the RAS. Increased central RAS activation is 
an indicator of many CVDs, like hypertension and heart failure (251, 252). On the other 
hand, data are accumulating about the newly discovered effects of the RAS related to 
neuroprotection, cognition and cerebral vasodilation. Angiotensin (AT) 1-7 also affects 
non-CV functions in the brain, such as learning, memory, and neuroprotection (253). 
Clinical studies have shown that AT II receptor type 1 (AT1R) blockers – independent 
of blood pressure-lowering effect – improve cognitive function in elderly hypertensive 
patients (254, 255). The background mechanism of this phenomenon was investigated 
in animal studies. Goel et al. showed the evidence that chronic neuroinflammation and 
memory impairment in hypertension – associated with increased apoptotic cell death 
and with amyloid beta deposition – can be prevented with candesartan treatment, 
suggesting partly to be explained by an increase of BDNF/CREB (cAMP response 
element binding protein) expression (256). Furthermore, the connection between RAS 
and TrkB signaling is proven in vitro (257) and in vivo as well, as Becker et al 
demonstrated the mediator role of BDNF-TrkB signaling on Ang II-induced mean blood 
pressure and renal sympathetic nerve activity elevation in male rats (258).  
Cumulating data suggest the connection between endothelial dysfunction and BDNF as 
well. In an animal study the protecting effect of the AT1R blocker candesartan after 
stroke was mediated by endothelial nitric oxide (NO) synthase and it was positively 
associated with BDNF expression (259). BDNF is probably indirectly associated with 
the NO-system as BDNF is secreted by endothelial cells (260), it increases vascular 
endothelial growth factor (VEGF) expression, which induces angiogenesis (261, 262) 
and VEGF also enhances the NO production of endothelial cells (263). The connection 
with endothelial dysfunction is also supported by the observation, that circulating 
BDNF level inversely correlates with vascular cell adhesion molecule-1 (264), which is 
an accepted biomarker of endothelial dysfunction (265). Taken together, RAS and NO 
production are also associated with BDNF, forming a possible bridge in the 




Another main finding of our study is that hyperthymic affective temperament is an 
independent determinant of seBDNF. In contrast to the other four temperaments 
(depressive, irritable, cyclothymic and anxious), which tend to have a mainly negative 
impact on life, hyperthymic temperament seems to have rather optimistic components. 
We suppose that patients with higher hyperthymic temperament scores might have 
reduced inclination to CV complications, thanks to the beneficial effect of elevated 
seBDNF and also through its association with AIx as was demonstrated in Study 2, 
hypotheses that need to be confirmed in follow-up studies. As the observed association 
between hyperthymic temperament score and seBDNF was only present in our 
hypertensive patients, we suppose an active role of affective temperaments not only in 
psychiatric but also in CV pathophysiology. 
Considering that BDNF is involved in CV physiology and through enhancing the 
neuroplasticity and neurogenesis it increases the resistance of neurons to metabolic and 
excitotoxic stress (266) a new therapeutic target of mood and CV disorders could be the 
restoration of BDNF level. Lifestyle changes like physical activity, such as running and 
other types of aerobic exercise (267, 268) or calorie restriction (266) could be 
cardioprotective through BDNF mediation. Long-term treatment with various 
antidepressants can also normalize serum BDNF level (181, 269). In animal studies 
antidepressants, including selective serotonin reuptake inhibitors, selective 
norepinephrine reuptake inhibitors, and monoamine oxidase inhibitors elevate BDNF 
mRNA level in hippocampus (270). In psychiatry practice BDNF level improvement 
can be evoked not only through medication, but also through electroconvulsive therapy 
(271). In relation with the CV pharmacology the AT1R blocker candesartan is proven to 
restore BDNF (259) and the ACE-inhibitor perindopril has beneficial effects as well 
(272), but interestingly in case of ramipril this feature seems to be missing (273). As we 
previously mentioned, RAS blockers probably restore BDNF through TrkB signaling 
pathway. In the future a possibility of BDNF restoration could be the inhibition of its 
degradation. The mechanism of BDNF degradation is not well investigated, in the 
literature there are only few studies about this process. More than 25% of synthesized 
BDNF is depredated by lysosomes. Soluble sortilin is a main protein, which directs the 
trafficking of BDNF. Sortilin binds to sorting motif of BDNF and facilitates BDNF 




degradation. Until now no pharmacological option exists to inhibit the degradation of 
BDNF. Modifying sortilin either with increasing its level or its binding action would be 
options to increase total BDNF levels through its decreased targeting to the lysosome 
(274). As there is no agent that would reduce BDNF degradation, direct receptor (TrkB) 
activation via ligands/agonists or mechanisms of increasing the BDNF level would be 
also appropriate therapeutic applications. Based on the listed psychopathological and 
CV effects of BDNF, such a medication can potentially be beneficial for both systems. 
On the other hand, we cannot exclude the possible influence of antihypertensive 
medication on seBDNF levels, on affective temperaments, on BDI and HAMA-A 
scores, or even on personality. Therefore in our next study we, investigated the 
psychometric, haemodynamic, arterial stiffness and laboratory parameters before as 
well as 3 months after the initiation of antihypertensive medication in untreated 
hypertensive patients (HT, n=31), and once in healthy controls (CONT, n=22). The used 
antihypertensive medication was mainly perindopril and amlodipin, which are known to 
penetrate into the central nervous system (275). Furthermore, cumulating data in animal 
models suggest their neuroprotective role (276, 277), and both of them were found to 
modify BDNF in a beneficial way on cellular level (272, 278). As we expected, brachial 
systolic blood pressure, as well as pulse wave velocity were significantly improved in 
the HT group over the 3-month follow-up (153.3±15.9 mmHg vs. 129.5±10.0 mmHg 
and 8.2±1.4 m/s vs. 7.5±1.6 m/s, respectively). Expectedly, no significant changes in 
affective temperaments were found after the initiation of antihypertensive medication, 
suggesting that these agents do not influence the measures of these personality 
constructs. However, we found improvements in BDI score (0.73 points) and in several 
Symptom Checklist 90 Revised (SCL-90) subscales. Interestingly, contrary to our third 
study, seBDNF did not differ between CONT and HT and did not evolve significantly 
during therapy – although an upward trend was observed. This phenomenon can be 
explained with the difference in the average duration of hypertension (in Study 3, it was 
11 years); it is plausible, that seBDNF elevation is not an acute event, but might be a 
part of a long-term compensatory process. Longer follow-up and a higher number of 
untreated hypertensive patients would be required to clarify this issue and the possible 
impact of specific antihypertensive agent groups on seBDNF. On the other hand, these 




medications in newly diagnosed patients may have a significant impact on the 
psychological well-being of patients and could influence their quality of life as 
well.(279). 
To understand how NT-s can have a connective role between psychopathology and 
cardiovascular diseases it must be noted, that they can cross the blood-brain barrier. NT 
pathways are supposed to mediate psychosomatic processes: its physiological 
background is based on the shared signalling pathways descending from Trk receptors 
and p75Ntr to both psychopathological and CV directions. Figure 9 summarizes our 
knowledge in this field, how these different diseases, such as mood disorders, 







Figure 9. Crossroads of neurotrophins in cardiovascular system and psychopathology. 
Neurotrophin family consist of four types of neurotrophins (NTs): nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4). 
NTs are synthesized as proforms that can be cleaved to release mature NTs. Both pro and 
mature forms of NTs are biologically active and eliciting opposite effects. ProNTs typically 
activate apoptotic down-stream pathways via neurotrophin receptor p75 (p75Ntr). The effects 
of mature NTs are mediated by three tyrosine kinase receptors: NGF interacts with tropomyosin 
receptor kinase (Trk) A, BDNF binds to TrkB, NT3 binds to TrkC and lower affinity to TrkA and 
TrkB (illustrated by the grey dashed line). Finally NT4 also interacts with TrkB. 
The effects of NTs on the cardiovascular (CV) system: (i) NGF may have a protective role in 
atherosclerosis by upregulating LDL receptor-related protein (LPR) and increasing glucose- 
induced insulin secretion, while NT-4 and NT-3 seem to be a profibrotic mediator in the aortic 
valve. (ii) Both BDNF and NGF promote angiogenesis through vascular endothelial cells 
directly or by influencing the action of other endogenous factors indirectly. (iii) BDNF is 
required for the survival of arterial baroreceptors. NT-3 is involved in the development of 
chemoafferent sensory neurons’ innervations of the carotid body. (iv) NGF promotes the 
survival of sympathetic and sensory neurons that innervate the heart. NT-3 promotes the 




The effects of NTs on mood disorders: (i) BDNF and NGF participate in the pathophysiology of 
depression: reduced levels of NGF and BDNF in serum and also in plasma have been 
demonstrated in patients suffering from depression. (ii) Association between mood disorders 
and NT-3, NT-4 is plausible, but results are still controversial (illustrated by the dashed 
narrows). 
Renin-angiotensin system (RAS) is one of the possible pathways which might explain the 
association between BDNF and CV function and the susceptibility to mental disorders. 
 
Interestingly, in our study, no association between seBDNF and anxiety or depression 
was found. We suppose that this phenomenon can be explained by the patients’ mild 
anxiety and depression severity. In contrast to the literature, the presence of diabetes or 
the use of the benzodiazepine alprazolam was not found to be significantly correlated 
with seBDNF; however, the direction of correlations was as expected. We think that in 
both cases, the lack of significance was caused by the low proportion of patients 
suffering from diabetes or using alprazolam in our cohort. 
The associations between seBDNF level and arterial stiffness parameters have never 
been evaluated in any patient population yet. Since BDNF has a relaxant effect on 
pulmonary arterial and aortic rings in different animal models (185, 187), we supposed 
a possible link between BDNF and arterial stiffness parameters. In contrast to this, in 
our study, seBDNF showed an association only with pulse pressure amplification, but 
even this failed to be an independent predictor in regression analysis. Based on these 
findings, we suppose that seBDNF may exert its protective role rather on the level of 
the endothelium and perivascular nerves rather on the level of large arteries. 
5.4. Limitation of the studies 
In all studies although we used standardized questionnaires and excluded patients with 
dementia, a complete exclusion of misinterpretations or mistakes by patients is 
impossible. 
5.4.1. Limitations of Study 1 
The main limitation of our study is the relatively low number of patients involved. Out 




with dominant affective temperament and 24 controls were analysed. The low number 
of patients limits the generalisability of our data and type I and type II errors cannot be 
excluded. As the detailed analysis of the impact of unique dominant affective 
temperaments on arterial stiffness, central blood pressure or seBDNF require higher 
number of involved patients, we defined this study as a “pilot”. Another limitation 
comes from the cross-sectional design of the study which precludes causal inference. 
5.4.2. Limitations of Study 2 
One of the limitations of the present analysis is the relatively low number of chronic 
hypertensive patients used to study the associations between affective temperaments and 
blood pressure or arterial stiffness parameters, which limits the generalizability of our 
results, as well as the number of entered confounders into regression analyses. Another 
main limitation stems from its cross-sectional design which precludes causal inference. 
5.4.3. Limitations of Study 3 
The main limitation of our third study also comes from its cross-sectional design which 
precludes causal inference. In addition, the number of the subjects involved into the 
study limited the number of potential confounding variables that were involved in the 
final regression model. Consequently, the presence of sleeping disorder, the amount of 
alcohol intake or the habit of regular exercise, variables with documented influence on 
BDNF level, were not involved into the final analysis (these were not significantly 
correlated with seBDNF in univariate models, data were not shown). Moreover, other 
potential confounders, like childhood trauma, stress or sunlight exposition were not 
evaluated. 
5.5. Future perspectives  
The main advantage of primary care practices is the possibility to follow the patients. 
Therefore, besides extending our patient population and investigating not only the static 
arterial stiffness, but also 24-hour arterial stiffness parameters, our aim is to carry out 
follow-up studies. These could show the role of affective temperaments in the 
development of diseases and their predictive value in already existing diseases. These 
could help us to find the factors mediating the effects of affective temperaments 
(perhaps smoking or alcohol consumption), and inter alia analyzing (CV) endpoints 





Although similar arterial stiffness parameters were found in hypertensive patients with 
depressive, cyclothymic, anxious and irritable dominant affective temperaments, their 
increased depression and anxiety scores, the decreased brachial and central diastolic 
blood pressures as well as the decreased seBDNF might refer to their higher 
vulnerability regarding the development not only of major mood disorders, but also of 
CV complications. 
On the other hand, since the ratio of those subjects who score high on different 
temperament directions while having a dominant affective temperament is relatively 
low, the evaluation of the continuous association between affective temperament scores 
and blood pressure or arterial stiffness parameters are meaningful. We have found 
elevated blood pressure among subjects (analysing also sex differences) with high 
cyclothymic temperament as well as an increased level of arterial stiffening in subjects 
with low hyperthymic scores, suggesting that affective temperaments scores are 
associated with hypertension and arterial stiffening and may thus represent markers of 
CV risk. 
Since the pathophysiological background of our findings is complex we tried to clarify 
the possible role of BDNF, as a potential psychosomatic connection between affective 
temperaments and CV risk. We have found significantly higher seBDNF levels in 
hypertensive patients compared to controls. Hyperthymic temperament score and the 






In our pilot study, we demonstrated that hypertensive patients with dominant 
cyclothymic, irritable, depressive or anxious affective temperaments without previous 
or present psychiatric medication had higher anxiety and depression scores, and lower 
seBDNF levels. They showed similar levels of arterial stiffening rates with a lower 
peripheral and central blood pressure as their hypertensive controls (László et al, Ann 
Gen Psychiatry, 14: 33, 2015). 
In our second study, we found for the first time in literature that in chronic hypertensive 
patients, cyclothymic temperament score is associated with brachial systolic blood 
pressure, while hyperthymic temperament scores are independently related to the 
augmentation index – after adjustment for potential confounders, including severity of 
depression and anxiety, and the use of alprazolam. We also demonstrated sex 
differences in relation to brachial systolic blood pressure and cyclothymic temperament 
score, to pulse wave velocity and irritable and anxious temperament scores, and to the 
augmentation index and hyperthymic temperament score (László at al, BMC Cardiovasc 
Disord, 16: 158, 2016). 
In our third study, we described for the first time in literature that in chronic 
hypertensive patients, seBDNF is elevated, and that a hyperthymic affective 
temperament score and the presence of hypertension are independent determinants of 
seBDNF levels. While in hypertensive patients the hyperthymic temperament score 
elevation is associated with a seBDNF elevation, this association could not be observed 
in healthy subjects (Nemcsik at al, Ann Gen Psychiatry, 15: 17, 2016). 
To summarize our findings, affective temperaments play a role not only in 
psychopathology, but also in CVDs. Hence, with further supporting studies, they can 
receive more attention both in regard to psychopathology and to CV health 
management. Since affective temperaments are easy to measure, constitute the core of a 
personality and are stable from young adulthood on, it would be possible to identify a 
subpopulation with a higher vulnerability towards psychopathological and CV diseases. 
Even if BDNF is not likely to have an effect on large arteries, it is elevated in cases of 
hypertension; furthermore, it is linked to the hyperthymic affective temperament. Our 
findings may suggest its complex psychosomatic mediator role in linking mood 





Az első vizsgálatunkban kimutattuk, hogy pszichiátriai anamnézissel, és ilyen irányú 
medikációval nem rendelkező ciklotím, irritábilis, depresszív vagy szorongó domináns 
affektív temperamentumú hipertóniás betegeknek magasabbak a szorongásos és 
depresszív pontszámuk és alacsonyabb a seBDNF szintjük. Hipertóniás kontrollokkal 
összehasonlítva az artériás érfalmerevségük nem emelkedett, perifériás és centrális 
vérnyomásuk alacsonyabb (László et al, Ann Gen Psychiatry, 14: 33, 2015). 
Második vizsgálatunkban elsőként mutattuk ki, hogy krónikus hipertóniás betegeknél a 
depresszió és a szorongás súlyosságára, valamint az alprazolam használatára vonatkozó 
korrekció után is a ciklotím temperamentum pontszám a brachiális szisztolés 
vérnyomás, míg a hipertím temperamentum pontszám az augmentációs index független 
prediktora. Nemek közötti különbségeket mutattunk ki a brachiális szisztolés 
vérnyomás és a ciklotím; a pulzushullám terjedési sebesség és az irritábilis és a 
szorongó; valamint az augmentációs index és a hipertím temperamentum pontszám 
között (László at al, BMC Cardiovasc Disord, 16: 158, 2016). 
Harmadik vizsgálatunkban elsőként írtuk le, hogy krónikus hipertóniás betegek 
seBDNF szintje emelkedett, valamint a hipertím affektív temperamentum pontszám és a 
hipertónia jelenléte a seBDNF szint független meghatározói. A hipertóniában 
megfigyelt hipertím temperamentum pontszám emelkedésének összefüggése a seBDNF 
szint emelkedéssel az egészséges kontrolloknál nem volt kimutatható (Nemcsik at al, 
Ann Gen Psychiatry, 15: 17, 2016). 
Összefoglalásul az affektív temperamentumoknak nem csak pszichopatológiai, hanem 
kardiovaszkuláris szerepük is lehet. Így több figyelmet érdemelnének mind a 
pszichipatológiai, mind a kardiovaszkuláris ellátásban. További megerősítő vizsgálatok 
birtokában egyszerű mérésüknek köszönhetően a személyiség stabil magját képező 
affektív temperamentumok megállapításának segítségével már fiatal felnőttkortól 
meghatározható lenne egy magasabb pszichoptalógiai és kardiovaszkuláris rizikóval 
rendelkező szubpopuláció, mely a rizikóbecslés részét képezhetné.  
Bár a BDNF úgy tűnik, nem hat a nagyereken, hipertóniában való emelkedése, valamint 
ezen belül a hipertim affektiv temperamentummal való kapcsolata komplex 
pszichoszomatikus mediátorszerepre utalhat: részben megmagyarázva a hiprtónia és a 
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Tempermant Scale of Memphis, Pisa, Paris and San Diego – Autoquestionnaire 
Version (TEMPS-A) 
Circle T (True) for all items that are true about you for much of your life. 
Circle F (False) for all the rest that don’t apply to you for much of your life. 
 1. T F I’m a sad, unhappy person. 
 2. T F People tell me I am unable to see the lighter side of things. 
 3. T F I have suffered a lot in life 
 4. T F I think things often turn out for the worst. 
 5. T F I give up easily. 
 6. T F For as long as I can remember, I’ve felt like a failure. 
 7. T F I have always blamed myself for what others might consider no big deal. 
 8. T F I don’t seem to have as much energy as other people. 
 9. T F I’m the kind of person who doesn’t like change very much. 
 10. T F In a group, I would rather hear others talk. 
 11. T F I often give in to others. 
 12. T F I feel very uneasy meeting new people. 
 13. T F My feelings are easily hurt by criticism or rejection. 
 14. T F I am the kind of person you can always depend on. 
 15. T F I put the needs of others above my own. 
 16. T F I am a hard working person. 
 17. T F I would rather work for someone else than be the boss. 
 18. T F It is natural for me to be neat and organized. 
 19. T F I’m the kind of person who doubts everything. 
 20. T F My sex drive has always been low. 
 21. T F I normally need more than 9 hours of sleep. 
 22. T F I often feel tired for no reason. 
 23. T F I get sudden shifts in mood and energy. 
 24. T F My moods and energy are either high or low, rarely in between. 





 26. T F I can really like someone a lot, and then completely lose interest in them. 
 27. T F I often blow up at people and then feel guilty about it. 
 28. T F I often start things and then lose interest before finishing them. 
 29. T F My mood often changes for no reason. 
 30. T F I constantly switch between being lively and sluggish. 
 31. T F I sometimes go to bed feeling down, but wake up in the morning feeling 
terrific. 
 32. T F I sometimes go to bed feeling great, and wake up in the morning feeling 
life is not worth living. 
 33. T F I am told that I often get pessimistic about things, and forget previous 
happy times. 
 34. T F I go back and forth between feeling overconfident and feeling unsure of 
myself. 
 35. T F I go back and forth between being outgoing and being withdrawn from 
others. 
 36. T F I feel all emotions intensely. 
 37. T F My need for sleep varies a lot from just a few hours to more than 9 
hours. 
 38. T F The way I see things is sometimes vivid, but at other times lifeless. 
 39. T F I am the kind of person who can be sad and happy at the same time. 
 40. T F I daydream a great deal about things that other people consider 
impossible to achieve. 
 41. T F I often have a strong urge to do outrageous things. 
 42. T F I am the kind of person who falls in and out of love easily. 
 43. T F I’m usually in an upbeat or cheerful mood. 
 44. T F Life is a feast which I enjoy to the fullest. 
 45. T F I like telling jokes, people tell me I’m humorous. 
 46. T F I’m the kind of person who believes everything will eventually turn out 
all right. 
 47. T F I have great confidence in myself. 
 48. T F I often get many great ideas. 




 50. T F I can accomplish many tasks without even getting tired. 
 51. T F I have a gift for speech, convincing and inspiring to others. 
 52. T F I love to tackle new projects, even if risky. 
 53. T F Once I decide to accomplish something, nothing can stop me. 
 54. T F I am totally comfortable, even with people I hardly know. 
 55. T F I love to be with a lot of people. 
 56. T F People tell me that I often get my nose into others’ business. 
 57. T F I am known to be generous, and spend a lot of money on other people. 
 58. T F I have abilities and expertise in many areas. 
 59. T F I feel I have the right and privilege to do as I please. 
 60. T F I am the kind of person who likes to be the boss. 
 61. T F When I disagree with someone, I can get into a heated argument. 
 62. T F My sex drive is always high. 
 63. T F Normally I can get by with less than 6 hours of sleep. 
 64. T F I am a grouchy (irritable) person. 
 65. T F I am by nature a dissatisfied person. 
 66. T F I complain a lot. 
 67. T F I am highly critical of others. 
 68. T F I often feel on edge. 
 69. T F I often feel wound up. 
 70. T F I am driven by an unpleasant restlessness that I don’t understand. 
 71. T F I often get so mad that I will just trash everything. 
 72. T F When crossed, I could get into a fight. 
 73. T F People tell me I blow up out of nowhere. 
 74. T F When angry, I snap at people. 
 75. T F I like to tease people, even those I hardly know. 
 76. T F My biting humor has gotten me into trouble. 
 77. T F I can get so furious I could hurt someone. 
 78. T F I am so jealous of my spouse (or lover), that I cannot stand it. 
 79. T F I am known to swear a lot. 
 80. T F I have been told that I become violent with just a few drinks. 




 82. T F I could be a revolutionary. 
 83. T F My sex drive is often so intense that it is truly unpleasant. 
 84. T F (Women only):  I have attacks of uncontrollable rage right before my 
period. 
 85. T F I have been a worrier for as long as I can remember. 
 86. T F I’m always worrying about one thing or another. 
 87. T F I keep on worrying about daily matters that others consider minor. 
 88. T F I cannot help worrying. 
 89. T F Many people have told me not to worry so much. 
 90. T F When stressed, my mind often goes blank. 
 91. T F I am unable to relax. 
 92. T F I often feel jittery inside. 
 93. T F When stressed, my hands often tremble. 
 94. T F I often have an upset stomach. 
 95. T F When I’m nervous, I may have diarrhea. 
 96. T F When I’m nervous, I often feel nauseous. 
 97. T F When I’m nervous, I have to go to the bathroom more often. 
 98. T F When someone is late coming home, I fear they have had an accident. 
 99. T F I am often fearful of someone in my family coming down with a serious 
disease. 
100. T F I’m always thinking someone might break bad news to me about a 
family member. 
101. T F My sleep is not restful. 
102. T F I frequently have difficulty falling asleep. 
103. T F I am, by nature, a very cautious person. 
104. T F I often wake up at night afraid that burglars are in the house. 
105. T F I easily get headaches when stressed. 
106. T F When stressed, I get an uncomfortable feeling in my chest. 
107. T F I’m an insecure person. 
108. T F Even minor changes in routine, stress me highly. 
109. T F While driving, even when I haven’t done anything wrong, I fear that the 




110. T F Sudden noises startle me easily. 
 
Interpreting the TEMPS-A 
depressive temperament: questions 1 to 21 (21 points) 
cyclothymic temperament: questions 22 to 42 (21 points) 
hyperthymic temperament: questions 23 to 63 (21 points) 
irritable temperament: questions 64 to 84 (21 points in women, 20 in the men’s version) 
anxious temperament: questions 85 to 110 (26 points). 
Those reaching the mean+2 SD level or higher in each subscale are considered to have 
dominant affective temperaments. 
Beck's Depression Inventory  
This depression inventory can be self-scored. Select one of the four responses for each 
of the 21 points. 
1.  
0  I do not feel sad.  
1  I feel sad  
2  I am sad all the time and I can't snap out of it.  
3  I am so sad and unhappy that I can't stand it.  
2.  
0  I am not particularly discouraged about the future.  
1  I feel discouraged about the future.  
2  I feel I have nothing to look forward to.  





0  I do not feel like a failure.  
1  I feel I have failed more than the average person.  
2  As I look back on my life, all I can see is a lot of failures.  
3  I feel I am a complete failure as a person.  
4.  
0  I get as much satisfaction out of things as I used to.  
1  I don't enjoy things the way I used to.  
2  I don't get realsatisfaction out ofanything anymore.  
3  I am dissatisfied or bored with everything.  
5.  
0  I don't feel particularly guilty  
1  I feel guilty a good part of the time.  
2  I feel quite guilty most of the time.  
3  I feel guilty all of the time.  
6.  
0  I don't feel I am being punished.  
1  I feel I may be punished.  
2  I expect to be punished.  
3  I feel I am being punished.  
7.  
0  I don't feel disappointed in myself.  




2  I am disgusted with myself.  
3  I hate myself.  
8.  
0  I don't feel I am any worse than anybody else.  
1  I am critical of myself for my weaknesses or mistakes.  
2  I blame myself all the time for my faults.  
3  I blame myself for everything bad that happens.  
9.  
0  I don't have any thoughts of killing myself.  
1  I have thoughts of killing myself, but I would not carry them out.  
2  I would like to kill myself.  
3  I would kill myself if I had the chance.  
10.  
0  I don't cry any more than usual. 
1  I cry more now than I used to.  
2  I cry all the time now.  
3  I used to be able to cry, but now I can't cry even though I want to.  
11.  
0  I am no more irritated by things than I ever was.  
1  I am slightly more irritated now than usual.  
2  I am quite annoyed or irritated a good deal of the time.  





0  I have not lost interest in other people.  
1  I am less interested in other people than I used to be.  
2  I have lost most of my interest in other people.  
3  I have lost all of my interest in other people.  
13.  
0  I make decisions about as well as I ever could.  
1  I put off making decisions more than I used to.  
2  I have greater difficulty in making decisions more than I used to.  
3  I can't make decisions at all anymore.  
14.  
0  I don't feel thatI look any worse than I used to.  
1  I am worried that I am looking old or unattractive.  
2  I feel there are permanent changes in my appearance that make me look  
unattractive  
3  I believe that I look ugly.  
15.  
0  I can work about as well as before.  
1  It takes an extra effort to get started at doing something.  
2  I have to push myself very hard to do anything.  





0  I can sleep as well as usual.  
1  I don't sleep as well as I used to.  
2  I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.  
3  I wake up several hours earlier than I used to and cannot get back to sleep.  
17.  
0  I don't get more tired than usual.   
1  I get tired more easily than I used to.  
2  I get tired from doing almost anything.  
3  I am too tired to do anything.  
18.  
0  My appetite is no worse than usual.   
1  My appetite is not as good as it used to be.  
2  My appetite is much worse now.  
3  I have no appetite at all anymore.  
19.  
0  I haven't lost much weight, if any, lately.  
1  I have lost more than five pounds.  
2  I have lost more than ten pounds.  
3  I have lost more than fifteen pounds.  
20.  
0  I am no more worried about my health than usual.  





2  I am very worried about physical problems and it's hard to think of much else.  
3  I am so worried about my physical problems that I cannot think of anything 
else.  
21.  
0  I have not noticed any recent change in my interest in sex.  
1  I am less interested in sex than I used to be.  
2  I have almost no interest in sex.  
3  I have lost interest in sex completely. 
 
Interpreting the Beck Depression Inventory 
Total Score Levels of Depression  
1-10 These ups and downs are considered normal  
11-16 Mild mood disturbance  
17-20 Borderline clinical depression  
21-30 Moderate depression  
31-40 Severe depression  
over 40 Extreme depression  
 
Hamilton Anxiety Rating Scale (HAM-A) 
Below is a list of phrases that describe certain feeling that people have. Rate the patients 
by finding the answer which best describes the extent to which he/she has these 
conditions. Select one of the five responses for each of the fourteen questions. Each 







Mild Moderate Severe 
Very 
Severe 
1. Anxious Mood 
Worries, anticipation of the worst, 
fearful anticipation, irritability.  
     
2. Tension 
Feelings of tension, fatigability, startle 
response, moved to tears easily, 
trembling, feelings of restlessness, 
inability to relax.  
     
3. Fears 
Of dark, of strangers, of being left alone, 
of animals, of traffic, of crowds.  
     
4. Insomnia 
Difficulty in falling asleep, broken sleep, 
unsatisfying sleep and fatigue on 
waking, dreams, nightmares, night 
terrors.  
     
5. Intellectual 
Difficulty in concentration, poor 
memory.  
     
6. Depressed Mood 
Loss of interest, lack of pleasure in 
hobbies, depression, early waking, 
diurnal swing.  
     
7. Somatic (muscular) 
Pains and aches, twitching, stiffness, 
myoclonic jerks, grinding of teeth, 
unsteady voice, increased muscular tone.  
     
8. Somatic (sensory) 
Tinnitus, blurring of vision, hot and cold 
flushes, feelings of weakness, pricking 





9. Cardiovascular Symptoms 
Tachycardia, palpitations, pain in chest, 
throbbing of vessels, fainting feelings, 
missing beat.  
     
10. Respiratory Symptoms 
Pressure or constriction in chest, 
choking feelings, sighing, dyspnea.  
     
11. Gastrointestinal Symptoms 
Difficulty in swallowing, wind 
abdominal pain, burning sensations, 
abdominal fullness, nausea, vomiting, 
borborygmi, looseness of bowels, loss of 
weight, constipation.  
     
12. Genitourinary Symptoms 
Frequency of micturition, urgency of 
micturition, amenorrhea, menorrhagia, 
development of rigidity, premature 
ejaculation, loss of libido, impotence.  
     
13. Autonomic Symptoms 
Dry mouth, flushing, pallor, tendency to 
sweat, giddiness, tension headache, 
raising of hair.  
     
14. Behavior at Interview 
Fidgeting, restlessness or pacing, tremor 
of hands, furrowed brow, strained face, 
sighing or rapid respiration, facial pallor, 
swallowing, etc.  
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Abstract 
Background: Although mood disorders and cardiovascular diseases have widely studied psychosomatic connec‑
tions, data concerning the influence of the psychopathologically important affective temperaments in hypertension 
are scarce. To define a possibly higher cardiovascular risk subpopulation we investigated in well‑treated hypertensive 
patients with dominant affective temperaments (DOM) and in well‑treated hypertensive patients without dominant 
temperaments the level of depression and anxiety, arterial stiffness and serum Brain‑derived Neurotrophic Factor 
(seBDNF).
Methods: 175 hypertensive patients, free of the history of psychiatric diseases, completed the TEMPS‑A, Beck 
Depression Inventory and Hamilton Anxiety Scale questionnaires in two primary care practices. Of those 175 patients, 
24 DOM patients and 24 hypertensive controls (matched in age, sex and the presence of diabetes) were selected for 
measurements of arterial stiffness and seBDNF level.
Results: Beck and Hamilton scores in DOM patients were higher compared with controls. Pulse wave velocity and 
augmentation index did not differ between the groups while in the DOM patients decreased brachial systolic and 
diastolic and central diastolic blood pressures were found compared with controls. SeBDNF was lower in the DOM 
group than in the controls (22.4 ± 7.2 vs. 27.3 ± 7.8 ng/mL, p < 0.05).
Conclusions: Although similar arterial stiffness parameters were found in DOM patients, their increased depression 
and anxiety scores, the decreased brachial and central diastolic blood pressures as well as the decreased seBDNF 
might refer to their higher vulnerability regarding the development not only of major mood disorders, but also of 
cardiovascular complications. These data suggest that the evaluation of affective temperaments should get more 
attention both with regard to psychopathology and cardiovascular health management.
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Background
Mood disorders are common public health problem in 
the Western world and their strong connection to cardio-
vascular diseases (CVD) is well known [1]. Moreover, the 
negative impact of adverse individual psychological traits 
and characteristics, like anger, hostility and anxiety is also 
well-documented in connection to the development and 
progression of coronary heart disease [2, 3], while indi-
vidual differences in antagonism-related traits seem to 
predict a variety of cardiovascular outcomes [4, 5].
There are multiple mechanisms by which depression 
could increase the probability of vascular diseases, such 
as increased platelet activation [6], inflammatory mark-
ers [7] as well as reduced heart rate variability [8]. Parallel 
to this, well-established biomarkers of inflammation were 
also found to be elevated in persons in states of anger or 
hostility [9, 10], while a reduced function of the auto-
nomic nervous system was observed in states of anxiety 
[11] and interpersonal antagonism was connected with 
carotid arterial intima-media thickening [12].
Another possible link might be the brain-derived neu-
rotrophic factor (BDNF), a member of the neurotrophic 
factor family, which is not only associated with major 
depressive disorder [13], but its higher serum level is also 
connected to a decreased  risk  of cardiovascular disease 
and mortality [14].
The independent continuous relationship between ele-
vated blood pressure and several cardiovascular events 
is well-known for patients in all ages and ethnic groups 
[15]. Besides elevated blood pressure, arterial stiffening 
is increasingly recognised as a risk factor for CVD. The 
determination of decreased arterial elasticity helps to 
identify the patient’s higher risk of cardiovascular mor-
bidity and mortality [16]. In Europe, the measurement 
of arterial stiffness is already a recommended method 
for cardiovascular risk assessment among hypertensive 
patients [17]. Previously, depressive symptoms, especially 
in diagnosed depressive disorders were found to be asso-
ciated with increased arterial stiffening [18].
According to our recent findings, specific affective tem-
perament types (depressive, cyclothymic, hyperthymic, 
irritable and anxious) are the subclinical, trait-related 
manifestations and commonly the antecedents of minor 
and major mood disorders [19]. Recently, in a study of 
primary care patients we also demonstrated a strong con-
nection between dominant cyclothymic temperament 
and hypertension [20]. Moreover, we also showed that 
cyclothymic temperament is connected to acute coro-
nary events in hypertensive patients [21].
We hypothesised that hypertensive patients with 
dominant affective temperaments (DOM) score higher 
depression and anxiety values and have impaired arte-
rial stiffness, central blood pressure or serum BDNF 
compared with hypertensive patients without dominant 




In our cross-sectional case–control study well-treated 
chronic (>12 months medication) hypertensive Caucasian 
patients were investigated in two primary care practices. 
All patients completed the TEMPS-A, Beck Depression 
Inventory (BDI) and Hamilton Anxiety Scale (HAM-A) 
questionnaires in order to evaluate the presence of affec-
tive temperaments, depression and anxiety, respectively. 
Following this initial screening, patients with dominant 
affective temperaments (reaching the mean + 2 SD point 
scores or higher in each affective temperament subscale, 
DOM) were identified. Hypertensive controls without 
DOM, matched in age, gender and presence of diabetes, 
were selected from the initial hypertensive patient cohort 
and included in the arterial stiffness and seBDNF meas-
urements. As blood pressure medication can highly influ-
ence arterial stiffness, it was further analysed, but patients 
were not matched in this aspect.
Exclusion criteria were the history or ongoing treat-
ment of depression or anxiety (as with arterial stiffen-
ing the associations are clarified [18]), and the presence 
of atrial fibrillation or uncontrolled hypertension 
(>145/95  mmHg in repeated office measurements). 
In patients with an average blood pressure between 
140/90 and 145/95 mmHg in repeated office blood pres-
sure measurements, ambulatory 24-h blood pressure 
monitoring or home blood pressure monitoring was 
performed and only well-controlled patients were admit-
ted to the study. Prior to the participation, all patients 
gave their written informed consent. The study was 
approved by the Scientific and Research Ethics Commit-
tee of the Medical Research Council, Hungarian Min-
istry of Health (ETT TUKEB 842/PI/2011) and carried 
out in accordance with the tenets of the Declaration of 
Helsinki.
Procedures
During the initial visit patients completed the question-
naires. Physical examination (blood pressure, heart rate, 
height, weight and waist circumference) were completed 
and data on medical history (with special attention to 
cardiovascular risk factors, complications and depres-
sion) as well as on current medication was collected.
After the analysis of the questionnaires, patients meet-
ing the criteria of dominant temperament and their 
controls were invited for arterial stiffness and seBDNF 
measurements, which took place  within 1  month after 
the initial visit.
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Questionnaires
The temperament evaluation of Memphis Pisa, Paris and 
San Diego (TEMPS-A) questionnaire is an 110-item, 
self-report instrument, developed to measure affective 
temperaments on depressive, cyclothymic, hyperthymic, 
irritable and anxious subscales and requiring the answers 
‘yes’ (score 1) or ‘no’ (score 0) [22]. TEMPS-A is used to 
assess the point scores of each subscale and also to meas-
ure the presence of the dominant form of affective tem-
peraments by taking the mean of the subscale and adding 
up two standard deviations to it. Those reaching the 
mean + 2 SD level or higher in each subscale are consid-
ered to have dominant affective temperaments.
The beck depression inventory (BDI), created by Aaron 
T. Beck, is a 21-question multiple-choice self-report 
questionnaire, one of the widely used instruments for 
measuring the severity of depression. Participants are 
asked to make ratings on a four-point scale, where a 
higher score correlates with more severe depression.
Hamilton Anxiety Scale (HAM-A) was evaluated by the 
examiner to study the severity of anxiety. The scale con-
sists of 14 items, each item is scored on a scale of 0 (not 
present) to 4 (severe anxiety).
Arterial stiffness recordings
Measurements were performed in a temperature-con-
trolled room in supine position, on the day of blood sam-
pling, before it, between 7.00 and 8.00 a.m. Patients were 
required to fast overnight and refrain from smoking and 
caffeine-containing beverages before the procedure, but 
to take the usual blood pressure regulating medication. 
Upon arrival at the investigation unit, the subjects were 
equipped with measurement devices, and then rested in 
supine position for approximately 15  min before being 
measured. Arterial stiffness parameters were evaluated 
using the validated, gold-standard PulsePen tonometer 
(DiaTecne, Milan, Italy, [23]). With this method the pulse 
wave velocity (PWV) augmentation index (AI), as well as 
the central systolic blood pressure (central SBP) and cen-
tral pulse pressure (central PP) can be calculated. In each 
subject two sequences of measurements were performed 
and their mean was used for statistical analysis. ECG was 
recorded continuously from the limb lead with the largest 
R wave.
In the PWV calculations 80  % of the carotid-femoral 
distance was used, following the recent guideline [24]. 
Previously we evaluated the intra- and interobserver vari-
abilities of PWV measurements obtained by the PulsePen 
device on hypertensive patients and found them to be 
4.6 and 6.3  % high, respectively. As PulsePen calculates 
pressure values using brachial diastolic blood pressure 
calibration, the calculated central and brachial diastolic 
blood pressure values were identical [23].
Measurement of seBDNF concentration
Peripheral blood samples of patients were collected in 
anticoagulant-free tubes, right after the measurement 
of arterial stiffness. After centrifugation (3600  rpm 
for 6  min) the serum was stored at −20  °C. SeBDNF 
was measured using commercially available sandwich 
enzyme-linked immunosorbent assay (R&D Systems, 
Minneapolis MN, USA) according to the manufacturer’s 
protocol and serum BDNF level was determined in ng/
mL.
Data analysis
Data were expressed as mean ± SEM and medians. Dif-
ferences in variables between controls and DOM patients 
were analysed using unpaired Student’s t tests or Mann–
Whitney rank-sum tests for data failing tests of normal-
ity. Blood pressure medications were calculated and 
compared using equivalent doses, differences were ana-
lysed with unpaired Student’s  t  tests or Mann–Whitney 
rank-sum tests. Significance was accepted at p  <  0.05. 
Statistical analysis was performed using the SigmaStat for 
Windows Version 3.5 (SPSS) program package.
Results and discussion
Characteristics of the patients
183 hypertensive patients were recruited to participate in 
the study and 175 of them completed the questionnaires. 
29 of the patients had dominant affective temperaments 
(DOM). Out of the 29 DOM patients one died 3  days 
prior to the planned arterial stiffness measurement and 
four declined to further participate in arterial stiffness 
measurements. The arterial stiffness and BDNF of alto-
gether 48 hypertensive patients was evaluated: 24 DOM 
and 24 control subjects matched in age, gender and pres-
ence of diabetes.
Among the DOM patients six subjects with depres-
sive, five irritable and four anxious dominant tempera-
ments were found. In the other patients, combinations 
of dominant temperaments were present: three patients 
had cyclothymic and depressive, two had cyclothymic 
and irritable, two had cyclothymic, depressive and anx-
ious, one had cyclothymic, irritable and anxious temper-
aments and one patient was dominant for cyclothymic, 
irritable, anxious and depressive affective temperaments. 
No patient with a dominant hyperthymic temperament 
was found in our cohort.
Comparing the control and DOM patients for statistical 
differences
Baseline demographic, anthropometric and laboratory 
parameters and the used cardiovascular medications of the 
patients are presented in Table 1. SeBDNF levels were lower 
in DOM patients. Compared with controls, beta-blockers 
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were prescribed more frequently and in higher dose in the 
DOM group [0.63 (0–5) vs. 5 (0.63–6.88) mg, calculated 
for bisoprolol, respectively, p < 0.05]. No differences were 
found in the mean duration of hypertension among con-
trols and DOM patients [10.5 (4–15.8) vs. 12 (6.5–17.8) 
p = 0.238, respectively]. No differences were found among 
the groups studied in smoking habits and in the frequency 
of physical training (data are not shown).
Table  2 represents the differences in the five affective 
temperaments and in the BDI and HAM-A scores. Com-
pared with controls, in DOM patients depressive, cyclo-
thymic, irritable and anxious scores were higher, while 
hyperthymic scores were equal. Both BDI and HAM-A 
scores were markedly higher in DOM patients than in the 
controls.
Brachial and central hemodynamic and arterial stiff-
ness parameters are shown in Table  3. Brachial systolic 
and both brachial and central diastolic and mean blood 
pressures were lower in DOM patients. PWV and AI, 
the two main arterial stiffness parameters, did not differ 
when compared with controls.
Our pilot study was performed on hypertensive 
patients with dominant cyclothymic, irritable, depressive 
or anxious affective temperaments without the history 
or any present psychiatric medications. We found that 
DOM patients had higher anxiety and depression scores 
and lower seBDNF level. DOM patients had similar levels 
of arterial stiffening with a lower peripheral and central 
blood pressure compared with hypertensive controls.
Table 1 Baseline demographic, anthropometric and  labo-
ratory parameters and the used cardiovascular medication 
of the patients
The values are mean ± SEM or medians (quartiles)
The groups were compared for differences by using Student’s t test or the 
Mann–Whitney rank-sum for data failing tests of normality
DOM patients with dominant affective temperament, AC abdominal 
circumference, BMI body mass index, CKD-EPI GFR glomerular filtration rate 
assessed by the chronic kidney disease epidemiology collaboration glomerular 
filtration rate equation; BDNF: brain-derived neurotrophic factor, ARBs 
angiotensin II receptor blockers
* p < 0.05 compared with controls
Control DOM
N (male:female) 24 (9:15) 24 (9:15)
Age (year) 63.7 ± 2.54 64.3 ± 2.52
Body height (cm) 164.5 ± 1.51 166 ± 2.06
Body weight (kg) 76.3 ± 2.66 81 ± 3.34
AC (cm) 101.5 ± 4.1 102 ± 5.5
BMI (kg/m2) 28.2 (26–31.2) 29.8 (24.4–34.6)
Glucose (mmol/l) 5.36 (5.03–6.07) 5.7 (4.94–6.63)
CKD‑EPI GFR (mmol/l) 77.5 (62.5–86) 78.5 (60.8–90)
Uric acid (µmol/l) 309.3 ± 15.26 321.6 ± 16.82
Cholesterol (mmol/l) 5.48 ± 0.22 5 ± 0.35
Triglyceride (mmol/l) 1.36 (1.08–2.18) 1.82 (0.99–2.15)
BDNF (ng/ml) 27.29 (24.2–30.35) 20.10 (14.74–27.11)*
ACE‑inhibitors [n (%)] 13 (54.2) 13 (54.2)
ARBs 9 (37.5) 5 (20.8)
Calcium‑channel blockers 11 (45.8) 11 (45.8)
Beta‑blockers 12 (50) 18 (75)*
Diuretics 11 (45.8) 11 (45.8)
Antiplatelet medication 8 (33.3) 11 (45.8)
Table 2 TEMPS-A scores of  affective temperaments, BDI 
and HAM-A scores
The values are mean ± SEM and medians (quartiles). The groups were compared 
for differences by using Student’s t test or the Mann–Whitney rank-sum for data 
failing tests of normality
DOM patients with dominant affective temperament, TEMPS-A the temperament 
evaluation of Memphis Pisa, Paris and San Diego questionnaire, BDI beck 
depression inventory, HAM-A Hamilton Anxiety Scale





Depressive 6 (4.25–8.75) 12.5 (7–13.75)*
Cyclothymic 3 (1–5) 9.5 (7–13.75)*
Hyperthymic 12.13 ± 0.73 10.46 ± 0.99
Irritable 2 (1–4.75) 9.5 (5–11)*
Anxious 5.08 ± 0.81 14.67 ± 0.88*
BDI 5 (2–7.75) 14.5 (8.5–19.75)*
HAM‑A 7 ± 1.27 16.67 ± 1.68*
Table 3 Brachial and  central hemodynamic and  arterial 
stiffness parameters
The values are mean ± SEM and medians (quartiles). The groups were compared 
for differences by using Student’s t test or the Mann–Whitney rank-sum for data 
failing tests of normality
DOM patients with dominant affective temperament, HR heart rate, SBPB systolic 
brachial blood pressure, DBPB diastolic brachial blood pressure, MBPB mean 
brachial blood pressure, PPB brachial pulse pressure, Central SBP central systolic 
blood pressure, Central DBP central diastolic blood pressure, Central MBP central 
mean blood pressure, Central PP central pulse pressure, PWV pulse wave velocity, 
AI Augmentation index





HR (1/min) 66 ± 1.25 63.1 ± 1.17
SBPB (Hgmm) 130.8 (122–137.1) 122.6 (116.4–129.7)*
DBPB (Hgmm) 71.2 ± 1.5 66.6 ± 1.71*
MBPB (Hgmm) 91.9 ± 1.53 86.6 ± 1.94*
PPB (Hgmm) 59.3 (49.4–67.5) 54.3 (50.1–61.9)
Central SBP (Hgmm) 124.3 (113.5–136.4) 117 (112.6–131.7)
Central DBP (Hgmm) 71.2 ± 1.5 66.5 ± 1.71*
Central MBP (Hgmm) 94.1 ± 1.55 88.9 ± 1.96*
Central PP (Hgmm) 50.6 (44.5–66.6) 52.3 (48.8–1.72)
PWV (m/s) 9.32 (8.02–11.25) 8.74 (8.32–9.87)
AI (%) 16.04 ± 2.24 14.54 ± 2.66
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Affective temperaments are associated with depression 
and anxiety
Affective temperaments are tightly related to affective 
disorders. Hyperthymic temperament was found to be 
associated with type-I and cyclothymic with type-II bipo-
lar disease [25] and atypical depression [19, 26], depres-
sive temperament, in contrast to this, with unipolar 
major depression [19, 27]. In our cohort DOM patients 
also had higher depression and anxiety scores suggesting 
the importance of a joint evaluation of affective tempera-
ments together with depression and anxiety even in those 
hypertensive patients who have no records of previous 
psychiatric diseases or any present antidepressant or 
anxiolytic medication.
Affective temperaments and cardiovascular risk
Although the presence of dominant affective tempera-
ments frequently precedes the onset of minor and major 
affective illness [19], and therefore screening for their 
presence would be an important target in the prevention 
and early intervention of cardiovascular disorders as well, 
only few studies are available which aim to investigate the 
role of affective temperaments in the development and 
risk of different cardiovascular diseases. Patients with 
depressive temperament were found to have worse meta-
bolic control in type-2 diabetes [28], while cyclothymic, 
irritable and anxious temperaments showed affinity to 
obesity [29]. Recently we evaluated the role of affective 
temperaments in primary hypertension and found a sig-
nificant association with the dominant cyclothymic tem-
perament [20]. Moreover, cyclothymic temperament was 
associated with acute coronary events in hypertensive 
patient population [21]. In our present study, patients 
with affective temperaments had lower brachial and 
central diastolic and mean blood pressure values than 
controls. It is well known that decreased diastolic blood 
pressure is associated with increased mortality [30]. Par-
allel to our previous findings in hypertensive patients 
mentioned above [20, 21], this phenomenon of decreased 
blood pressure values might be more expressed in cyclo-
thymic patients and would in this case suggest their 
increased susceptibility to cardiovascular complications. 
However, the clarification of this hypothesis requires fur-
ther studies.
As our DOM patients had higher depression score 
compared with control patients, one explanation of the 
decreased blood pressure might reflect the fact that lower 
blood pressure levels are often accompanied by a pro-
nounced presence of depressive symptoms and in follow-
up studies symptoms of anxiety and depression predicted 
the development of lower blood pressure [31, 32]. In 
case of a co-occurring onset of depression and hypoten-
sion, the pathophysiological mechanisms are considered 
to be the alterations in neurohormonal, immune and 
autonomic regulations [33]. Whether only the increased 
depression per se caused the decreased blood pressure in 
our DOM patients, or another independent factor is also 
involved, is a question still to be answered.
Most of the studies support the idea that antagonistic 
traits, depression and anxiety increase the probability of 
the development of cardiovascular diseases [12, 34, 35], 
and data are also available with respect to arterial stiff-
ness. In their population-based, cross-sectional study 
including 3704 elderly patients, Tiermeier et  al. found 
that patients with increased arterial stiffness were more 
likely to have depressive symptoms. The association was 
stronger in cases with diagnosed depressive disorders. 
The authors concluded that arterial stiffness may partly 
cause the proposed relationship between vascular fac-
tors and depression [18]. In contrast to this we found no 
difference in PWV or augmentation index between our 
DOM and control hypertensive patients. An explanation 
to this phenomenon can be that in the study of Tiermeier 
et  al. the patients’ arterial stiffness was much higher, as 
the border of the lowest PWV quartile was 11.4 m/s. This 
suggests a very poor vascular status of those patients, 
while in our patients PWV values were much lower.
In a recent study of Seldenrijk et  al., depression and 
anxiety sensitivity and their association with arterial 
stiffening were evaluated. The authors found that out of 
these only anxiety sensitivity was associated with arterial 
stiffness; however, they studied only the augmentation 
index, which is a more variable parameter compared to 
PWV and is influenced by resistance vessels, that can be 
dysfunctional in patients with anxiety [36, 37]. It is also 
worth mentioning that the population of Seldenrijk et al. 
was much younger (46  years) compared with ours and 
only 18 % of the patients regularly took antihypertensive 
medication which suggests their better general resistance 
vessel function. Considering all these results we suppose 
that in older patients besides optimal vascular therapy, 
the deleterious effects of depression and anxiety for arte-
rial stiffening can be attenuated, but in younger popula-
tion without vascular medication the deleterious effects 
of anxiety can lead to detectable dysfunction of resistance 
vessels in comparison to healthy controls.
Serum BDNF level, affective temperaments and allostatic 
load
In our study seBDNF, too, was measured and we 
observed its decreased level in our DOM patients. 
SeBDNF was found to be lower in patients suffering 
from major depressive disorder and some types of anxi-
ety disorders, while in animal models the regulation of 
BDNF was suggested to contribute both to anxiety-like 
behaviour and hypertension [38–40]. BDNF was found 
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to be decreased also in such pathological conditions as 
acute coronary syndrome and type 2 diabetes [41, 42]. 
Whether the decreased seBDNF in our hypertensive 
DOM patients is correlated with their higher depression 
and anxiety and bears any clinical relevance with respect 
to the cardiovascular outcome or not, further studies 
need to clarify.
The term “allostatic load” refers to a cumulative, mul-
tisystem view of the physiologic toll that is required for 
adaptation to stress. In mood disorders, especially in 
bipolar disorder allostatic load increases progressively 
as mood episodes occur over time [43]. Among many 
mediators, neurotrophic factors such as decreased level 
of BDNF indicates allostatic load [44]. Seeman et  al. 
found in their longitudinal, community-based study that 
allostatic load may play a role in cardiovascular disorders 
[45] and there is evidence that reduction in allostatic 
load is associated with lower all-cause mortality, even 
in geriatric patients [46]. As affective temperaments 
are the subclinical manifestations of minor and major 
mood disorders and we found decreased BDNF level in 
patients with dominant temperaments, it can indicate an 
increased allostatic load among them, as well. Accord-
ing to this theory the increased cardiovascular risk could 
also be explained with the phenomenon of allostatic 
load.
In our study the depressive, cyclothymic, irritable and 
anxious temperaments or their combinations were inves-
tigated together. The neurobiological background of 
these temperaments seems to be at least partly common, 
as all were found to be associated with the 5-HTTLPR 
polymorphism of the serotonin transporter gene, namely 
the presence of the s allele, which is connected with 
decreased serotonin uptake of cells [47]. Moreover, the 
scales of depressive, anxious, cyclothymic and irritable 
temperaments were found to be closely associated in 
different populations suggesting real phenotypical con-
nections beyond the similarities in the neurobiological 
background [48, 49]. Whether the clustering of dominant 
temperaments has any pronounced clinical relevance 
above single dominant temperaments is another question 
to be answered.
Risk stratification of hypertensive patients
The calculation of total cardiovascular risk of hyperten-
sive patients is a very important task of hypertension care 
[17]. Our results support the possibility that in the future 
the evaluation of affective temperaments might be the 
part of the risk stratification procedure of hypertensive 
patients as besides the obvious connection with mood 
disorders, the identification of DOM patients could 
determine a higher cardiovascular risk patient popula-
tion as well.
Limitations
The main limitation of our study is the relatively low 
number of patients involved. Out of 183 invited hyper-
tensive patients, the arterial stiffness parameters of only 
24 subjects with dominant affective temperament and 
24 controls were analysed. The low number of patients 
limits the generalisability of our data and type I and type 
II errors cannot be excluded. As the detailed analysis of 
the impact of unique dominant affective temperaments 
on arterial stiffness, central blood pressure or seBDNF 
require higher number of involved patients, we defined 
this study as a “pilot”. Another limitation comes from 
the cross-sectional design of the study which precludes 
causal inference.
Conclusions
In conclusion, although arterial stiffness parameters did 
not differ between the DOM subgroup of well-treated 
hypertensive patients and their hypertensive controls, 
their higher depressive and anxious scores and lower 
seBDNF might reflect their higher susceptibility for car-
diovascular complications. Furthermore, DOM patients 
might bear a higher risk, as they have lower brachial and 
central diastolic blood pressure values in comparison to 
patients without dominant temperaments. The clinical 
significance of our findings with respect to the cardio-
vascular outcome of these patients needs further exami-
nations on higher number of patients involved, but the 
cumulating data suggest that the evaluation of affective 
temperaments might improve both psychopathological 
and cardiovascular risk stratification.
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Association of affective temperaments with
blood pressure and arterial stiffness in
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Abstract
Background: Affective temperaments (anxious, depressive, cyclothymic, irritable and hyperthymic) measure
subclinical manifestations of major mood disorders. Furthermore, cumulating evidence suggests their involvement
in somatic disorders as well. We aimed to assess associations between affective temperament scores and blood
pressure and arterial stiffness parameters in hypertensive patients.
Methods: In this cross-sectional study, 173 patients with well-controlled or grade 1 chronic hypertension, with
no history of depression, completed the TEMPS-A, Beck Depression Inventory (BDI) and Hamilton Anxiety
Scale (HAM-A) questionnaires in three GP practices. Arterial stiffness was measured with tonometry (PulsePen).
Results: According to multiple linear regression analysis, cyclothymic temperament score was positively
associated with brachial systolic blood pressure independently of age, sex, total cholesterol, brachial diastolic
blood pressure, BDI, HAM-A and the use of alprazolam (β = 0.529, p = 0.042), while hyperthymic temperament
score was negatively related to augmentation index independent of age, sex, smoking, heart rate, BDI, HAM-A
and the use of alprazolam (β = -0.612, p = 0.013). A significant interaction was found between cyclothymic
temperament score and sex in predicting brachial systolic blood pressure (p = 0.025), between irritable and
anxious temperament scores and sex in predicting pulse wave velocity (p = 0.021, p = 0.023, respectively) and
an interaction with borderline significance between hyperthymic temperament score and sex in predicting
augmentation index (p = 0.052).
Conclusions: The present findings highlight elevated blood pressure among subjects with high cyclothymic
temperament as well as an increased level of arterial stiffening in subjects with low hyperthymic scores suggesting that
affective temperaments may play a role in the development of hypertension and arterial stiffening and may thus
represent markers of cardiovascular risk. Sex differences were also present in these associations.
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Cardiovascular diseases are the leading cause of morbidity
and mortality in most industrialized countries worldwide,
despite highly effective preventive treatments. A continu-
ous linear relationship between elevated blood pressure
and incident cardiovascular events is well known at all
ages and in all ethnic groups [1–5]. In addition to elevated
blood pressure, arterial stiffening – integrating the damage
of risk factors on the aortic wall over a long period [6] – is
increasingly recognized as a marker and mediator of car-
diovascular diseases. Accordingly, carotid-femoral pulse
wave velocity (PWV), an accepted non-invasive measure
of arterial stiffness, is recommended for cardiovascular
risk prediction among hypertensive patients in European
Guidelines [7].
Depression is also a common public health problem in
the Western world and its strong connection with cardio-
vascular diseases is broadly recognized [8]. The pathophys-
iologies of depression and cardiovascular diseases show
several similarities that include the dysregulation of meta-
bolic, immune-inflammatory and autonomic systems as
well as the hypothalamic-pituitary axis [9]. In addition to
depression, anger, hostility and anxiety – the negative
impact of adverse individual psychological traits and char-
acteristics – are also well-documented risk factors of cor-
onary heart diseases [10, 11], while antagonism-related
traits also appear to predict a variety of cardiovascular out-
comes [12, 13].
Temperament is regarded as an inherited part of
personality and represents the biologically stable core
of emotional reactivity [14, 15]; however, there is on-
going discussion regarding the influence of age on de-
pressive temperament with differences between man
and women also being present [16]. Affective tempera-
ments can be measured on five temperament scales by
the Temperament Evaluation of Memphis, Pisa, Paris
and San Diego Autoquestionnaire (TEMPS-A) [17].
Hyperthymic temperament is characterized by upbeat,
overconfident and over-energetic traits while depressive
temperament is self-denying, striving to live in harmony
with others and sensitive to suffering. Anxious tempera-
ment can best be explained by exaggerated worries espe-
cially toward family members. Cyclothymic temperament
shows affective instability with rapid mood shifts and in-
tense emotions, while irritable temperament incorporates
skeptical and critical traits [15, 18, 19]. Affective tempera-
ments are also associated with numerous other measures
of psychopathology [20]. Specific affective temperament
types are the subclinical, trait-related manifestations and
commonly the antecedents of minor and major mood dis-
orders [21], where hyperthymic affective temperament can
inversely be related to depression [22]. Recently, we de-
scribed an association between chronic hypertension and
the dominant cyclothymic temperament [23]. Cyclothymic
temperament was also associated with acute coronary
events in hypertensive patients [24]. In a small matched
case-control study comparing hypertensive patients with
and without dominant affective temperaments, we found
lower peripheral and central diastolic blood pressure
values and decreased serum brain-derived neurotrophic
factor levels in patients with dominant temperaments
[25]. Since the ratio of those subjects who score high on
different temperament directions while having a dominant
affective temperament is relatively low (rarely does a sub-
ject have multiple dominant temperaments), as found in
only 16.8 % of the general population [26], it would be
important to ascertain the continuous association between
affective temperament scores and blood pressure or
arterial stiffness parameters.
We hypothesized that individual affective tempera-
ment scores may be related to brachial blood pressure as
well as arterial stiffness in chronic hypertensive patients.
We speculated a positive association in instances of de-
pressive, cyclothymic, irritable or anxious temperaments
and an inverse association in instances of hyperthymic
temperament. We also hypothesized the presence of sex
differences in relation to these studied associations.
Methods
Patients
In the present cross-sectional study, 173 Caucasian pa-
tients with well-controlled or grade 1 chronic (on medi-
cation for >3 months) hypertension were investigated
in three primary care practices. Patients with atrial
fibrillation and treated depression or with dementia
potentially interfering with the completion of question-
naires were excluded. Patients on moderate doses of
alprazolam (<0.5 mg/day) were not excluded. All of the
48 patients of our previous pilot study [25] were also
involved in the present study.
Evaluation of affective temperaments, depression and
anxiety
The Temperament Evaluation of Memphis, Pisa, Paris
and San Diego Autoquestionnaire (TEMPS-A) was used
to assess affective temperaments on depressive, cyclothy-
mic, hyperthymic, irritable and anxious subscales, re-
quiring ‘yes’ (score 1) or ‘no’ (score 0) answers [17].
TEMPS-A contains 110 items (109 in the version for
males) and the questions of the various temperament
types are grouped together as follows:
1. depressive temperament: questions 1 to 21
(21 points)
2. cyclothymic temperament: questions 22 to 42
(21 points)
3. hyperthymic temperament: questions 23 to 63
(21 points)
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4. irritable temperament: questions 64 to 84
(21 points in women, 20 in the men’s version)
5. anxious temperament: questions 85 to 110
(26 points).
TEMPS-A has been extensively studied, translated into
more than 25 languages and validated in several of the
latter. Similarities and differences were also found in na-
tional samples which suggest that distribution of
affective temperaments has both universal and cultural-
specific characteristics [16].
The Beck Depression Inventory (BDI), created by
Aaron T. Beck, is a 21-question multiple-choice self-
report questionnaire and is one of the widely used in-
struments for measuring depression severity. Partici-
pants are asked to make ratings on a four point scale,
where a higher score correlates with more severe depres-
sion [27].
The Hamilton Anxiety Scale (HAM-A) was used to
study the severity of anxiety. The scale consists of 14
items, each item is scored on a scale of 0 (not present)
to 4 (severe anxiety) [28].
Blood pressure and arterial stiffness measurements
Measurements were performed in a temperature-
controlled room, between 7.00 and 8.00 a.m. prior to
blood collection. Patients were required to fast overnight
and refrain from smoking and drinking caffeine-
containing beverages before the procedure, but to take
their usual blood pressure medication. Upon arrival and
after 5 min rest, two brachial blood pressure measure-
ments were taken on each arm in the sitting position
with a validated oscillometric blood pressure device
(Omron M3). The mean value of the higher side of arms
was further taken into calculation as brachial systolic
(SBPbrach) and diastolic (DBPbrach) blood pressures
and heart rate. Brachial pulse pressure (PPbrach) was
also calculated from these data. The subjects were next
fitted with arterial stiffness measurement device and
were asked to rest in the supine position for approxi-
mately 15 min before being measured. Arterial stiffness
parameters were evaluated with the gold-standard tono-
metric method (PulsePen, DiaTecne, Milan, Italy) [29].
This method provides estimates of pulse wave velocity
(PWV) and in which central systolic blood pressure
(SBPcentr), central pulse pressure (PPcentr) and pulse
pressure amplification (PPAmp) can be calculated. Aug-
mentation index (Aix), a widely used wave reflection
parameter, can also be measured by automatic identifica-
tion of the “first shoulder” (inflection point) of the aver-
aged carotid pulse signal by the PulsePen software. This
index is provided by the pressure amplitude following
this point divided by the pulse pressure and calculated
as a percentage. In these calculations, brachial blood
pressure values measured in the supine position were
used, which were required for calibration after each (ca-
rotid or femoral) pulse wave detection. In each subject,
two sequences of arterial stiffness measurements were
performed and their mean used for statistical analysis. In
the PWV calculations, 80 % of the carotid-femoral dis-
tance was used, according the most recent recommenda-
tion [30]. The intra- and interobserver variability of
PWV measurements obtained by the PulsePen device in
hypertensive patients was 4.6 and 6.3 %, respectively.
Since PulsePen calculates pressures based on brachial
diastolic blood pressure calibration, the calculated cen-
tral diastolic blood pressure is identical to the brachial
diastolic blood pressure assessed in the supine position
[29].
Statistical analysis
Descriptive data are expressed as mean ± standard devi-
ation or median with interquartile ranges or percentages.
Normality of continuous parameters was tested with the
Kolmogorov-Smirnov test. Pearson correlation coeffi-
cients were calculated to study the relationship between
affective temperament scores and demographic,
hemodynamic or arterial stiffness parameters. Multiple
linear regression analysis was used to study the determi-
nants of these hemodynamic or arterial stiffness parame-
ters which were associated in univariate analysis with
affective temperaments. Based on literature data, sex dif-
ferences in the association between affective tempera-
ments and the studied hemodynamic or arterial stiffness
parameters [16] were expected, and therefore sex and its
interaction with the given affective parameter was in-
cluded into all regression models and where an inter-
action was found, such interaction was further studied.
A two-sided p < 0.05 was considered to be significant.
SPSS 13.0 for Windows was used for all calculations.
Results
A total of 173 subjects were included. Baseline demo-
graphic and laboratory parameters, current medication,
TEMPS-A, BDI and HAM-A scores, central blood pres-
sure and arterial stiffness parameters are summarized in
Table 1. The median number of antihypertensive drugs
taken was 2 (IQR: 2-3).
Table 2 lists the hemodynamic or arterial stiffness pa-
rameters and their significant correlations for which
affective temperaments were also significantly associated.
Table 2 also shows those variables which were not sig-
nificantly correlated with outcome variables, but were
entered into the final multiple regression models. Partial
correlations corrected for age and sex are also demon-
strated. Although, in univariate models, affective tem-
perament scores were associated with hemodynamic or
arterial stiffness parameters in many cases, however,
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upon further correction for age and sex, certain temper-
aments failed to be independent covariables of these
parameters, notably irritable temperament score of bra-
chial systolic blood pressure (p = 0.056) and depressive
temperament score of Aix (p = 0.595). Table 3 demon-
strates that cyclothymic temperament score was an inde-
pendent covariate of brachial systolic blood pressure and
hyperthymic temperament of Aix after adjustment for
further relevant confounders. In the final model adjusted
for all potential confounders, a one-unit increase in cyclo-
thymic score was associated with 0.529 (95 % CI: 0.019-
1.040) mmHg higher brachial systolic blood pressure
while a one-unit increase in hyperthymic score was associ-
ated with -0.612 (95 % CI: -1.092–0.132) % lower Aix.
With regard to the association between PWV and irrit-
able temperament score, the correlation still remained sig-
nificant (p = 0.012) after adjustment for age, sex, brachial
systolic blood pressure, GFR-EPI, blood glucose and dur-
ation of hypertension, although became non-significant
after further adjustment for BDI and HAM-A scores and
the use of alprazolam (p = 0.078). The same results were
also found for anxious temperament score and PWV: the
significant association (p = 0.043) that was present after
adjustment for age, sex, brachial systolic blood pressure,
GFR-EPI, blood glucose and duration of hypertension
disappeared after further adjustment for BDI and HAM-A
scores and the use of alprazolam (p = 0.475).
When studying the interaction between cyclothymic tem-
perament score and sex in predicting brachial systolic blood
pressure, a significant association was found (p = 0.025,
Fig. 1a). There was a positive association between cyclothy-
mic temperament score and brachial systolic blood pres-
sure in men (B = 1.012, SE = 0.392, p = 0.011) which was
absent in women (B = 0.294, SE = 0.311, p = 0.346). After
adjustment for age, brachial diastolic blood pressure, chol-
esterol and triglycerides, this interaction became non-
significant (p = 0.090; in men B = 0.680, SE = 0.347, p =
0.052 and in women B = 0.279, SE = 0.272, p = 0.307).
Table 1 Baseline characteristics of study participants
N (male/female) 173 (68/105)
Age (years) 63 (53-70)
Duration of hypertension (year) 9 (3-16)
Diabetes [n (%)] 38 (22)
CV disease [n (%)] 26 (15)
Current smoker [n (%)] 33 (19.1)
Body height [cm] 168 (160-174)
Body weight [kg] 80 (70-90)
BMI [kg/m2] 27.8 (25.3-31.2)
Blood glucose [mmol/l] 5.6 (5.1-6.6)
GFR-EPI [ml/min/1.73 m2] 81.9 (67.9-90)
Uric acid [μmol/l] 324.2 ± 79.6
Total cholesterol [mmol/l] 5.2 ± 1.1
Triglyceride [mmol/l] 1.4 (1.1-2.1)
Medications
ACE-inhibitor [n (%)] 116 (67.1)




Beta-blocker [n (%)] 98 (56.6)
Diuretic [n (%)] 72 (41.6)
Antiplatelet drug [n (%)] 52 (30.1)
Statin [n (%)] 57 (33.4)
Alprazolam [n (%)] 23 (13.3)










Heart rate [1/min] 70.8 (64.8-78)
SBPbrach [mmHg] 133.5 ± 12
DBPbrach [mmHg] 75.6 ± 9.2
PPbrach [mmHg] 54.2 (47.1-62.4)
SBPcentr [mmHg] 123 (113.2-130.8)
Table 1 Baseline characteristics of study participants (Continued)
PPcentr [mmHg] 51 (43.5-60.4)
PPAmp 1.07 (1.00-1.13)
PWV (m/sec) 8.7 (7.7-9.9)
Aix (%) 15.5 (8.5-25.2)
Data are presented as mean ± SD or median (interquartile range). Categorical
parameters are presented as n (%). CV diseases cardiovascular diseases, BMI
body mass index, GFR-EPI glomerular filtration rate assessed by the chronic
kidney disease epidemiology collaboration glomerular filtration rate equation,
ACE Angiotensin converting enzyme, ARB angiotensin II receptor blocker,
TEMPS-A Temperament Evaluation of Memphis Pisa, Paris and San Diego
questionnaire, BDI Beck Depression Inventory, HAM-A Hamilton Anxiety Scale,
SBPbrach brachial systolic pressure, DBPbrach brachial diastolic pressure,
PPbrach brachial pulse pressure, SBPcentr central systolic pressure, PPcentr
central pulse pressure, PPAmp pulse pressure amplification, PWV carotid-
femoral pulse wave velocity, Aix augmentation index
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There was also a significant interaction between irrit-
able temperament score and sex in predicting PWV (p =
0.021). There was a positive association between irritable
temperament score and PWV in men (B = 0.154, SE =
0.060, p = 0.012) which was absent in women (B = 0.076,
SE = 0.064, p = 0.235) (Fig. 1b). After adjustment for age,
blood glucose, brachial systolic blood pressure and GFR-
EPI, the interaction p-value was attenuated (p = 0.037),
however the strength of the association remained similar
(in men B = 0.104, SE = 0.050, p = 0.039 and in women B
= 0.082, SE = 0.052, p = 0.116). The interaction became
non-significant (p = 0.168) after further adjustment for
BDI and HAMA-A scores and the regular use of
alprazolam (in men B = 0.091, SE = 0.051, p = 0.078 and
in women B = 0.054, SE = 0.061, p = 0.375).
Similarly to irritable temperament, there was also a
significant interaction between the anxious temperament
score and sex in predicting PWV (p = 0.023). There was
a positive association between anxious temperament
score and PWV in men (B = 0.106, SE = 0.043, p = 0.015)
which was absent in women (B = 0.047, SE = 0.036, p =
0.189) (Fig. 1c). After adjustment for age, blood glucose,
brachial systolic blood pressure and GFR-EPI, the inter-
action p-value was attenuated (p = 0.046), however the
strength of the association remained similar in men (in
men B = 0.088, SE = 0.036, p = 0.017 and in women B =
0.021, SE = 0.030, p = 0.484). The interaction became
non-significant (p = 0.135) after further adjustment for
BDI and HAMA-A scores and the regular use of al-
prazolam (in men B = 0.070, SE = 0.039, p = 0.075 and in
women B = -0.017, SE = 0.037, p = 0.656).
An interaction with borderline significance (p = 0.052)
was found between sex and hyperthymic affective tem-
perament in predicting Aix. An inverse association was
found in women (B = -0.754, SE = 0.326, p = 0.022) which
was absent in men (B = -0.305, SE = 0.370, p = 0.411)
(Fig. 1d). This interaction became weaker (p = 0.064)
after further adjustment for age, smoking, heart rate and
uric acid (in women B = -0.678, SE = 0.312, p = 0.032 and
in men B = -0.327, SE = 0.352, p = 0.325).
Table 2 Variables with significant Pearson correlations and
variables entered in the final multiple linear regression model
showing the independent predictors of brachial systolic blood
pressure, pulse wave velocity and augmentation index
Variable R p Partial Ra p
Brachial systolic blood pressure
Sex -0.155 0.048 - -
Cholesterol [mmol/l] -0.179 0.022 -0.072 0.365
DBPbrach [mmHg] 0.428 <0.001 0.474 <0.001
PPbrach [mmHg] 0.484 <0.001 0.489 <0.001
SBPcentr [mmHg] 0.591 <0.001 0.598 <0.001
DBPcetr [mmHg] 0.284 <0.001 0.329 <0.001
PPcentr [mmHg] 0.461 <0.001 0.471 <0.001
SBP amplification [mmHg] 0.281 <0.001 0.300 <0.001
PWV [m/s] 0.261 <0.001 0.265 0.001
TEMPS-A Irritable 0.171 0.030 0.151 0.056
TEMPS-A Cyclothymic 0.167 0.032 0.171 0.030
Age 0.037 0.630 - -
BDI 0.006 0.932 0.026 0.738
HAM-A 0.062 0.430 0.082 0.299
Alprazolam 0.007 0.932 0.018 0.820
Pulse wave velocity
Age [year] 0.544 <0.001 - -
Duration of hypertension [year] 0.250 <0.001 -0.019 0.808
CV disease 0.241 0.001 0.095 0.218
Blood glucose [mmol/l] 0.213 0.005 0.128 0.097
GFR-EPI [ml/min/1.73 m2] - 0.308 <0.001 -0.112 0.154
SBPbrach [mmHg] 0.260 <0.001 0.265 0.001
PPbrach [mmHg] 0.507 <0.001 0.408 <0.001
SBPcentr [mmHg] 0.410 <0.001 0.369 <0.001
PPcentr [mmHg] 0.478 <0.001 0.338 <0.001
TEMPS-A Irritable 0.156 0.040 0.173 0.025
TEMPS-A Anxious 0.157 0.039 0.156 0.043
BDI 0.164 0.031 0.104 0.176
HAM-A 0.173 0.024 0.179 0.021
Sex -0.143 0.059 - -
Alprazolam 0.121 0.111 0.078 0.308
Augmentation index
Age [year] 0.203 <0.001 - -
Sex 0.347 <0.001 - -
Current smoking [p/y] 0.159 0.038 0.175 0.023
Body height [cm] 0.247 0.001 -0.021 0.791
Heart rate [1/min] -0.195 0.013 -0.151 0.058
Uric acid [μmol/l] -0.255 <0.001 -0.163 0.035
TEMPS-A Depressive 0.168 0.027 0.041 0.595
Table 2 Variables with significant Pearson correlations and
variables entered in the final multiple linear regression model
showing the independent predictors of brachial systolic blood
pressure, pulse wave velocity and augmentation index
(Continued)
TEMPS-A Hyperthymic -0.215 0.004 -0.158 0.034
BDI 0.054 0.478 -0.097 0.210
HAM-A 0.040 0.605 -0.057 0.467
Alprazolam 0.048 0.525 -0.023 0.768
aPartial R: partial correlation coefficient, corrected for age and sex. See Table 1
for the rest of abbreviations
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Discussion
To the best of our knowledge, this is the first study to
demonstrate that, in chronic hypertensive patients, cyclo-
thymic temperament score is associated with brachial sys-
tolic blood pressure while hyperthymic temperament
score is independently related to the augmentation index
after adjustment for potential confounders including se-
verity of depression and anxiety and the use of alprazolam.
Sex differences were also found in relation with brachial
systolic blood pressure and cyclothymic temperament
score, pulse wave velocity and irritable and anxious tem-
perament scores and augmentation index and hyperthy-
mic temperament score.
Previous findings support our present observations
that affective temperaments are associated with cardio-
vascular pathology. For example, patients with cyclo-
thymic, irritable and anxious temperaments were shown to
have a tendency to obesity [31]. Depressive temperament
was also found to be associated with worse metabolic
control in type-2 diabetes [32], while anxious temperament
Table 3 Predictive value of cyclothymic affective temperament scores on brachial systolic blood pressure and of hyperthymic
affective temperament scores on augmentation index in the various models. The progressive involvement of variables into models
and other significant predictors in the final models are also demonstrated
Model B Std. Error Std. Beta P Adj. R2
Brachial systolic blood pressure
Model 1 0.023
Cyclothymic temp. score 0.539 0.247 0.171 0.030
Model 2: Model 1 + Age + Sex 0.041
Cyclothymic temp. score 0.568 0.245 0.180 0.022
Model 3: Model 2 + DBPbrach 0.245
Cyclothymic temp. score 0.464 0.218 0.147 0.034
Model 4: Model 3 + Triglyceride + Cholesterol 0.275
Cyclothymic temp. score 0.431 0.214 0.137 0.045
Model 5: Model 4 + BDI + HAM-A + Alp 0.269
Cyclothymic temp. score 0.529 0.258 0.167 0.042
Age 0.177 0.076 0.181 0.021
DBPbrach 0.629 0.094 0.482 <0.001
Triglyceride -1.981 0.987 -0.141 0.047
Augmentation index
Model 1 0.045
Hyperthymic temp. score -0.733 0.255 -0.227 0.004
Model 2: Model 1 + Age + Sex 0.187
Hyperthymic temp. score -0.509 0.239 -0.158 0.034
Model 3: Model 2 + Smoking 0.209
Hyperthymic temp. score -0.562 0.237 -0.174 0.019
Model 4: Model 3 + Heart rate 0.231
Hyperthymic temp. score -0.555 0.234 -0.172 0.019
Model 5: Model 4 + Uric acid 0.243
Hyperthymic temp. score -0.523 0.232 -0.162 0.026
Model 6: Model 5 + BDI + HAM-A + Alp 0.244
Hyperthymic temp. score -0.612 0.243 -0.189 0.013
Age 0.297 0.087 0.258 0.001
Sex 7.445 2.189 0.264 0.001
Smoking 6.159 2.610 0.176 0.020
Heart rate -0.209 0.098 -0.152 0.035
Std. Error standard error, Std. Beta Standardized Beta, Adj. R2 adjusted R2, Cyclothymic temp. score cyclothymic affective temperament score, DBPbrach brachial
diastolic blood pressure, BDI Beck Depression Inventory, HAM-A Hamilton Anxiety Scale, Alp patients regularly using alprazolam, Hyperthymic temp. score
Hyperthymic affective temperament score
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was associated with an increased likelihood for the pres-
ence of prediabetic condition [33]. Our result with regard
to cyclothymic temperament is in line with our previous
findings in which dominant cyclothymic temperament
demonstrated a significant association with the presence
of hypertension [23] and with acute coronary events in a
hypertensive patient population [24].
An increasing cyclothymic temperament score was
found herein to be associated with a higher brachial
systolic blood pressure. This temperament shows a
central dimension that includes rapid fluctuations in
mood and emotional instability. Such alterations can
span from lethargy to eutonia, from pessimistic brood-
ing to optimistic, from hypersomnia to decreased need
for sleep or from introverted self-absorption to unin-
hibited people-seeking [18]. In contrast, hyperthymic
temperament, which was associated in our study with
better wave reflection, can be described as a tempera-
ment that displays extroversion, emotional intensity, a
high level of life-energy and little need for sleep. Sub-
jects with hyperthymic temperament are cheerful, over-
optimistic, overconfident as well as over-talkative and
vigorous [18]. While the hyperthymic temperament is
associated with better quality of life (QOL), the cyclothy-
mic temperament is conversely associated with worse
QOL [18]. Moreover, people with hyperthymic tempera-
ment can better cope with somatic problems [34], while
cyclothymic disposition is related to a high somatic risk
[35]. Based on these results, we hypothesize that there is a
likely differential impact of these two temperaments on
vascular pathology, although prospective studies are re-
quired to confirm this hypothesis.
There are existing data in the literature regarding the as-
sociation between personality traits and arterial stiffening.
In a study by Midei and Matthews, higher trait anxiety
and hostility were associated with a higher PWV [36]. In
the Baltimore Longitudinal study of Aging, middle-aged
adults with suppressed anger had elevated carotid arterial
stiffness [37]. In keeping with these studies, irritable and
anxious affective temperament scores were found herein
to be covariates of PWV after adjustment for age, sex,
brachial systolic blood pressure, blood glucose, GFR-
EPI and duration of hypertension. However, these
associations became non-significant after further ad-
justment with severity of depression and anxiety and
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Fig. 1 The interaction between sex and different affective temperaments in the prediction of the studied variables. a cyclothymic temperament
score and brachial systolic blood pressure; b irritable temperament score and pulse wave velocity; c anxious temperament score and pulse wave
velocity; d hyperthymic temperament score and augmentation index. Error bars represent ± 1 standard errors
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associated with depression and anxiety [38, 39], we can
hypothesize that, similarly to the relationship between
life stress and arterial stiffness [40], the association
between anxious and irritable affective temperaments
and PWV is partly mediated by severity of depressive
and anxiety symptoms.
Augmentation index is an accepted parameter of pulse
wave analysis. Aix is associated with age, sex, body height,
smoking and heart rate [41, 42], associations which were
also reproduced in the present study. Aix is furthermore
reported to be a predictor of mortality in various patho-
logical conditions, such as end-stage renal disease [43] or
coronary artery disease [44], and its predictive value was
also confirmed by a meta-analysis [45]. In the study of
Seldenrijk et al., anxiety-related symptoms were found to
be associated with Aix [39]. Our present results indicate
that hyperthymic affective temperament score is an inde-
pendent covariable of Aix with higher scores being associ-
ated with better wave reflection and thus a preserved
elasticity of the arteries. This suggests a protective role of
hyperthymic temperament on cardiovascular pathology
and emphasizes the potential of further evaluation of
affective temperaments with wave reflection parameters.
Significant interactions were also found in the present
study between sex and cyclothymic temperament score
in predicting brachial systolic blood pressure, between
sex and irritable temperament as well as between sex
and anxious temperament scores in predicting PWV,
while the interaction between sex and hyperthymic tem-
perament score in predicting Aix had borderline signifi-
cance. These findings are consistent with the study of
Williams et al., where trait anger was associated with
elevated arterial stiffness in men, while in women the
association was marginally significant [46]. These results
suggest that, similarly to the presence of sex differences
in scoring in different affective temperament directions
[16], sex differences are also present in the associations
between affective temperament scores and brachial
systolic blood pressure and arterial stiffness parame-
ters. Additional studies are likely needed to specify
these observed sex differences, including taking into
consideration menopausal status or the use of hormone
replacement therapy.
The pathophysiological background of our findings is
complex and remains to be clarified. Subjects in states
of anger or hostility show elevated levels of inflamma-
tion [47, 48] and those with anxiety show reduced auto-
nomic nervous system function [49]. The involvement
of neurotrophic molecules should also be considered since
we recently demonstrated decreased serum brain-derived
neurotrophic factor levels in chronic hypertensive patients
with dominant cyclothymic, depressive, anxious or irrit-
able affective temperament [25]. However, this area also
requires further studies.
One of the limitations of the present analysis is the
relatively low number of chronic hypertensive patients
used to study the associations between affective temper-
aments and blood pressure or arterial stiffness parame-
ters, which limits the generalizability of our results, as
well as the number of entered confounders into regres-
sion analyses. Another main limitation stems from its
cross-sectional design which precludes causal inference.
Moreover, although our methodology used standardized
questionnaires and excluded patients with dementia, a
complete exclusion of misinterpretations or mistakes by
patients is nevertheless impossible.
Conclusions
In conclusion, the elevated blood pressure among sub-
jects with high cyclothymic temperament and the in-
creased level of arterial stiffening in subjects with low
hyperthymic scores suggest that affective temperaments
might play a role in the development of hypertension
and arterial stiffening and thus could represent potential
markers of cardiovascular risk. The discovered sex differ-
ences in numerous studied associations may be the
consequence of the known differences in affective tem-
peraments between men and women. Cumulating data
suggest that the identification of affective temperaments
in the future can improve both the psychopathological
and cardiovascular risk stratification of patients leading
to a more accurate, personalized patient management.
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Hyperthymic affective temperament 
and hypertension are independent 
determinants of serum brain-derived 
neurotrophic factor level
János Nemcsik1,2†, Andrea László1†, Lilla Lénárt3,4†, Dániel Eörsi1, Péter Torzsa1, Beáta Kőrösi1, Orsolya Cseprekál5, 
András Tislér6, Ádám Tabák6,7, Xenia Gonda8,9,10* , Zoltán Rihmer9,10, Judit Hodrea3,4, Zsófia Nemcsik‑Bencze11 
and Andrea Fekete3,4
Abstract 
Background: Brain‑derived neurotrophic factor (BDNF) has neuroprotective, proangiogenic and myogenic effects 
and, therefore, possibly acts as a psychosomatic mediator. Here, we measured serum BDNF (seBDNF) level in hyper‑
tensive patients (HT) and healthy controls (CONT) and its relation to affective temperaments, depression and anxiety 
scales, and arterial stiffness parameters.
Methods: In this cross‑sectional study, affective temperaments, anxiety, and depression were studied with question‑
naires (TEMPS‑A, HAM‑A, and BDI, respectively). SeBDNF level and routine laboratory parameters were measured as 
well. Arterial stiffness was evaluated with a tonometric method.
Results: Allover, 151 HT, and 32 CONT subjects were involved in the study. SeBDNF level was significantly higher in 
HT compared to CONT (24880 ± 8279 vs 21202.6 ± 6045.5 pg/mL, p < 0.05). In the final model of regression analy‑
sis, hyperthymic temperament score (Beta = 405.8, p = 0.004) and the presence of hypertension (Beta = 6121.2, 
p = 0.001) were independent determinants of seBDNF. In interaction analysis, it was found that in HT, a unit increase 
in hyperthymic score was associated with a 533.3 (95 %CI 241.3–825.3) pg/mL higher seBDNF. This interaction was 
missing in CONT.
Conclusions: Our results suggest a complex psychosomatic involvement of BDNF in the pathophysiology of hyper‑
tension, where hyperthymic affective temperament may have a protective role. BDNF is not likely to have an effect on 
large arteries.
Keywords: Brain‑derived neurotrophic factor, Hypertension, Affective temperaments, Arterial stiffness
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Brain-derived neurotrophic factor (BDNF) is a member 
of the neurotrophic factor family, playing a central role 
in the regulation of neuronal growth, maintenance, and 
survival [1]. Its involvement in psychiatric conditions is 
well described and was confirmed by a meta-analysis, 
as in major depressive disorder, the decreased serum 
BDNF (seBDNF) level was elevated following a course 
of antidepressant treatment [2]. In addition to its neu-
rotrophic effects, BDNF has proangiogenic features as 
well. The importance of BDNF was suggested also in high 
cardiovascular risk conditions, such as obesity, meta-
bolic syndrome, and coronary atherosclerosis [3–5]. It is 
hypothesized to play a protective role in cardiovascular 
pathophysiology as its higher serum level was found to be 
associated with decreased risk of cardiovascular disease 
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and mortality [6]. It was demonstrated that circulating 
BDNF is influenced by age and gender [7], the presence 
of diabetes [8], and the use of benzodiazepines in differ-
ent neurological diseases [9], correlates with total choles-
terol [4], and BDNF is stored and released from platelets 
during activation [10]. Hypertension has widely studied 
psychosomatic connections [11, 12]; however, the role of 
BDNF in this condition has not been extensively evalu-
ated yet.
Affective temperament types (depressive, cyclothymic, 
hyperthymic, irritable, and anxious) are subclinical, trait-
related manifestations and commonly the antecedents 
of minor and major mood disorders [13]. Previously, we 
clarified an association between dominant cyclothymic 
affective temperament and hypertension [14]. Recently, 
we demonstrated decreased seBDNF level in chronic 
hypertensive patients with dominant anxious, irritable, 
depressive or cyclothymic temperaments compared with 
hypertensive controls without dominant temperaments 
[15]. However, the association between affective tem-
perament scores, as continuous variables and seBDNF in 
chronic hypertension, has not been clarified yet.
Arterial stiffening is increasingly recognized as an inde-
pendent risk factor for cardiovascular diseases. Carotid–
femoral pulse wave velocity (PWV) is the most accepted 
non-invasive arterial stiffness parameter for cardiovascu-
lar risk assessment among hypertensive patients [16]. In 
different animal models, BDNF was shown to be vasore-
laxant not only on pulmonary arteries [17] but also on rat 
aortic rings [18]. Based on these data, a possible associa-
tion between the seBDNF level and different arterial stiff-
ness parameters can also be supposed in humans.
We hypothesized that as hypertension is a risk fac-
tor for cardiovascular diseases and BDNF is protective 
in cardiovascular pathology, seBDNF can be altered in 
hypertension. We also presumed that seBDNF is associ-
ated with different affective temperaments, depression, 
anxiety, and arterial stiffness parameters providing a new 
bridge of psychosomatic processes.
Methods
In this cross-sectional study, chronic (>12 months medi-
cation) well-controlled or grade 1 consecutive hyperten-
sive Caucasian patients (HT) and age-matched healthy 
controls (CONT) of three primary care practices were 
involved. All of the chronic hypertensive patients of our 
previous, pilot study [15] were involved into this study as 
well. Data of the involved subjects were analyzed for the 
relationship between the seBDNF level, routine labora-
tory parameters, affective temperaments, anxiety, depres-
sion, and arterial stiffness parameters. Exclusion criteria 
for HT were the presence of atrial fibrillation, treated 
depression, bipolar disorder or dementia posing an 
obstacle to completing questionnaires. Moderate use of 
the anxiolytic alprazolam (less than 0.5 mg/day) was not 
a restrictive criterion. In the case of CONT, the denial of 
consent was the only exclusion criterion.
Evaluation of affective temperaments, depression, 
and anxiety
The Temperament Evaluation of Memphis, Pisa, Paris 
and San Diego Autoquestionnaire (TEMPS-A) was used 
to assess affective temperaments on depressive, cyclo-
thymic, hyperthymic, irritable, and anxious subscales, 
requiring ‘yes’ (score 1) or ‘no’ (score 0) answers [19]. It 
contains 110 items (109 in the version for males), and the 
questions of the various temperament types are grouped 
together as follows:
1. depressive temperament: questions 1 to 21 (21 
points);
2. cyclothymic temperament: questions 22 to 42 (21 
points);
3. hyperthymic temperament: questions 23 to 63 (21 
points);
4. irritable temperament: questions 64 to 84 (21 points 
in women and 20 points in men version);
5. anxious temperament: questions 85 to 110 (26 
points).
The Beck depression inventory (BDI) is a 21-question 
multiple-choice self-report questionnaire, one of the 
widely used instruments for measuring the severity of 
depression. Participants are asked to make ratings on a 
four-point scale, where a higher score correlates with 
more severe depression [20].
Hamilton anxiety scale (HAM-A) was evaluated by the 
examiner to study the severity of anxiety. The scale con-
sists of 14 items, and each item is scored on a scale of 0 
(not present) to 4 (severe anxiety) [21].
Measures of blood pressure and arterial stiffness
Arterial stiffness parameters were evaluated with the 
validated tonometric PulsePen device (DiaTecne, Milan, 
Italy). Measurements were performed in a temperature-
controlled room in supine position, on the day of blood 
sampling, prior to it, between 7:00 and 8:00 a.m. Patients 
were asked to refrain from eating, smoking, and caffeine-
containing drinks in the morning of the procedure, but to 
take the regular blood pressure medication. Upon arrival 
after 5  min rest, two brachial blood pressure measure-
ments were taken on each arm in the sitting position with 
a validated oscillometric blood pressure device (Omron 
M3). The mean value of the higher side was further taken 
into calculation as brachial systolic (brachial SBP) and 
diastolic (brachial DBP) blood pressures and heart rate. 
DOI:10.14753/SE.2020.2300
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Next, subjects were equipped with arterial stiffness meas-
urement devices and then rested in the supine position for 
approximately 15  min before being measured. The mean 
of two successful measurements was used in the statistical 
calculations. In the PWV calculations, 80 % of the carotid–
femoral distance was used following the recent guide-
line [22]. Augmentation index (AI), central systolic blood 
pressure (cSBP), central pulse pressure (cPP), and pulse 
pressure amplification (PPAmp) were also calculated. As 
PulsePen calculates pressure values using brachial diastolic 
blood pressure calibration, the calculated central and bra-
chial diastolic blood pressure values were identical [23].
Measurement of seBDNF concentration
Peripheral blood samples of patients were collected in 
anticoagulant-free tubes, right after the measurement 
of arterial stiffness. After centrifugation (3600  rpm 
for 6  min), the serum was stored at −20  °C. SeBDNF 
was measured using commercially available sandwich 
enzyme-linked immunosorbent assay (R&D Systems, 
Minneapolis MN, USA) according to the manufacturer’s 
protocol, and serum BDNF level was determined in pg/
mL.
Statistical analysis
Normality of the parameters was tested with the Kol-
mogorov–Smirnov test. Descriptive characteristics, labo-
ratory, arterial stiffness parameters and TEMPS-A, BDI, 
HAM-A scores were compared between CONT and HT 
groups using unpaired Student’s t tests or Mann–Whitney 
rank sum test for data failing tests of normality. The equal-
ity of variances was studied with Levene’s test. Pearson 
correlation coefficients were calculated to study the rela-
tionship between seBDNF and all other factors measured. 
Hierarchic linear regression analysis was used to study 
the determinants of seBDNF in the whole population 
with a stepwise entry of variables with either previously 
described association with seBDNF or with a significant 
univariate correlation with seBDNF in the present data 
set. As a bidirectional association can be hypothesized 
between affective temperaments and hypertension [14], 
predetermined interaction analysis was performed to 
investigate moderation between hypertension and affec-
tive temperament scores on seBDNF level.
Data were expressed as mean ± standard deviation or 
mean with interquartile ranges. p < 0.05 was considered 
to be significant. SPSS 13.0 for Windows was used in 
calculations.
Results
Altogether, 151 HT and 32 CONT subjects were 
involved. Eleven of the invited HT and four CONT did 
not give their informed consent and were excluded. 
Baseline demographic and laboratory parameters, cur-
rent medication, TEMPS-A, BDI, and HAM-A scores, 
central blood pressure, and arterial stiffness parame-
ters as well as seBDNF levels are shown in Table 1. The 
median number of the used antihypertensive compounds 
was 2 (IQR: 2–3). Differences between CONT and HT 
were found in body weight and BMI, serum glucose, 
cholesterol, LDL and HDL, BDI and HAM-A scores, in 
the brachial and central systolic blood pressure and the 
brachial pulse pressure. SeBDNF was elevated in HT 
(Table 1). In the analysis of simple correlations, the fol-
lowing parameters were found to be associated signifi-
cantly with seBDNF: hypertension (r = 0.174, p = 0.018), 
serum cholesterol (r = 0.194, p = 0.009), LDL (r = 0.208, 
p = 0.015) and HDL level (r = 0.204, p = 0.006), platelet 
count (r =  0.188, p =  0.011), pulse pressure amplifica-
tion (r =  0.157, p =  0.037), and hyperthymic tempera-
ment score (r = 0.189, p = 0.010). Tendencies of inverse 
correlations were found with the presence of diabetes 
or the use of alprazolam, but these were not signifi-
cant (r = −0.114, p =  0.12 and r = −0.103, p =  0.16, 
respectively).
Table  2 demonstrates the results of hierarchical lin-
ear regression models. In the final model adjusted 
for all potential confounders, one unit increase in the 
hyperthymic score was associated with a 405.8  pg/mL 
higher seBDNF and the presence of hypertension with 
a 6121.2  pg/mL higher seBDNF. We found an interac-
tion (p = 0.002) between hypertension and hyperthymic 
temperament score on seBDNF in the whole study pop-
ulation: there was no significant association between 
hyperthymic score and seBDNF in CONT (p  =  0.545) 
and a unit increase in hyperthymic score was associated 
with a 533.3 (95 %CI 241.3–825.3) pg/mL higher seBDNF 
level in HT (p  <  0.001). The different impact of hyper-
thymic score in seBDNF in HT and CONT is shown in 
Fig. 1. 
Discussion
Here, we demonstrated for the first time in the literature 
that in chronic hypertensive patients, seBDNF is ele-
vated, and hyperthymic affective temperament score and 
the presence of hypertension are independent determi-
nants of seBDNF level. In hypertensive patients, the ele-
vation of hyperthymic temperament score is associated 
with the elevation of seBDNF; however, this association is 
not present in healthy subjects.
We suppose that the observed BDNF elevation in HT 
can be part of a protective compensatory mechanism tar-
geting peripheral neurons and vascular cells. BDNF has 
beneficial effects on the regulation of blood pressure, as 
it is involved not only in the development, but also in the 
survival of arterial baroreceptor system [24]. Vascular 
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endothelial cells are proved to produce BDNF [25]. In 
patients with angina pectoris, Jiang et  al. demonstrated 
that low plasma BDNF level was associated with a higher 
probability of major cardiovascular events than a middle 
level or a high level during the 4-year follow-up period 
[26]. Moreover, in a recently published population-based 
study, higher seBDNF was found to be associated with 
decreased risk of cardiovascular morbidity and mortality 
[6]. On the contrary, decreased serum BDNF was found 
to be associated with increased risk of incident stroke/
TIA [27]. In our study, the positive correlation with 
HDL and also with pulse pressure amplification, where 
higher values refer to better vascular conditions [28], 
also supports the plausible beneficial effect of BDNF in 
hypertension.
Some of the findings of our study were already 
described in the literature, such as the seBDNF correla-
tion with cholesterol and LDL [4], as well as with platelets 
[10]. As stored BDNF is released from platelets during 
clotting [10] and in essential hypertension, increased 
platelet activation is a trigger of hypercoagulable state 
[29], our finding that platelet count is positively corre-
lated with seBDNF may refer to a chief source of seBDNF 
in this pathological condition.
Another main finding of our study is that hyperthymic 
affective temperament is an independent determinant 
of seBDNF. This temperament is characterized by exu-
berant, upbeat, overenergetic, and overconfident life-
long traits [30]. We suppose that patients with higher 
hyperthymic temperament scores might have reduced 
inclination to cardiovascular complications, due to 
the beneficial effect of elevated seBDNF, a hypothesis 
that needs to be confirmed in follow-up studies. As the 
observed association between hyperthymic temperament 
score and seBDNF was only present in our hypertensive 
patients, we suppose an active role of affective tempera-
ments not only in psychiatric but also in cardiovascular 
pathophysiology.
Interestingly, in our study, no association of seBDNF 
with anxiety or depression was found. We suppose that 
this phenomenon can be explained by the mild anxiety 
and depression severity of HT patients.
Table 1 Demographic, laboratory, hemodynamic, and arte-
rial stiffness parameters; subjects’ questionnaire scores
CONT HT
N (male:female) 32 (12:20) 151 (58:93)
Age [year] 61.1 (55.9–70.5) 63.7 (57–71)
Duration of hypertension [year] – 11 (5–18)
Diabetes [n (%)] – 38 (25.2)
Cardiovascular disease [n (%)] – 21 (13.9)
Current smoker [n (%)] 3 (9.4) 22 (14.6)
Body height [cm] 168.8 ± 8.6 166.8 ± 8.6
Body weight [kg] 72.4 ± 12.1 79.7 ± 14*
BMI [kg/m2] 24.5 ± 5.4 28.6 ± 4.5*
Platelet count [G/l] 239.6 (215–277) 257 (209.7–303.2)
Glucose [mmol/l] 5.36 (4.88–5.81) 6.15 (5.11–6.7)*
GFR‑EPI [ml/min/1.73 m2] 79.7 (69.5–82.2) 77.9 (67–90)
Uric acid [µmol/l] 313.7 ± 11.6 318.4 ± 6.3
Cholesterol [mmol/l] 5.57 (4.97‑6.05) 5.18 (4.37- 5.98)*
LDL [mmol/l] 3.46 ± 0.91 3.07 ± 1.04
HDL [mmol/l] 1.68 (1.31–1.98) 1.40 (1.15–1.61)*
Triglyceride [mmol/l] 1.16 (0.75–1.43) 1.67 (1.08–2.06)*
Regular medication [n (%)]
 ACE inhibitors – 93 (61.5)
 ARBs – 34 (22.5)
 CCBs – 67 (44.4)
 Beta blockers – 87 (57.6)
 Diuretics – 68 (45)
 Antiplatelet drugs – 44 (29.1)
 Statins 5 (15.7) 54 (35.7)
 Alprazolam – 23 (15.2)
TEMPS‑A
 Depressive 5.9 (4–7) 7.1 (5–9)
 Cyclothymic 2.9 (0–4) 3.9 (1–6)
 Hyperthymic 11.2 ± 4 11 (4.2)
 Irritable 3.2 (2–4) 4.3 (2–6)
 Anxious 4.1 (1–6) 6.3 (2–9)
BDI 2.8 (1–4) 6.3 (3–9)*
HAM‑A 3.9 (1–6) 7.4 (2–10)*
Heart rate [1/min] 72.1 (66.6–78.2) 72.7 (64.1–77.2)
Brachial SBP [Hgmm] 125.5 ± 9.3 133.0 ± 12.3*
Brachial DBP [Hgmm] 72 ± 6.4 75 ± 9
Brachial PP [Hgmm] 51.5 (46.4–56.7) 56.7 (46.4–63)*
Central SBP [Hgmm] 117 (111.2–122.3) 124.1 (113.4–131.6)*
Central DBP [Hgmm] 67.1 ± 7 69.8 ± 8.2
Central PP [Hgmm] 49.9 (43.2–54.5) 54.3 (45.2–61)
PP amplification 1.08 (1.03–1.14) 1.07 (0.98–1.12)
PWV [m/sec] 8.6 (7.4–9.2) 9.3 (7.8–10)
Continuous data are presented as mean (SD) or mean (interquartile range)
Categorical parameters are presented as % (n)
BMI body mass index, ARBs angiotensin II receptor blockers, CCBs calcium 
channel blockers, SBP systolic blood pressure, DBP diastolic blood pressure, 
PP pulse pressure, PWV pulse wave velocity, AIx augmentation index, 
TEMPS-A Temperament Evaluation of Memphis, Pisa, Paris and San Diego 




AIx (%) 13.2 (5.75–23) 17.8 (8.5–25.1)
Serum BDNF (pg/ml) 21202.6 ± 6045.5 24880 ± 8279*
Table 1 countined
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In contrast to the literature, the presence of diabetes 
or the use of the benzodiazepine alprazolam was not sig-
nificantly correlated with seBDNF; however, the direc-
tion of correlations was as expected. We think that in 
both cases, the lack of significance was caused by the low 
proportion of diabetic or alprazolam user patients in our 
cohort.
The associations between seBDNF level and arterial 
stiffness parameters have never been evaluated in any 
patient population yet. Since BDNF has a relaxant effect 
on pulmonary arterial and aortic rings in different ani-
mal models [17, 18], we supposed a possible link between 
BDNF and arterial stiffness parameters. In contrast to 
this, in our study seBDNF showed an association only 
with pulse pressure amplification, but even this failed to 
be an independent predictor in regression analysis. We 
Table 2 The predictive values of hypertension and hyperthymic affective temperament score on serum BDNF level in dif-
ferent models evaluated with linear regression analysis in the whole study population (n = 183)
Hyp. temp. score hyperthymic affective temperament score, BDI Beck depression inventory, HAM-A Hamilton anxiety scale, Alp patients regularly using alprazolam, 
PPamp pulse pressure amplification
Models Beta Std. Error Std. Beta p R2
Model 1 0.036
 Hypertension 4149.6 1681.8 0.190 0.015
Model 2 0.050
 Hyp. temp. score 410.7 140 0.225 0.004
Model 3
 Hypertension + hyp. temp. score 0.089
 Hypertension 4310.3 1640.6 0.198 0.009
 Hyp. temp. score 422.2 137.6 0.231 0.003
Model 4: Model 3 + age + sex 0.107
 Hypertension 4365.1 1636.7 0.200 0.008
 Hyp. temp. score 449.8 138.1 0.246 >0.001
Model 5: Model 4 + diabetes 0.132
 Hypertension 5161.4 1661.2 0.237 0.002
 Hyp. temp. score 459.4 136.6 0.251 >0.001
Model 6: Model 5 + cholesterol + HDL 0.158
 Hypertension 5954.7 1685.5 0.273 >0.001
 Hyp. temp. score 430.6 136.8 0.235 0.002
Model 7: Model 6 + platelet number 0.176
 Hypertension 5540 1688.4 0.254 >0.001
 Hyp. temp. score 431.9 135.8 0.236 0.002
Model 8: Model 7 + BDI + HAM‑A + Alp. 0.191
 Hypertension 6167 1748.4 0.283 >0.001
 Hyp. temp. score 408 140.9 0.223 0.004
Model 9: Model 8 + PPamp. 0.202
 Hypertension 6121.2 1742.3 0.281 >0.001






















Hyperthymic affective temperament score (95% CI)
HT
CONT
Fig. 1 Association between serum BDNF level and hyperthymic 
affective temperament score in hypertensive patients (HT) and in 
controls (CONT). Continuous line with squares represents CONT, while 
broken line with rhombs represents HT
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suppose from these findings that seBDNF may exert its 
protective role rather on the level of the endothelium and 
perivascular nerves than on the level of large arteries.
The main limitation of our study comes from its cross-
sectional design which precludes causal inference. In 
addition, the number of the subjects involved into the 
study limited the number of potential confounding vari-
ables that were involved in the final regression model. 
Consequently, the presence of sleeping disorder, the 
amount of alcohol intake or the habit of regular exercise, 
variables with documented influence on BDNF level, were 
not involved into the final analysis (these were not signifi-
cantly correlated with seBDNF in univariate models, data 
are not shown). Moreover, other potential confounders, 
like childhood trauma, stress or sunlight exposition were 
not evaluated. In addition to these limitations, although 
we used standardized questionnaires and excluded 
patients with dementia, a complete exclusion of misinter-
pretations or mistakes by the patients is impossible.
Conclusions
In conclusions, our results suggest a complex psychoso-
matic involvement of BDNF in the pathophysiology of 
hypertension, where hyperthymic affective temperament 
may have a protective role. The impact of this phenom-
enon for cardiovascular outcome has to be clarified in 
prospective studies, but its mechanism is probably not 
mediated by large arteries.
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